quinazolines has been researched along with Adenocarcinoma in 1151 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (1.39) | 18.7374 |
| 1990's | 21 (1.82) | 18.2507 |
| 2000's | 379 (32.93) | 29.6817 |
| 2010's | 724 (62.90) | 24.3611 |
| 2020's | 11 (0.96) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, D; Liu, J; Liu, X; Pan, Y; Qiu, Y; Shi, Y; Wan, H; Wang, P; Ying, K; Zhu, Y | 1 |
| Chen, D; Li, J; Mao, C; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M | 1 |
| Fujita, M; Igata, F; Ikeuchi, N; Ito, K; Masutani, K; Morita, D; Murayama, H; Nakamura, T; Nishida, Y; Oda, T; Takahashi, K; Uesugi, N; Watanabe, M; Yasuno, T | 1 |
| Igai, H; Kamiyoshihara, M; Numajiri, K; Ohsawa, F | 1 |
| Cui, Y; Kang, X; Liang, J; Liu, M; Zhang, H; Zhang, Q | 1 |
| Bernards, N; Creemers, GJ; de Hingh, IHJT; Legué, LM; Lemmens, VEPP; van Erning, FN | 1 |
| Aul, R; Hill, M; Howlett, S; Pinato, DJ | 1 |
| Alishahi, Z; Esmaeili, F; Ghaffari, SH; Hamzehlou, S; Karimi, B; Kashani, B; Momeny, M; Mousavi, SA; Mousavipak, SH; Nasrollahzadeh, A; Sabourinejad, Z; Sankanian, G; Shamsaiegahkani, S; Yousefi, H; Zandi, Z | 1 |
| Kaushik, AC; Wang, X; Wang, YJ; Wei, DQ | 1 |
| Ding, K; Ding, Y; Wang, J; Xu, D; Yuan, Y; Zhu, N | 1 |
| Cho, J; Lai, D; Luo, C; Shen, X; Zeng, Q; Zhang, X; Zhou, W | 1 |
| Cardin, DB; Glazer, PM; Grossman, SR; Ivy, SP; Kato, S; Kim, JW; LoRusso, PM; Shyr, Y; Vaishampayan, UN | 1 |
| Awasthi, S; Bansal, M; Belkina, N; Biswas, R; Califano, A; Chaerkady, R; Charles Jacob, HK; Cultraro, CM; Gao, S; Guha, U; Kashyap, MK; Kirkali, G; Maity, T; Marimuthu, A; Pandey, A; Pitts, S; Singh, S; Venugopalan, A; Zhang, X | 1 |
| Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wu, J; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L | 1 |
| Higo, H; Hotta, K; Ichihara, E; Kato, Y; Kayatani, H; Kiura, K; Kubo, T; Kudo, K; Kurata, Y; Makimoto, G; Minami, D; Ninomiya, T; Ohashi, K; Sato, A; Takami, Y; Tanimoto, M; Yoshino, T | 1 |
| Dokuni, R; Kiriu, T; Kobayashi, K; Kunimasa, K; Nagano, T; Nishimura, Y; Satouchi, M; Shimono, Y; Tachihara, M; Tamura, D; Tokunaga, S; Yamamoto, M | 1 |
| Jean-Claude, B; Thibault, B | 1 |
| Chong, IW; Chou, SH; Hsu, JS; Huang, MS; Hung, JY; Lee, JY; Liu, TC; Tsai, MJ; Wu, KL; Yang, CJ | 1 |
| Beadling, C; Corless, CL; Gay, ND; Neff, T; Tolba, K; Wang, Y; Warrick, A | 1 |
| Chu, T; Dong, Y; Gu, A; Han, B; Jin, B; Lou, Y; Niu, Y; Pei, J; Shi, C; Wang, H; Xu, J; Zhang, W; Zhang, X; Zhang, Y; Zhong, H; Zhu, L | 1 |
| Atallah, JP; Ibrahim, U; Saqib, A | 1 |
| Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY | 1 |
| Hayashi, R; Inomata, M; Kambara, K; Kashii, T; Konishi, H; Miwa, T; Okazawa, S; Shimokawa, K; Tanaka, H; Tobe, K; Tokui, K; Yamada, T | 1 |
| Akiyama, N; Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Iwaizumi, M; Karayama, M; Kono, M; Kusama, Y; Nakamura, Y; Suda, T; Suzuki, Y | 1 |
| Guo, R; Jin, S; Min, H; Shu, Y; Wen, W; Wu, H; Xu, T; Zhang, Z | 1 |
| Arata, S; Ohba, M; Ohmori, T; Yamaoka, T | 1 |
| Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y | 1 |
| Ch'ng, C; Chia, S; Gelmon, K; Ho, C; Ho, J; Ionescu, D; Jones, MR; Jones, SJM; Laskin, J; Leelakumari, S; Lim, H; Ma, Y; Marra, MA; Moore, RA; Mungall, AJ; Mungall, KL; Ng, T; Pleasance, E; Reisle, C; Renouf, DJ; Schaeffer, DF; Shen, Y; Yip, S; Zhao, C; Zhao, Y; Zhong, E | 1 |
| Katsuta, E; Rashid, OM; Takabe, K | 1 |
| Cao, H; Ding, L; Dong, S; Du, Y; Fan, F; Feng, J; Li, H; Liu, S; Lou, R; Ma, R; Ni, J; Wang, Z; Wu, J; Zhao, X; Zhou, LL | 1 |
| Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L | 1 |
| Boumber, Y; Chaudhary, S; Kesari, K; Khan, H; Khan, M; Smith, S; Wahab, A | 1 |
| Kodama, K; Maniwa, T; Takeda, M; Yamamoto, Y | 1 |
| Cheema, PK; Doherty, M; Tsao, MS | 1 |
| Fang, YF; Hsu, PC; Kao, KC; Li, SH; Liu, CY; Tseng, LC; Wang, CC; Yang, CT | 1 |
| Fukumoto, S; Harada, M; Kiuchi, S; Oizumi, S; Watanabe, M; Yamada, N; Yokouchi, H | 1 |
| Chong, IW; Hsu, JF; Huang, MS; Hung, JY; Lee, MH; Liu, TC; Tsai, MJ; Tsai, YC; Tsai, YM; Yang, CJ | 1 |
| Akizuki, R; Endo, S; Ikari, A; Maruhashi, R; Matsunaga, T; Sakai, H; Sato, T; Yamaguchi, M; Yamazaki, Y | 1 |
| Fan, T; Liu, XL; Song, YJ; Wei, YN; Yang, H; Zhou, J | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Araki, M; Chauhan, R; Goto, K; Ichikawa, H; Ishii, G; Knowles, PP; Kohno, T; Matsumoto, S; McDonald, NQ; Mimaki, S; Nagatoishi, S; Nakaoku, T; Niho, S; Okuno, Y; Shimada, Y; Tsuchihara, K; Tsumoto, K; Yoh, K | 1 |
| Karpov, I; Kovalenko, S; Kozlov, V; Shamanin, V | 1 |
| Chan, RT | 1 |
| Cao, J; Chen, Y; Cui, Y; Jiang, N; Jiang, W; Ke, Z; Lei, Y; Sun, Y; Wang, H; Wang, Y; Xu, D; Zhang, Y | 1 |
| Imamura, Y; Matsuda, S; Sano, K; Umeda, Y; Yoshida, H; Yoshimura, H | 1 |
| Chai, Y; Wu, Y; Yao, Y; Zhu, Z | 1 |
| Homma, S; Isobe, K; Iyoda, A; Kaburaki, K; Kakimoto, A; Kobayashi, H; Makino, T; Mikami, T; Nakano, Y; Otsuka, H; Sakamoto, S; Sano, G; Sugino, K; Takai, Y; Tochigi, N; Yoshizawa, T | 1 |
| Chen, G; Du, KQ; Lv, TF; Song, Y; Song, ZB; Wang, WX; Xu, CW; Zhu, YC; Zhuang, W | 1 |
| Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Zhou, J | 1 |
| Gu, J; Jin, Y; Liang, X; Liu, T; Ma, H; Ma, X; Tao, J; Yang, T | 1 |
| Bai, C; Chang, M; Hu, J; Kwak, KJ; Lee, LJ; Li, J; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhou, J | 1 |
| Chi, Y; Jiang, ZC | 1 |
| Choi, CM; Hur, JY; Kim, HJ; Kim, SJ; Kim, YC; Lee, JC; Lee, KY; Lee, MK; Oh, IJ; Park, CK | 1 |
| Li, J; Li, Y; Pan, W; Yang, M; Zhang, L; Zhang, N; Zhu, H | 1 |
| Abraham, RG; Dedi, B; Krucher, NA; Thomas, NA | 1 |
| Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Liu, J; Qu, G; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhang, G; Zhou, J | 1 |
| Ansarin, K; Aria, M; Asadi, M; Baradaran, B; Farajnia, S; Zarredar, H | 1 |
| Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y | 1 |
| Bertran-Alamillo, J; Carcereny, E; Costa, C; Gasco, A; Gimenez-Capitan, A; Jimeno, J; Karachaliou, N; Majem, M; Massuti, B; Mayo, C; Molina-Vila, MA; Moran, T; Rosell, R; Sanchez, JJ; Souglakos, J; Viteri, S; Wannesson, L | 1 |
| Fujiwara, Y; Horinouchi, H; Kanda, S; Kubota, K; Nakamichi, S; Nokihara, H; Tamura, T; Yamamoto, N | 1 |
| Adelberg, D; Chau, CH; Choyke, PL; Dahut, WL; Figg, WD; Gulley, JL; Karakunnel, JJ; Madan, RA; Mulquin, M; Parnes, HL; Spencer, SD; Steinberg, SM; Turkbey, IB; Wright, J | 1 |
| Chen, HJ; Cheng, YP; Chiu, HC | 1 |
| Sterman, DH | 1 |
| Arcila, ME; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rekhtman, N; Riely, GJ; Sima, CS; Yu, HA; Zakowski, MF | 1 |
| Kim, R; Kothari, N; Saif, MW | 1 |
| Arriola, E; Martínez-Avilés, L; Mompradé, E | 1 |
| Atagi, S; Fukuoka, M; Imai, M; Katakami, N; Kudoh, S; Matsui, S; Ogiwara, A; Ueda, M; Yoshioka, H | 1 |
| Clément-Duchêne, C; Lamaze, R; Martinez, L | 1 |
| Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK | 1 |
| Hayashi, N; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Masuda, N; Nagashima, Y | 1 |
| Dong, Z; Kang, Y; Liu, G; Ma, X; Qian, Q; Zhang, X | 1 |
| Acharyya, S; Chakraborty, A; Dasgupta, P; Gangopadhyay, S; Sau, S | 1 |
| Megahed, M; Wahl, RU | 1 |
| Beasley, MB; Cagle, PT; Chitale, DA; Dacic, S; Giaccone, G; Jenkins, RB; Kwiatkowski, DJ; Ladanyi, M; Lindeman, NI; Saldivar, JS; Squire, J; Thunnissen, E | 1 |
| Chen, X; Guo, R; Liu, Y; Qian, Y; Røe, OD; Shu, Y; Yin, Y; Zhu, L | 1 |
| Furukawa, T; Hamasaki, S; Itakura, S; Miyata, M; Suenaga, M; Tabata, S; Yamamoto, M | 1 |
| Chang, CX; Hu, RH; Li, R; Qi, JL; Shi, SB; Tang, XY; Tian, J | 1 |
| Esumi, H; Goto, K; Ishii, G; Kohno, T; Makinoshima, H; Matsumoto, S; Matsushima, K; Mimaki, S; Ochiai, A; Shibata, T; Suzuki, A; Suzuki, M; Suzuki, Y; Tsuchihara, K; Tsuta, K; Yoh, K | 1 |
| Belaid, I; Ben Ayed, F; Debbiche, G; Jlassi, H; Rais, H | 1 |
| Aebi, S; Diebold, J; Gautschi, O; Hirschmann, A; Keller, FA; Strobel, K; Zander, T | 1 |
| Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Blons, H; Chouaid, C; Cortot, AB; Dansin, E; Diebold, J; Felip, E; Gautschi, O; Lepage, B; Mansuet-Lupo, A; Mazières, J; Milia, JD; Moro-Sibilot, D; Peters, S; Rouquette, I; Urban, T; Wislez, M | 1 |
| Hou, YH; Pan, JB; Zhang, GJ | 1 |
| Bai, H; Chen, J; Fang, F; Fang, J; Feng, Q; Feng, Y; Li, S; Lv, C; Ma, Y; Pei, Y; Wang, J; Wang, Y; Wu, N; Yan, S; Yang, Y; Zhao, B; Zheng, Q | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Imamura, F; Kijima, T; Komuta, K; Kumanogoh, A; Minami, S; Mori, M; Namba, Y; Nonen, S; Otani, Y; Tachibana, I; Takimoto, T; Tsuruta, N; Uchida, J; Yokota, S | 1 |
| Barzotti, E; Crinò, L; Drudi, F; Mangianti, M; Papi, M; Poggi, B; Ravaioli, A; Salvi, M; Santelmo, C | 1 |
| Chen, J; Li, JY; Shi, JY; Su, B; Tang, L; Yang, XJ; Zhang, J; Zhao, YM | 1 |
| Lazarus, DR; Ost, DE | 1 |
| Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Bellevicine, C; Carlomagno, C; De Luca, C; de Rosa, N; De Stefano, A; Iaccarino, A; Illiano, A; Malapelle, U; Micheli, P; Pepe, F; Piantedosi, FV; Rocco, D; Russo, S; Salatiello, M; Troncone, G; Vitiello, F | 1 |
| Kieszko, R; Kowalski, DM; Krawczyk, KW; Krawczyk, P; Krzakowski, M; Milanowski, J; Mlak, R; Rolski, A; Szczyrek, M; Szudy, A; Winiarczyk, K | 1 |
| Bae, MK; Cho, BC; Haack, H; Hwang, SK; Jewell, SS; Kang, DR; Kim, HJ; Kim, HR; Kim, JH; Lim, SM; Ou, SH; Park, JK; Shim, HS; Shin, E; Soo, RA; Wang, J | 1 |
| Han, ZG; Shan, L; Wang, Q; Zhang, Y | 1 |
| Aydiner, A; Seyidova, A; Yildiz, I | 1 |
| Bennouna, J; Boyer, M; Geater, SL; Gorbunova, V; Hirsh, V; Kato, T; Lee, KH; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Schuler, M; Sequist, LV; Shah, R; Shahidi, M; Su, WC; Tsai, CM; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N | 1 |
| Hirsh, V; Lungershausen, J; Massey, D; Mok, TS; O'Byrne, KJ; Palmer, M; Schuler, M; Sequist, LV; Shahidi, M; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, Y; Yun, T | 1 |
| Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Chhatrala, R; Iyer, R; Khushalani, N; Levea, C; Malhotra, U; Robins, M; Shefter, T; Tan, W; Yang, G | 1 |
| Ohkawa, S; Sakamoto, Y; Ueno, M | 1 |
| Li, X; Lv, J; Nong, J; Qin, N; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S | 1 |
| Ellis, PM; Leighl, NB; Sehdev, S; Verma, S; Younus, J | 1 |
| Aurisicchio, L; Ciliberto, G; Coluccia, P; D'Andrilli, A; De Vitis, C; Fattore, L; Giovagnoli, MR; Luberto, L; Malpicci, D; Mancini, R; Marra, E; Normanno, N; Noto, A; Roscilli, G; Ruco, L | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M | 1 |
| Aisner, DL; Berge, EM; Doebele, RC | 1 |
| Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Langer, CJ | 1 |
| Fujii, T; Matsumura, S; Okamoto, T; Shinyama, M; Tanaka, H | 1 |
| Gao, HJ; Liu, H; Qin, HF; Qu, LL; Wang, SS | 1 |
| Hasegawa, Y; Hatano, K; Iizasa, T; Itakura, M; Iuchi, T; Kageyama, H; Kawasaki, K; Nagano, O; Sakaida, T; Shingyoji, M; Yokoi, S | 1 |
| Köhler, J; Schuler, M | 1 |
| Gilbert, JA | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; Donehower, RC; Edil, BH; Fan, KY; Herman, JM; Hidalgo, M; Hruban, RH; Iacobuzio-Donahue, CA; Laheru, DA; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD | 1 |
| Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O | 1 |
| Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Döme, B; Fehniger, TE; Jansson, B; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, Á; Welinder, C | 1 |
| Abraham, I; Bustin, F; De Vos, L; Galdermans, D; Lechat, I; Van Meerbeeck, J | 1 |
| Goss, GD; Hirsh, V; Laurie, SA; Leighl, NB; Nicholas, G; Oza, A; Philip, L; Reaume, MN; Schwock, J; Shepherd, FA; Tsao, MS; Wang, L; Wright, JJ | 1 |
| Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G | 1 |
| Ema, T; Enomoto, Y; Kawano, R | 1 |
| Hishima, T; Hosomi, Y; Kato, K; Nagamata, M; Okamura, T; Okuma, Y; Sekihara, K; Yamada, Y | 1 |
| Koyama, N; Uchida, Y | 1 |
| Gemma, A; Kitamura, K; Kubota, K; Matsuda, K; Minegishi, Y; Miyanaga, A; Mizutani, H; Noro, R; Okano, T; Seike, M | 1 |
| Han, JY; Kim, H; Kim, HT; Lee, GK; Lee, YJ; Yun, T | 1 |
| Bansal, R; Blackburn, C; Brown, L; Colombo, R; Gasaway, R; Gore, J; Grimes, BR; Herbert, BS; Jeong, J; Korc, M; March, KL; Slee, RB; Victorino, J | 1 |
| Gu, QH; Hu, CP; Li, YY; Lu, RL; Wu, L; Yang, HP | 1 |
| Gong, XD; Guo, YH; Jiang, B; Shi, J; Wang, JY; Yuan, HH | 1 |
| Chang, GJ; Clemons, MV; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kopetz, SE; Krishnan, S; Maru, DM; Munsell, MF; Rodriguez-Bigas, MA; Shureiqi, I; Skibber, JM; You, YN | 1 |
| Meng, X; Teng, FF; Yu, JM; Zhang, JD | 1 |
| Koh, Y; Serizawa, M; Takahashi, T; Yamamoto, N | 1 |
| Liang, YC; Liu, Q; Liu, T; Shi, LL; Wu, G; Wu, HG; Xue, HJ | 1 |
| Allen, JN; Berger, DL; Blaszkowsky, LS; Borger, DR; Clark, JW; Cusack, JC; Hong, TS; Kwak, EL; Mamon, HJ; Ryan, DP; Shellito, PC; Szymonifka, J; Vasudev, E; Zhu, AX | 1 |
| Chan, V; Fukuoka, M; Kurnianda, J; McCormack, R; McWalter, G; Mok, TS; Nakagawa, K; Saijo, N; Wu, YL; Yang, JC | 1 |
| Bennouna, J; Besse, B; Blais, N; Gogov, S; Jehl, V; Johnson, BE; Leighl, N; Miller, N; Papadimitrakopoulou, VA; Soria, JC; Traynor, AM | 1 |
| Choi, CM; Chun, SM; Jang, SJ; Ji, W; Kim, SW; Kim, WS; Lee, DH; Lee, JC; Lee, JS; Park, YS; Rho, JK | 1 |
| Guan, Y; Jiao, S; Meng, J; Yan, X; Zhao, H | 1 |
| Brambilla, E; Busser, B; Cadranel, J; Coll, JL; Hurbin, A; Jeannot, V; Robin, B; Wislez, M | 1 |
| Cao, F; Fan, FT; Kang, XH; Wang, LF; Xu, ZY | 1 |
| Borczuk, AC; Siegelin, MD | 1 |
| Chan, AW; Lo, SH; To, KF; Tong, JH | 1 |
| Bria, E; Garassino, M; Massari, F; Pelosi, G; Peretti, U; Pilotto, S; Tortora, G | 1 |
| Bellezza, G; Bennati, C; Chiari, R; Crinò, L; Duranti, S; Ludovini, V; Minotti, V; Pireddu, A | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Ishii, Y; Isobe, H; Kobayashi, K; Maemondo, M; Minegishi, Y; Sugawara, S; Watanabe, S; Yoshizawa, H | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Hida, T; Horio, Y; Kondo, C; Park, J; Shimizu, J; Yoshida, K | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Liu, XQ; Qiao, TK | 1 |
| Horn, L; Lammers, PE; Lovly, CM | 1 |
| Cao, X; Hong, Z; Lan, L; Li, N; Luo, L; Pan, X; Shen, L; Yin, Z; Zhang, Y; Zhou, Y | 1 |
| Chan, EH; Chan, SL; Chan, ST; He, ZX | 1 |
| Li, N; Liu, QW; Ou, W; Wang, BX; Wang, SY; Yang, H; Zhang, SL | 1 |
| Cinquini, M; De Braud, F; Garassino, MC; Gelsomino, F; Haspinger, ER; Torri, V | 1 |
| de Marinis, F; Passaro, A | 1 |
| Sequist, LV; Yang, JC | 2 |
| Camidge, DR; Campbell, AK; Engelman, JA; Gadgeel, SM; Gernhardt, D; Giaccone, G; Jänne, PA; Khuri, FR; Koczywas, M; Letrent, S; Liang, J; O'Connell, JP; Rajan, A; Reckamp, KL; Ruiz-Garcia, A; Taylor, I | 1 |
| Bogatyreva, L; Braun, JA; Faller, G; Fichter, CD; Geddert, H; Gudernatsch, V; Hauschke, D; Klimstra, D; Lassmann, S; Schöpflin, A; Tang, L; Timme, S; Werner, M | 1 |
| Cho, S; Choi, DL; Choi, HE; Jang, SJ; Lee, JY; Lee, KT; Rim, HK | 1 |
| Funakoshi, Y; Maeda, H; Takeuchi, Y | 1 |
| Deng, Y; Fan, X; Fu, X; Gao, Y; Li, W; Ping, W | 1 |
| Blumenschein, GR; El-Naggar, AK; Glisson, BS; Gonzalez-Angulo, AM; Jakob, JA; Kies, MS; Kupferman, ME; Lee, JJ; Liu, DD | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J | 1 |
| Fukuoka, M; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS | 1 |
| Li, S; Ren, S; Zhou, C; Zhou, F | 1 |
| Carcereny, E; Cardenal, F; Cardona, AF; De Castro, J; Insa, A; Isla, D; Majem, M; Molina, MA; Moran, T; Pallarès, MC; Palmero, R; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Taron, M | 1 |
| Beal, K; Chan, TA; Gerber, NK; Riely, GJ; Rimner, A; Shi, W; Wu, AJ; Yamada, Y; Yu, HA; Zhang, Z | 1 |
| Iwase, T; Kishimoto, Y; Mori, H; Yano, T | 1 |
| Ebina, M; Iida, S; Ise, K; Iwabuchi, E; Kondo, T; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nihira, K; Ono, K; Saito, M; Sasano, H; Sato, I; Yamada-Okabe, H | 1 |
| Hirai, F; Ichinose, Y; Inamasu, E; Seto, T; Shiraishi, Y; Taguchi, K; Takenaka, T; Takenoyama, M; Takeo, S; Toyokawa, G; Toyozawa, R; Ushijima, C; Yamaguchi, M; Yoshida, T | 1 |
| Chang, YW; Chen, HA; Chen, JC; Chiu, CF; Su, JL; Su, YH; Tseng, CF; Yu, YH | 1 |
| Ahn, JS; Ahn, MJ; Lee, JY; Lim, SH; Park, K; Sun, JM | 1 |
| Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Karaseva, NA; Kulikova, YE; Lozhkina, AM; Mitiushkina, NV; Orlov, SV; Tiurin, VI; Togo, AV; Volodina, LN | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Bergbower, E; Dennis, PA; Dogan, I; Ekmekci, A; Gills, JJ; Kawabata, S; Rudin, CM; Wilson, W | 1 |
| Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S | 1 |
| Guo, L; Li, M; Liu, Z; Meng, Q; Shi, L; Tang, J; Tao, H; Tong, L; Wu, H; Wu, W; Xu, L; Zhu, Y | 1 |
| Harada, D; Honda, Y; Ichihara, E; Kiura, K; Murakami, T; Ninomiya, T; Ochi, N; Ohashi, K; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Chung, JH; Jheon, S; Jin, Y; Kim, H; Kim, JE; Kim, K; Lee, CT; Sun, PL; Yoo, SB | 1 |
| Fukai, T; Hasegawa, T; Hirasawa, Y; Ikeda, S; Kamiya, Y; Kudo, Y; Matsumura, M; Nagata, A; Shiraishi, E | 1 |
| Cai, G; Carbone, DP; de Stanchina, E; Gale, M; Gettinger, S; Horn, L; Jia, P; Miller, V; Nebhan, C; Pao, W; Pirazzoli, V; Politi, K; Shapiro, EM; Song, X; Stephens, PJ; Walther, Z; Wurtz, A; Yin, R; Zhao, Z | 1 |
| Ebi, H; Ishikawa, D; Matsumoto, K; Nakade, J; Nakagawa, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Yonekura, K; Zhao, L | 1 |
| Arriola, E; Luque, A; Martínez-Avilés, L; Vollmer, I | 1 |
| Ali, SM; Chan, CA; Halmos, B; Jia, Y; Miller, VA; Saad, S | 1 |
| Leighl, NB; Zer, A | 1 |
| Liu, C; Qu, G; Sun, B; Wang, P; Zhang, Z; Zhou, C | 1 |
| Hao, X; Hu, X; Li, J; Liu, Y; Shi, Y; Sun, Y; Wang, H; Wang, Y; Wang, Z; Zhang, X | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| Chen, XG; Jin, J; Wang, TE; Wang, YK; Xu, BL | 1 |
| Chang, J; Hu, A; Luo, Z; Sun, S; Wang, H; Wang, J; Wu, X; Xing, K; Yu, H; Zhao, X; Zhou, X | 1 |
| Belani, CP; Gusani, N; Jiang, Y; Kaifi, J; Kimchi, ET; Mackley, HB; Staveley-O'Carroll, KF; Zhu, J | 1 |
| Altiok, S; Doshi, P; Fulp, W; Haura, EB; Sasser, K; Smith, MA; Song, L | 1 |
| Koh, Y; Kusuhara, M; Serizawa, M; Takahashi, T; Urakami, K; Watanabe, M; Yamaguchi, K; Yamamoto, N; Zangiacomi, V | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M; Topolcan, O | 2 |
| Ma, D; Mathur, G | 1 |
| Li, QX; Lu, X; Wu, HL; Yang, M; Yu, SY; Yuan, XL; Zhang, L | 1 |
| Christopoulou, A; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katopodis, O; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Polyzos, A; Souglakos, J; Stathopoulos, E | 1 |
| Dong, CS; Li, JH; Liu, QL; Liu, RJ; Luo, BH; Luo, GQ; Wang, JP; Wang, KS; Wen, JF; Xiao, H; Xiao, N; Xie, B; Xiong, F; Yang, XJ; Zhong, M | 1 |
| Ford, HE | 1 |
| Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J | 1 |
| Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M | 1 |
| Escudero-Vilaplana, V; Gonzalez-Haba, E; Ribed, A; Sanjurjo, M | 1 |
| Fekrat, S; Proia, AD; Rao, V; Schneider, E | 1 |
| Ho, CC; Kuo, YW; Lin, CH; Lin, MT | 1 |
| Fernandes, J; Jampol, LM; Johnson, ML; Mets, M; Munk, MR; Patel, JD | 1 |
| Balázs, G; Kovalszky, I; Losonczy, G; Moldvay, J; Pápay, J; Puskás, R | 1 |
| Benedetti, JK; Blanke, CD; Gaur, R; Goldman, B; Iqbal, S; Lenz, HJ; Lowy, AM; Philip, PA; Ramanathan, RK; Wakatsuki, T; Whitehead, RP | 1 |
| McCulloch, T; Røe, OD; Szejniuk, WM | 1 |
| Imai, T; Ishigame, T; Kohno, T; Kumamoto, K; Saito, M; Tsuta, K | 1 |
| Cao, Y; Du, P; Kim, HJ; Lee, HJ; Settleman, J; Zhuang, G | 1 |
| Dohrmann, T; Drenckhan, A; Dupree, A; Grob, T; Gros, SJ; Izbicki, JR; Mann, O | 1 |
| Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Bosch-Barrera, J; Brunet, J; Izquierdo, A; Lorencio, C; Menéndez, JA; Porta, R; Rosell, R; Sais, E; Sirvent, JM | 1 |
| Chen, HW; Chen, WJ; Ho, CC; Ho, CL; Hsieh, WY; Lee, JY; Li, LH; Li, PR; Wang, CC; Wu, P; Yang, SM; Yen, MY | 1 |
| Dome, B; Francovszky, E; Galffy, G; Hegedus, B; Losonczy, G; Ostoros, G; Sarosi, V; Tolnay, E; Torok, S | 1 |
| Ge, N; Jiao, W; Qiu, T; Shen, Y; Tang, D; Wang, Y; Xuan, Y; Yan, G; Yao, R | 1 |
| Bi, F; Chen, L; Chen, Q; Ge, X; Leng, W; Pang, X; Tang, Q; Wu, YP; Xia, H; Yuan, D; Zhang, Y | 1 |
| Chang, CY; Chang, GC; Chen, CY; Chen, KC; Chen, YM; Hsu, KH; Huang, MS; Su, KY; Tsai, CR; Tsai, MH; Tseng, JS; Wang, CL; Wu, CW; Yang, CT; Yang, TY; Yu, SL | 1 |
| Ahmed, ZA; Moatter, T; Pervez, S; Siddiqui, A | 1 |
| Celik, T; Kosker, M | 1 |
| Alifano, M; Damotte, D; Dupouy, S; Fléjou, JF; Forgez, P; Lupo, AM; Mourra, N; Régnard, JF; Takahashi, T; Trédaniel, J; Wu, Z; Younes, M | 1 |
| Ferrer, L; Ferretti, G; Meynet, E; Moro-Sibilot, D; Pirvu, A; Sakhri, L | 1 |
| Chen, M; Gao, B; Qin, X; Wang, J; Wang, Y; Zhang, Z | 1 |
| Chu, NM; Feng, AC; Hsu, LH; Kao, SH; Liu, KJ; Tsai, MF; Wu, CR | 1 |
| Bi, F; Ge, X; Huang, M; Wang, Y; Zheng, L | 1 |
| Dawson, DW; Donahue, TR; Kadera, BE; Li, L; Nguyen, AH; Toste, PA; Wu, N | 1 |
| Bass, AJ; Fox, C; Hong, SW; Hong, YS; Kim, J; Ma, Q; Pectasides, E; Peng, S; Stachler, MD; Thorner, AR; Van Hummelen, P; Wong, GS | 1 |
| Ellis, S; Fayers, PM; Griebsch, I; Palmer, M | 1 |
| Byeon, JH; Jung, YH; Kim, HR; Kim, TJ; Lim, JU; Park, CK; Woo, IS | 1 |
| Goto, K; Hashimoto, H; Iida, S; Ishii, G; Matsumoto, S; Nagai, K; Neri, S; Niho, S; Niimi, A; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Belkina, N; Biswas, R; Chaerkady, R; Guha, U; Jacob, HK; Kim, MS; Maity, T; Pandey, A; Shaw, PG; Venugopalan, A; Zhang, X | 1 |
| Adaire, B; Cescon, TP; Choi, M; Cohen, SJ; Duncan, G; Hall, MJ; Joiner, M; Konski, A; McSpadden, E; Meropol, NJ; Meyer, JE; Philip, P; Shields, A | 1 |
| Braun, M; Cassidy, J; Chau, I; Falk, S; Finnigan, H; Ford, H; Harrison, M; Hickish, T; Iveson, T; Jones, H; Lee, C; Macpherson, IR; Potter, V; Propper, D | 1 |
| Chen, H; Du, N; Li, F; Yang, P; Zhao, X; Zhu, G | 1 |
| Balikó, Z; Sárosi, V | 1 |
| Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H | 1 |
| Arcila, ME; Hellmann, MD; Kris, MG; Reva, B; Rizvi, NA; Rusch, VW; Yu, H | 1 |
| Han, JY; Hwang, KH; Kim, HT; Kim, JY; Lee, GK; Lee, SH; Lee, YJ; Yun, T | 1 |
| Chou, YH; Hsieh, MS; Hua, SF; Jhuang, JY | 1 |
| Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB | 1 |
| Bi, J; Ke, Y; Liu, T; Ma, H; Zhang, S; Zhang, T | 1 |
| Igishi, T; Izumi, H; Kodani, M; Kurai, J; Makino, H; Matsumoto, S; Nakazaki, H; Nirodi, CS; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takata, M; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yanai, M | 1 |
| Chang, H; Chang, WC; Ho, CL; Hsu, HH; Hsu, YC; Huang, TW; Ko, KH; Tung, HJ; Wu, YC | 1 |
| Di Maio, M; Rossi, A | 1 |
| Bennouna, J; Boyer, M; Feng, J; Geater, SL; Gorbunova, V; Hirsh, V; Hu, CP; Huang, Y; Kato, T; Lee, KH; Lee, KY; Lu, S; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Popat, S; Schuler, M; Sebastian, M; Sequist, LV; Shahidi, M; Su, WC; Tsai, CM; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V; Zhou, C | 1 |
| Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D | 1 |
| Bantikassegn, A; Fan, PD; Guha, U; Politi, K; Song, X; Threadgill, DW; Varmus, H | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Hutchinson, L | 1 |
| Han, YF; Lin, X; Wu, LQ; Zhang, QY; Zhang, T | 1 |
| Bachelot, T; Bernard-Marty, C; Bonneterre, J; Conforti, R; Le Rhun, E; Taillibert, S | 1 |
| Abraham, RR; Girotra, M; Jones, J; Klair, JS | 1 |
| Chang, FK; Chih-Hsin Yang, J; Chiu, CH; Chuang, CY; Ho, CL; Hsia, TC; Hsiao, SH; Huang, MS; Lai, CL; Lai, RS; Lee, KY; Lin, CB; Lin, YC; Perng, RP; Shih, JY; Su, WC; Tsai, CM; Wang, CC; Wu, MF; Yang, CT; Yu-Wung Yeh, D | 1 |
| Canon, JL; Chand, VK; De Grève, J; Decoster, L; Galdermans, D; Graas, MP; Massey, D; Moran, T; Schallier, D; Teugels, E; Vansteenkiste, J; Vuylsteke, P | 1 |
| Chang, SM; Chen, LH; Chen, TS; Chiu, KL; Liu, CM; Ma, WL; Ni, YL; Sher, YP; Yang, SY; Yu, SL | 1 |
| Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F | 1 |
| Aoe, K; Bessho, A; Chikamori, K; Fujii, M; Harada, D; Hisamoto-Sato, A; Hosokawa, S; Hotta, K; Ichihara, E; Kishino, D; Kiura, K; Kozuki, T; Kubo, T; Kuyama, S; Nogami, N; Oze, I; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Ambrosio, F; Barbato, C; Cartenì, G; Mocerino, C; Otero, M; Riccardi, F; Scagliarini, S; Vitale, MG | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Chang, WA; Chong, IW; Chou, SH; Huang, MS; Hung, JY; Kuo, TY; Lee, JY; Liu, TC; Shen, CH; Tsai, MJ; Wu, KL; Yang, CJ; Yen, CJ | 1 |
| Lee, JG; Wu, R | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Kortmann, RD; Seidel, C | 1 |
| Hu, HG; Huang, JJ; Shen, H; Zhao, J | 1 |
| Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y | 1 |
| Bai, C; Huang, Y; Liao, M; Luo, F; Ma, S; Qin, S; Shi, Y; Wang, C; Yu, S; Zhang, L; Zhang, Q; Zhi, X; Zhou, C | 1 |
| Beraldi, E; Bishop, JL; Cordonnier, T; Gleave, ME; Kuruma, H; Nip, KM; Shiota, M; Takeuchi, A; Zoubeidi, A | 1 |
| Chudacek, Z; Pesek, M; Svaton, M; Vosmiková, H | 1 |
| Gemma, A; Kitamura, K; Kosaihira, S; Kubota, K; Matsuda, K; Matsumoto, M; Minegishi, Y; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T; Yoshimura, A; Zou, F | 1 |
| Kohno, T; Makinoshima, H; Matsushima, K; Sugano, S; Suzuki, A; Suzuki, Y; Tsuchihara, K | 1 |
| Gao, K; Li, XY; Liang, Y; Wu, N; Zhang, LF; Zhou, LN | 1 |
| Ahn, JS; Ahn, MJ; Chang, WJ; Choi, MK; Choi, YL; Do, IG; Hong, JY; Jung, HA; Kim, MJ; Kim, SM; Park, K; Sun, JM | 1 |
| Amato, E; Bria, E; Brunelli, M; Chilosi, M; Corbo, V; Fassan, M; Giglioli, E; Kinspergher, S; Milella, M; Novello, S; Peretti, U; Pilotto, S; Righi, L; Santo, A; Scarpa, A; Sperduti, I; Tortora, G; Vavalà, T | 1 |
| Chen, X; Dong, S; Li, P; Li, W; Qu, X; Shao, M; Yang, S; Zhang, L; Zhong, X | 1 |
| Hu, C; Li, M; Wang, Q | 1 |
| Aprile, G; Cardellino, GG; Foltran, L; Macerelli, M; Mazzer, M | 1 |
| Aoyama, A; Chen, F; Date, H; Menju, T; Omasa, M; Sato, M; Sato, T; Sonobe, M; Yamada, T; Yokoyama, Y | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Hall, PE; Popat, S; Spicer, J | 1 |
| Ai, YQ; He, WJ; Li, RQ; Li, WH; Li, YF; Wang, Y; Xia, YX; Zhang, J; Zhao, PZ | 1 |
| Abbruzzese, JL; Eng, C; Fogelman, D; Gallick, G; Jacobs, C; Jimenez, CA; Kopetz, S; Malik, Z; Morris, J; Overman, MJ; Parikh, N; Qiao, W; Reddy, SM; Shureiqi, I; Wolff, RA | 1 |
| Hida, T; Kato, T; Kiura, K; Massey, D; Okamoto, I; Seki, Y; Seto, T; Yamamoto, N; Yokoyama, A; Yoshioka, H | 1 |
| Girard, N | 1 |
| Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ | 1 |
| Gow, CH; Liao, WY; Liu, YN; Shih, JY | 1 |
| Fang, WF; Hong, SD; Huang, Y; Ma, YX; Sheng, J; Tian, Y; Xue, C; Yang, YP; Zhang, L; Zhao, YY | 1 |
| Fuchs, BC; Gilpin, SE; Lanuti, M; Ott, HC; Ren, X; Tanabe, KK; Tapias, LF; Wei, L | 1 |
| Ando, T; Hirose, Y; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Maruyama, T; Minagawa, M; Nagahashi, M; Ohtsubo, A; Okabe, Y; Sakata, J; Shimada, Y; Takizawa, K; Wakai, T; Watanabe, S | 1 |
| Adachi, K; Okamoto, S | 1 |
| Asakuma, M; Fukui, T; Hamada, A; Hayashi, N; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katagiri, M; Katono, K; Kimura, M; Kubota, M; Maki, S; Masuda, N; Mitsufuji, H; Otani, S; Ryuge, S; Saito, H; Sasaki, J; Takakura, A; Toyooka, I; Wada, M; Yamamoto, M; Yokoba, M | 1 |
| Cheung, WY; Doll, C; Goodwin, R; Heng, DY; Jiang, DM; Kumar, A; MacLean, A; Mercer, J; Monzon, J; Powell, E; Price-Hiller, J; Raissouni, S; Tang, PA; Vickers, MM | 1 |
| Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N | 1 |
| Watzka, SB | 1 |
| Fujita, A; Gotoh, N; Higashiyama, M; Higuchi, T; Imoto, S; Kimura, T; Kondoh, K; Miyano, S; Nakata, A; Nishihara, H; Nokihara, H; Nomura, M; Shimamura, T; Tamada, Y; Tojo, A; Yamaguchi, R; Yamauchi, M; Yano, S; Yoshida, R | 1 |
| Chan, CH; Chan, HL; Chen, JT; Chou, HC; Chung, TW; Lin, CC; Lin, MW; Lyu, KW; Wen, YF; Wu, SB | 1 |
| Fang, L; Li, F; Lin, N; Ma, S; Song, Y; Sun, X; Xu, Y; Zhang, Y | 1 |
| Chang, GC; Chen, HW; Chen, JJ; Chen, MH; Lai, YH; Lin, SY; Wong, YH; Yang, CH; Yu, SL | 1 |
| Khuri, FR; Ramalingam, SS | 1 |
| Fu, F; Geng, J; Sun, D; Wang, H; Xie, X; Yu, G; Zhang, L | 1 |
| Ayeni, D; de Stanchina, E; Goldberg, SB; Hyder, F; Meador, CB; Pao, W; Pirazzoli, V; Politi, K; Sanganahalli, BG | 1 |
| Liu, X; Shi, Y; Xu, J; Yang, S; Zhang, X | 1 |
| Fang, YF; Hsieh, MH; Li, SH | 1 |
| Cao, HX; Feng, JF; Hu, Y; Liu, SW; Wu, Y; Yu, DD; Yu, SR | 1 |
| Liu, G; Liu, H; Ma, T; Zhang, X | 1 |
| Cheow, H; De Silva, N; Fitzgerald, R; Ford, H; Godfrey, E; Hochhauser, D; Jobanputra, M; Lao-Sirieix, P; O'Donovan, M; Paterson, A; Qain, W; Schulz, L; Secrier, M | 1 |
| Choi, J; Kim, A; Kim, C; Kim, J; Lee, J | 1 |
| Chen, CS; Chen, CY; Chen, JJ; Hong, TM; Hsiao, TH; Huang, KY; Kao, SH; Salunke, SB; Su, KY; Wang, WL; Yang, PC; Yang, SC | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Cappuzzo, F; Cortot, A; Dansin, E; Filleron, T; Fournel, P; Früh, M; Gautschi, O; Mazières, J; Milia, J; Monnet, I; Moro-Sibilot, D; Peters, S; Pless, M; Rosell, R; Westeel, V; Wislez, M | 1 |
| Jin, J; Liu, BZ; Wu, ZM | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Garcia, A; Hecht, JR; Hoff, PM; Houé, V; Huang, Y; Jeziorski, K; Kaneko, T; Khan-Wasti, S; Li, J; Park, JO; Press, MF; Protsenko, SA; Qin, SK; Salman, P; Santillana, S; Shparyk, Y; Slamon, D; Sobrero, A; Wainberg, ZA; Xu, JM | 1 |
| Favaudon, V; Fernet, M; Giocanti, N; Huguet, F; Larsen, AK | 1 |
| Deng, Y; Feng, W; Liang, J; Wu, J; Xian, H; Yang, S; Zhang, H | 1 |
| Gao, B; Li, GH; Shao, GG; Yang, B; Yang, ZG | 1 |
| Dong, X; Li, K; Li, Q; Li, Z; Liu, L; Meng, R; Wu, G; Zhang, S; Zhou, F; Zhou, Y | 1 |
| Hasegawa, T; Hirai, S; Kojima, T; Niki, T; Nishikiori, H; Sakuma, Y; Takahashi, H; Watanabe, A; Yamada, G; Yamaguchi, M | 1 |
| Chen, Z; Wu, JH; Zhang, X; Zhao, J | 1 |
| Chang, BC; Hong, GR; Shim, CY; Shim, HS; Song, S | 1 |
| Boye, M; Kang, JH; Kim, JS; Orlando, M; Puri, T; Rajan, N; Srimuninnimit, V; Tsai, CM; Wang, X; Yang, JC | 1 |
| Du, LW; Feng, JG; Jiang, H; Li, JH; Ma, SL; Song, SC; Zhao, PJ; Zhou, GH; Zhu, XH | 1 |
| Chang, YL; Liu, YN; Shih, JY; Tsai, MF; Wen, YF; Wu, SG; Yang, JC; Yang, PC; Yu, CJ | 1 |
| Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
| Cai, J; Li, QX; Ning, J; Wery, JP; Xu, X; Yang, M | 1 |
| Dong, XR; Li, K; Li, QW; Li, ZY; Liu, L; Ma, H; Meng, R; Wu, G; Zhang, S; Zhou, FZ; Zhou, Y | 1 |
| Chen, L; Li, Q; Peng, S; Wang, R; Wang, W; Yang, H | 1 |
| Costa, DB; Freed, JA; Huberman, MS; Jorge, SE; Kobayashi, SS; Moran, JP; Zerillo, JA | 1 |
| Ebata, T; Ishiwata, T; Iwama, A; Iwasawa, S; Koide, S; Kurimoto, R; Sekine, I; Tada, Y; Takiguchi, Y; Tatsumi, K | 1 |
| Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM | 1 |
| Astsaturov, IA; Berger, AC; Boland, PM; Burtness, BA; Cheng, JD; Cohen, SJ; Cooper, HS; Davey, M; Lebenthal, A; Meyer, JE; Neuman, T; Olszanski, AJ; Scott, WJ | 1 |
| Chen, C; Lian, ZZ; Sun, YF | 1 |
| Daga, H; Fujimoto, D; Goto, I; Ikeda, N; Imamura, F; Iwamoto, Y; Kaji, R; Kanehara, M; Katakami, N; Morita, S; Murakami, H; Nakagawa, K; Nakanishi, Y; Negoro, S; Nogami, N; Oguri, T; Saka, H; Satouchi, M; Seto, T; Sugawara, S; Urata, Y; Yoshioka, H | 1 |
| Arrieta, O; Astudillo-de la Vega, H; Caballe-Perez, E; Cruz-Rico, G; Macedo-Pérez, EO; Martinez-Alvarez, I; Martínez-Hernández, JN; Ramírez-Tirado, LA; Soca-Chafre, G; Soto-Perez-de-Celis, E | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Contreras-Díaz, M; López-Herrero, F; Martínez-Bernal, G; Medina-Tapia, A; Molina-Socola, FE; Rueda-Rueda, T; Sánchez-Vicente, JL | 1 |
| Dandekar, G; Dandekar, T; Göttlich, C; Kunz, M; Müller, LC; Nietzer, SL; Schmitt, F; Walles, H; Walles, T | 1 |
| Mitsudomi, T; Mizuuchi, H; Nishio, K; Sakai, K; Sato, K; Shimizu, S; Suda, K; Takemoto, T; Tomizawa, K | 1 |
| Conte, P; Fassan, M; Frega, S; Pasello, G; Polo, V | 1 |
| Choi, YL; Han, J; I, H; Kim, J; Kim, RN; Kim, YD; Kim, YJ; Lee, CH; Lee, MK; Lee, MS; Lira, ME; Mao, M; Noh, KW; Oh, DY; Song, JY; Yang, JW | 1 |
| Cho, E; Han, H; Han, JY; Jung, J; Kim, HY; Kim, SW; Lee, GK; Lee, JS; Lee, KH; Lee, SH; Lee, Y; Min, YJ; Nam, BH | 1 |
| Hattori, Y; Honda, Y; Katsura, S; Manabe, T; Miyachi, Y; Otsuka, A; Terashima, T | 1 |
| Gong, J; Hu, P; Sun, S; Tang, F; Wang, Y; Wang, Z; Xie, C | 1 |
| Choi, YR; Kim, KY; Lee, Y; Shin, DH | 1 |
| Batliner, J; Fey, MF; Gautschi, O; Gugger, M; Rothschild, SI; Tschan, MP | 1 |
| Chang, GC; Close, S; Garrus, JE; Geater, SL; Han, M; Komarnitsky, P; Mok, TS; Park, K; Payumo, F; Su, WC; Tan, EH; Yang, JC | 1 |
| Creighton, CJ; Deng, B; Gibbons, DL; Guo, L; Lu, Q; Molina, JR; Sun, Z; Yang, P; Yang, Y; Yi, ES; Zhang, T | 1 |
| Li, Y; Liu, W; Luo, E; Tian, L; Wang, Y; Wen, L; Wen, M; Wen, N; Yang, H; Yun, Y; Zhang, W; Zhao, L; Zhu, X | 1 |
| Maeda, A; Nakata, M; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H | 1 |
| Baba, T; Futaki, M; Iwasawa, T; Kato, T; Ogura, T; Sakuranaka, H; Sekine, A; Suido, A | 1 |
| Du, Z; Tang, X; Yang, M; Zhou, Y; Zhuang, J | 1 |
| Dickgreber, N; Feng, J; Geater, SL; Hirsh, V; Hu, CP; Huang, Y; Lu, S; Märten, A; Massey, D; Mok, T; O'Byrne, K; Okamoto, I; Schuler, M; Sebastian, M; Sequist, LV; Shah, R; Wind, S; Wu, YL; Yamamoto, N; Yang, JC; Zhou, C | 1 |
| Arata, S; Hirose, T; Ishida, H; Kishino, Y; Kusumoto, S; Murata, Y; Ohba, M; Ohmori, T; Ohnishi, T; Sasaki, Y; Shirai, T; Yamaoka, T | 1 |
| Fukuoka, M; Hohjoh, H; Takahashi, M; Yoshioka, K | 1 |
| Nakamura, H; Nishimura, T | 1 |
| Doki, Y; Fukuoka, J; Hori, T; Isobe, M; Kurose, K; Nakayama, E; Nishio, Y; Nozawa, R; Ohue, Y; Oka, M; Tanaka, T | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Lee, JK; Lee, SH; Min, HS; Park, K; Sun, JM | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Ellis, CE; Estrada, MC; Gagnon, RC; Grob, TJ; Hecht, JR; Jeziorski, K; Liang, Z; Ma, Y; Park, JO; Press, MF; Qin, SK; Robinson, DM; Sauter, G; Scherer, SJ; Slamon, DJ; Villalobos, I; Wu, S; Xu, J | 1 |
| Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA | 1 |
| Chen, G; Gao, Y; Huang, C; Lu, Z; Shi, L; Song, Z; Wang, B; Wang, Y; Xu, D; Zhang, H; Zhang, W; Zhang, Y; Zhuang, N | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Ang, MK; Chowbay, B; Jain, A; Kanesvaran, R; Lim, WT; Ng, QS; Sutiman, N; Tan, EH; Tan, SW; Tan, WL; Toh, CK | 1 |
| Pakkala, S; Ramalingam, SS | 1 |
| Hayama, M; Hirashima, T; Morishita, N; Nishida, T; Nishihara, T; Okamoto, N; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A | 1 |
| Feng, J; Gibson, N; Hirsh, V; Hou, M; Hu, CP; Huang, Y; Kim, M; Li, W; Lu, S; Massey, D; Mok, T; O'Byrne, K; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC | 1 |
| Diebold, J; Froesch, P; Früh, M; Gautschi, O; Jochum, W; Klingbiel, D; Mark, M; Reichegger, H; Rothschild, S; Schmid, S | 1 |
| Bandoh, S; Chiba, Y; Ishii, T; Kadowaki, N; Kanaji, N; Kita, N; Sato, A; Tadokoro, A; Ueno, M; Watanabe, N | 1 |
| Bertolini, F; Bettelli, S; Longo, L; Manfredini, S; Mengoli, MC; Rossi, G | 1 |
| Bashir, ES; Chan, CY; Kwan, AK; Mun Keong, K | 1 |
| Jänne, PA; Saxon, JA; Sholl, LM | 1 |
| Ali, SM; Allen, JM; Erlich, RL; Miller, VA; Ou, SI; Ross, JS; Schrock, AB; Stephens, PJ; Vafai, D | 1 |
| Bai, Y; Cao, J; Fan, S; Hua, Y; Li, J; Liu, T; Pan, H; Shen, L; Su, W; Wang, L; Xu, J; Xu, RH; Zhang, D | 1 |
| Bae, E; Ikeda, N; Kato, M; Kuroda, M; Makino, Y; Mamura, M; Miyazawa, K; Ohira, T; Yoon, JH | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Kattan, J; Moussa, T | 1 |
| Acquaviva, G; Brand, T; Brandes, AA; Cavallo, G; de Biase, D; Degli Esposti, R; Di Battista, M; Genestreti, G; Pession, A; Tallini, G; Visani, M | 1 |
| Chuang, JC; Das, M; Diehn, M; Huang, J; Liang, Y; Neal, JW; Stehr, H; Wakelee, HA | 1 |
| Akamatsu, H; Azuma, K; Fukuhara, T; Goto, K; Harada, D; Harada, T; Hotta, K; Iwama, E; Kishimoto, J; Kurata, T; Nakanishi, Y; Nishio, K; Nosaki, K; Ohyanagi, F; Okamoto, I; Sakai, K; Shimose, T | 1 |
| Ellison, K; Hirsch, FR; Kim, J; Mitsudomi, T; Murakami, I; Rivard, CJ; Suda, K; Yu, H | 1 |
| Chewaskulyong, B; Fukuoka, M; Haddad, V; Han, B; Ichinose, Y; Margono, B; Mok, TS; Ohe, Y; Rukazenkov, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ; Young, H | 1 |
| Fraser, A | 1 |
| Baltazar, F; Barbosa, AM; Cardoso-Carneiro, D; Cury, FP; de Paula, FE; Evangelista, AF; Granja, S; Longatto-Filho, A; Marques, F; Martinho, O; Miranda-Gonçalves, V; Moreira, MA; Reis, RM; Scapulatempo-Neto, C; Silva-Oliveira, R; Zanon, M | 1 |
| Ando, K; Arata, S; Ishida, H; Kusumoto, S; Murata, Y; Ohba, M; Ohmori, T; Ohnishi, T; Sasaki, Y; Yamaoka, T | 1 |
| Balleyguier, C; Besse, B; Soria, JC; Wagner, M | 1 |
| Belli, C; Giovannini, M; Gregorc, V; Villa, E | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kawano, O; Kitahara, N; Matsumura, A; Okuda, K; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yokoyama, T; Yukiue, H | 1 |
| Fujiwara, Y; Hirano, S; Kiura, K; Kondo, E; Ohashi, K; Osawa, M; Rai, K; Takata, K; Takata, M; Tanimoto, M; Yoshino, T | 1 |
| Fujisaki, K; Hirakata, H; Iida, M; Inoshima, I; Katafuchi, R; Maeda, H; Masutani, K; Takayama, K; Toyonaga, J; Tsuruya, K | 1 |
| Biagi, J; Cutz, JC; Dancey, J; Dore, N; Eisenhauer, EA; Elit, L; Fyles, A; Ghatage, P; Hoskins, PJ; Mazurka, J; Oza, AM; Provencher, D; Sakurada, A; Tsao, MS | 1 |
| Fukai, M; Fushitani, K; Kimura, H; Mori, M; Naka, N; Nakagawa, M; Nakazawa, Y; Namba, Y; Niinaka, M; Okada, T; Yano, Y; Yokota, S | 1 |
| Bolognese, A; Caputo, M; Di Cello, P; Izzo, L; Izzo, P; Meloni, P; Pietrasanta, D | 1 |
| Ishikawa, H; Kikuchi, N; Ohara, G; Satoh, H; Sekizawa, K | 1 |
| Evans, TR; Kalofonos, HP; Koutras, AK; Makatsoris, T; Mastronikolis, NS; Papadeas, ES | 1 |
| Aoe, K; Bessho, A; Fujiwara, Y; Gemba, K; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Matsuo, K; Moritaka, T; Segawa, Y; Shibayama, T; Sugimoto, K; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Ackman, JB; Iafrate, AJ; Sequist, LV; Settleman, JE | 1 |
| Chella, A; Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Han, HS; Han, JY; Hwang, SW; Lim, KY | 1 |
| Alessio, M; Balsamo, M; Di Modugno, F; Gertler, FB; McConkey, DJ; Melucci, E; Milella, M; Mottolese, M; Natali, PG; Nisticò, P; Philippar, U; Pino, MS | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Kollar, LE; Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, DP; Parsels, LA | 1 |
| Dacic, S; Dubey, S; Eickhoff, JC; Hoang, T; Kolesar, JM; Marcotte, SM; Schiller, JH; Siegfried, JM; Stabile, LP; Traynor, AM | 1 |
| Battaglia, M; Boccardo, F; Conti, G; Cruciani, G; Lapini, A; Manganelli, A; Ricci, S; Rubagotti, A | 1 |
| Bachariou, A; Chasapi, V; Papadopoulos, R | 1 |
| Fukuhara, T; Inoue, A; Kanehira, M; Kikuchi, T; Kuroki, Y; Maemondo, M; Nukiwa, T; Saijo, Y; Suzuki, T; Xin, H | 1 |
| Fukui, T; Furuta, K; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Takano, T; Tamura, T; Tsuta, K; Yamamoto, N; Yamamoto, S | 1 |
| Bafaloukos, D; Bobos, M; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalogera-Fountzila, A; Kalogeras, KT; Karayannopoulou, G; Kosmidis, P; Koutras, AK; Linardou, H; Murray, S; Samantas, E; Xiros, N | 1 |
| Jing, DD; Lu, YY; Wang, XP; Wu, K; Xu, M | 1 |
| Eguchi, K; Ishizaka, A; Kawada, I; Kawamura, M; Kobayashi, K; Nakachi, I; Naoki, K; Soejima, K; Watanabe, H; Yasuda, H | 1 |
| Alfieri, RR; Ardizzoni, A; Boni, L; Bortesi, B; Bozzetti, C; Camisa, R; Capelletti, M; Cavazzoni, A; De Palma, G; Franciosi, V; Galetti, M; Goldoni, M; Loprevite, M; Mozzoni, P; Petronini, PG; Rindi, G; Tiseo, M | 1 |
| Akamine, SJ; Ebi, N; Kuraki, T; Nakanishi, Y; Okamoto, I; Semba, H; Takayama, K; Tokunaga, SJ; Wataya, H; Yamamoto, H | 1 |
| Black, J; Iyer, R; Javle, M; LeVea, C; Nava, H; Nwogu, C; Pande, A; Wilding, G; Yang, G | 1 |
| Ishihara, S; Minato, K; Mogi, A; Naito, Y; Saito, R; Shitara, Y; Suga, T; Takise, A; Tsuchiya, S; Yamabe, K | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Chang, GC; Chen, JC; Hsu, SL; Tsai, CH; Tsai, JR; Wu, CC; Wu, WJ; Yu, CT | 1 |
| Endo, T; Funayama, Y; Furukawa, K; Hashimoto, T; Hayashibara, K; Ichimura, H; Inagaki, M; Ishikawa, H; Ishikawa, S; Kaburagi, T; Kagohashi, K; Kamiyama, K; Kishi, K; Kurishima, K; Matsumura, T; Nawa, T; Satoh, H; Shinohara, Y; Sumi, M | 1 |
| Dastane, AM; Gupta, R; Marchevsky, AM; McKenna, R | 1 |
| Bertran-Alamillo, J; Botia, M; Carrasco, E; Castellà, E; Costa, C; Llatjós, M; Mate, JL; Mayo, C; Molina-Vila, MA; Moran, T; Pérez-Cano, M; Pradas, A; Queralt, C; Reguart, N; Rosell, R; Taron, M; Tomàs, M | 1 |
| Cho, BC; Costa, DB; Halmos, B; Huberman, MS; Jackman, DM; Jänne, PA; Kim, JH; Kobayashi, S; Nguyen, KS; Pao, W; Riely, GJ; Sequist, LV; Tenen, DG; Yeap, BY | 1 |
| Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI | 1 |
| Copeman, M | 1 |
| Beales, IL; Ogunwobi, OO | 1 |
| Im, KC; Kim, SW; Lee, DH; Lee, JS; Moon, DH; Oh, SJ; Ryu, JS; Sohn, HJ; Suh, C; Yang, YJ | 1 |
| Balak, M; Bean, J; Ladanyi, M; Marks, JL; Miller, VA; Pao, W; Riely, GJ | 1 |
| Hanibuchi, M; Kakiuchi, S; Li, Q; Matsumoto, K; Mitsudomi, T; Nakamura, T; Nishioka, Y; Ogino, H; Sakurama, H; Sone, S; Uehara, H; Wang, W; Yano, S; Yatabe, Y | 1 |
| Balko, JM; Black, EP | 1 |
| Fukuoka, M; Hida, T; Katakami, N; Kawahara, M; Kubota, K; Matsui, K; Nakagawa, K; Nishiwaki, Y; Noda, K; Saijo, N; Takeda, K; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Bodenstein, H; Digel, W; Franke, A; Guschall, WR; Gütz, S; Heigener, D; Laack, E; Reck, M; Schmidtgen, C; Schneider, CP; Schott-von-Römer, K | 1 |
| Chang, YL; Hsu, YC; Shih, JY; Tsai, MF; Wu, JY; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Cardona, AF; Reguart, N; Reveiz, L | 1 |
| Angagaw, MH; Bettano, KA; Chenard, M; Haines, BB; Reilly, JF; Sevilla, RS; Sur, C; Tong, C; Ware, C; Winkelmann, CT; Zhang, W | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sim, SH | 1 |
| Ailawadhi, S; Derby, L; Fetterly, G; Natarajan, R; Ramnath, N; Reid, M | 1 |
| Galvany, L; Herrera-Acosta, E; Iglesias, M; Márquez, G; Umbert, P; Vidal, I | 1 |
| Aoyagi, D; Kanda, S; Kobayashi, N; Koizumi, T; Kubo, K; Nakayama, J; Ushiki, A; Yamamoto, H; Yasuo, M | 1 |
| Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH | 1 |
| Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH | 1 |
| Akerley, W; Arbogast, K; Bentz, JS; Boucher, KM; Walters, T | 1 |
| Kometani, T; Maehara, Y; Miura, N; Ohba, T; Okazaki, H; Shoji, F; Takenaka, T; Yano, T; Yoshino, I | 1 |
| Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC | 1 |
| Godwood, A; Oliver, S; Peeters, M; Saunders, MP; Smith, R; Van Cutsem, E; Wilson, R | 1 |
| Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C | 1 |
| Andreu, J; Baselga, J; Cedrés, S; del Campo, JM; Felip, E; Martínez, P; Pallisa, E; Prat, A; Quispe, I; Sala, G | 1 |
| Ginsberg, MS; Heelan, R; Hussain, S; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rusch, VW; Zakowski, MF | 1 |
| Fimognari, FL; Franco, A; Pastorelli, R; Pellegrinotti, M; Repetto, L | 1 |
| Hirai, Y; Kawago, M; Kiyoi, M; Naito, K; Ohta, F; Okamura, Y; Oura, S; Shimizu, Y; Tamaki, T; Yoshimasu, T | 1 |
| Chen, H; Chen, Y; Eckhardt, SG; Kane, M; Leong, S; Mack, P; McCarter, MD; Olsen, CC; Raben, D; Schefter, TE; Stiegmann, G | 1 |
| Chen, TM; Chen, YH; Chern, JW; Tseng, SY; Yu, ST | 1 |
| Curigliano, G; de Braud, F; De Cobelli, O; Sbanotto, A; Scardino, E; Spitaleri, G | 1 |
| Alexandrescu, DT; Dasanu, CA; Kauffman, CL | 1 |
| Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Chatta, G; Evans, CP; Gandara, DR; Lara, PN; Longmate, J; Posadas, E; Quinn, DI; Stadler, W; Twardowski, P | 1 |
| Agelaki, S; Georgoulias, V; Kallergi, G; Markomanolaki, H; Mavroudis, D; Spiliotaki, M; Stournaras, C | 1 |
| Chang, CP; Chao, HS; Chen, YM; Chiu, CH; Chu, LS; Tsai, CM | 1 |
| Ichihara, E; Kiura, K; Ogino, A; Ohashi, K; Osawa, M; Takigawa, N; Tanimoto, M | 1 |
| He, C; Liu, M; Ouyang, M; Xu, J; Zhang, J; Zhong, N; Zhou, C | 1 |
| Chikaishi, Y; Inoue, M; Nose, N; So, T; Sugio, K; Yasumoto, K | 1 |
| Baudrin, L; Cadranel, J; Milleron, B; Morere, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Souquet, PJ | 1 |
| Jiang, W; Wu, JX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY | 1 |
| Fujita, S; Harada, Y; Hata, A; Imai, Y; Ishihara, K; Katakami, N; Nishimura, T; Seo, R; Takeshim, Y; Tomii, K | 1 |
| Goto, Y; Hojo, M; Kobayashi, N; Kudo, K; Takeda, Y | 1 |
| Hirano, S; Ichihara, E; Kiura, K; Kubo, T; Ohashi, K; Osawa, M; Takata, M; Takeda, H; Takigawa, N; Tanimoto, M; Yoshino, T | 1 |
| Armour, AA; Chewaskulyong, B; Chu, DT; Duffield, EL; Fukuoka, M; Han, B; Ichinose, Y; Jiang, H; Margono, B; Mok, TS; Nishiwaki, Y; Ohe, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Watkins, CL; Wu, YL; Yang, CH; Yang, JJ | 1 |
| Hirano, S; Kobayashi, N; Kudo, K; Morii, S; Morita, A; Sano, K; Sugiyama, H; Takeda, Y; Uruga, K | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
| Alì, G; Baldini, E; Boldrini, L; Camacci, T; Comin, CE; Fontanini, G; Gisfredi, S; Lucchi, M; Maddau, C; Melfi, F; Mussi, A; Servadio, A; Tibaldi, C; Ursino, S | 1 |
| An, SJ; Chen, ZH; Huang, YS; Wu, YL | 1 |
| Kim, YH; Mio, T; Mishima, M | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Yamada, K | 1 |
| Buttitta, F; Cappuzzo, F; Carlone, D; Ceribelli, A; Cognetti, F; Del Grammastro, M; Felicioni, L; Finocchiaro, G; Gelibter, AJ; Iacobelli, S; Irtelli, L; Malatesta, S; Marchetti, A; Mezzetti, A; Milella, M; Nuzzo, C; Perrucci, B; Sciarrotta, M | 1 |
| Goto, D; Hizawa, N; Kohno, M; Ohara, G; Satoh, H; Sumida, T | 1 |
| Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hung, MC; Krishnamurthy, S; LaFortune, TA; Liu, P; Lucci, A; Singh, B; Ueno, NT; Zhang, D | 1 |
| Nagai, A; Shiroma, T; Yamaguchi, M | 1 |
| Iizasa, T; Itakura, M; Kimura, H; Nakajima, T; Nishimura, H; Shingyoji, M | 1 |
| Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Beckett, LA; Burich, RA; Davies, AM; Gandara, DR; Holland, WS; Lara, PN; Li, Y; Mack, PC; Sangha, R; Solis, LJ | 1 |
| Bai La, BL; Endo, J; Funaguchi, N; Ito, F; Minatoguchi, S; Mori, H; Nakano, M; Ohno, Y; Yanase, K | 1 |
| Bessho, A; Harita, S; Hayashi, H; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Umemura, S; Yoshioka, H | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE | 1 |
| Abdallah, N; Altiok, S; Berman, D; Forastiere, A; Gibson, MK; Jagannath, S; Mezzadra, H; Rudek, MA; Tsottles, N | 1 |
| Cattaneo, MT; Clementi, E; Ferrario, S; Filipazzi, V; Gambaro, A; Isabella, L; Oteri, A; Piazza, E; Radice, S; Tosca, N | 1 |
| Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM | 1 |
| Harichand-Herdt, S; Ramalingam, SS | 1 |
| Chen, HY; Lee, CN; Liu, HE | 1 |
| Iwakawa, J; Kawamata, Y; Kumamoto, T; Suetsugu, T; Tanoue, A | 1 |
| Adelstein, DJ; Ives, DI; Mason, DP; Murthy, SC; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Videtic, GM | 1 |
| Bosenberg, M; Bressel, A; Chin, L; Chiu, MI; Clark, SC; Depinho, RA; Heyer, J; Horner, JW; Jacks, T; Rancourt, R; Reddypalli, S; Rideout, WM; Robinson, MO; Woo, JK; Zhou, Y; Zi, T | 1 |
| Kris, MG; Ladanyi, M; Pao, W; Rizvi, NA; Rusch, VW; Solomon, SB; Thornton, RH; Zakowski, MF | 1 |
| Fukui, T; Hataishi, R; Igawa, S; Jiang, SX; Katagiri, M; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Otani, S | 1 |
| Duan, HQ; Han, Y; Liu, XQ; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Ando, M; Fukuoka, M; Hida, T; Ichinose, Y; Iwamoto, Y; Kashii, T; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Nakagawa, K; Okamoto, I; Sasaki, J; Sato, T; Satouchi, M; Sawa, T; Seto, T; Takayama, K; Takeda, K; Yamamoto, N | 1 |
| Chin, JL; Dancey, JE; Gregg, R; Hedley, D; Hotte, SJ; Hudes, GR; Moore, MJ; Pham, NA; Sridhar, SS; Trachtenberg, J; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA | 1 |
| Amir, E; Seruga, B; Tannock, I | 1 |
| Desai, RU; Rachakonda, LP; Saffra, NA | 1 |
| Ma, PC; Manson, GV | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Chang, SC; Kuo, LC; Lin, PC; Wang, KF; Yuan, MK | 1 |
| Chen, YM; Chou, KT; Fan, WC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Wu, CH | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Sung, JH; Yun, T | 1 |
| Ayabe, E; Endo, M; Horie, Y; Kaira, K; Kondo, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Carney, D; Forde, P; Murphy, C; O'Sullivan, C | 1 |
| Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O | 1 |
| Clarke, JL; Lassman, AB; Miller, VA; Pao, W; Wu, N | 1 |
| Hatsuse, M; Morihara, K; Murakami, S; Nagata, K; Okano, A; Shimazaki, C; Shiotsu, S; Yuba, T | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Mimeault, M | 1 |
| Glynne-Jones, R; Harrison, M; Mawdsley, S | 1 |
| Han, YH; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Jørgensen, JT | 1 |
| Arao, T; Fujita, Y; Fukuoka, M; Ito, H; Nakagawa, K; Nishio, K; Okamoto, I; Takeda, M | 1 |
| Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G | 1 |
| Alzani, R; Ciomei, M; Degrassi, A; Fanti, S; Giusti, AM; Nanni, C; Patton, V; Pesenti, E; Russo, M; Texido, G | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Aikou, T; Akiba, S; Baba, M; Castillo, A; Eizuru, Y; Higashi, M; Itoh, T; Khan, N; Koriyama, C; Matsumoto, H; Natsugoe, S; Shuyama, KY; Yanagi, M | 1 |
| Gao, ZQ; Gu, AQ; Han, BH; Shi, CL; Wang, HM; Xiong, LW | 1 |
| Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ | 1 |
| Fujita, S; Fukudo, M; Ikemi, Y; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Hasegawa, S; Hashimoto, M; Kondo, N; Matsumoto, S; Okumura, Y; Takuwa, T; Tanaka, F; Torii, I; Yoneda, K | 1 |
| Eguchi, K; Fukuoka, M; Horai, T; Ichinose, Y; Masuda, N; Mitsudomi, T; Mori, K; Nukiwa, T; Saijo, N; Segawa, Y; Takahashi, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Garber, K | 1 |
| Harris, TJ; McCormick, F | 1 |
| Lind, JS; Postmus, PE; Smit, EF | 1 |
| Barchuk, AS; Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Protsenko, SA; Semenov, II; Togo, AV | 1 |
| Mehta, SP | 1 |
| Doi, S; Fukuda, M; Hayashi, T; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Nakatomi, K; Soda, H; Takasu, M; Takatani, H; Tomonaga, N; Tsukamoto, K; Yamaguchi, H | 1 |
| Gao, HJ; Guo, WF; Li, JJ; Li, XY; Liu, B; Liu, XQ; Qu, LL; Tang, CH; Wang, WW; Wang, WX | 1 |
| Chen, J; Liu, H; Xu, Y; Zhou, Q | 1 |
| Cai, CJ; Deng, QH; He, JX; Huang, J; Li, HL; Wang, DY; Wang, W; Wen, DP; Xie, SM; Zhang, L; Zhong, NS | 1 |
| Arnold, A; Ciuleanu, T; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Goodwin, R; Laberge, F; Laurie, SA; LeMaître, A; Seymour, L; Shepherd, FA; Vincent, M; Walde, D; Zukin, M | 1 |
| Heo, DS; Kang, JH; Kim, DW; Kim, HK; Kim, SY; Lee, JS; Lee, MA; Lee, SH; Shin, SW | 1 |
| Anthoney, A; Blatter, J; Dean, E; Hanauske, AR; Kletzl, H; Klingelschmitt, G; Melezinek, I; Ranson, M; Reck, M; Twelves, C | 1 |
| Aloi, L; Avallone, A; Budillon, A; Comella, P; Delrio, P; Iaffaioli, VR; Iodice, G; Lastoria, S; Marone, P; Pecori, B; Petrillo, A; Sandomenico, C; Scala, D; Scott, N; Tatangelo, F | 1 |
| Fujita, S; Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Besse, B; Buisine, MP; Copin, MC; Dansin, E; Ferté, C; Parent, F; Penel, N; Soria, JC | 1 |
| Barchuk, AS; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Procenko, SA; Semionov, II; Togo, AV | 1 |
| Bodio, K; Costa, DB; Huberman, MS; Kobayashi, S; Kris, MG; Lau, MW; Pao, W; Riely, GJ; Tenen, DG; Warner, JL; Yeap, BY; Yeo, WL | 1 |
| Eckert, R; Faehling, M; Kamp, T; Kuom, S; Schumann, C; Stoiber, KM | 1 |
| Choi, YJ; Kim, CH; Kim, HR; Kim, HT; Kim, YM; Koh, JS; Kook, EH; Lee, JC; Rho, JK | 1 |
| Batra, S; Batra, U; Dhiman, A; Doval, DC; Suresh, P; Talwar, V | 1 |
| Cunningham, D; Okines, AF | 1 |
| Ge, XQ; Huang, JJ; Shen, H; Yuan, Y; Zhong, X | 1 |
| Belsanova, B; Benesova, L; Minarik, M; Pesek, M; Sekerka, P | 1 |
| Brückl, WM; Ficker, JH; Wiest, GH | 1 |
| Chang, CY; Chang, SC; Chen, CY; Yu, CJ | 1 |
| Ackerman, J; Albain, KS; Barlesi, F; Berkowitz, L; Besse, B; Gabrail, N; Hart, LL; Herbst, RS; Leighl, NB; Massarelli, E; Melnyk, O; Miller, VA; Raez, LE; Rosen, PJ; Shepherd, FA; Shun, Z; Sternas, L | 1 |
| Breen, L; Clynes, M; Collins, DM; Dunne, G; O'Connor, R; Roche, S | 1 |
| English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A | 1 |
| Abbruzzese, JL; Davis, D; Fogelman, D; Javle, MM; Reddy, SA; Shroff, RT; Varadhachary, GA; Wolff, RA; Xiong, H; Zhang, Y | 1 |
| Chang, SH; Hsu, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Antoniou, C; Chasapi, V; Dilana, KD; Karapanagiotou, EM; Matekovits, AE; Stratigos, AJ; Syrigos, KN; Tsimboukis, S; Vergou, T | 1 |
| Dempsey, EC; Karoor, V; Le, M; Merrick, D; Miller, YE | 1 |
| Arnoletti, JP; Frolov, A; Heslin, MJ; Howard, JH; Kossenkov, AV; Kulesza, P; Liles, JS; Tzeng, CW | 1 |
| Fukuda, M; Hayashi, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Sano, K; Soda, H; Takatani, H; Tsukamoto, K | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishihara, K; Kaji, R; Katakami, N; Nishimura, T; Takahashi, Y; Tomii, K | 1 |
| Landgraf, R | 1 |
| Hanagiri, T; Iwata, T; Onitsuka, T; Oyama, T; Shimokawa, H; Uramoto, H | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Bogart, J; Dipetrillo, T; Garst, J; Graziano, S; Green, MR; Gu, L; Jänne, PA; Ready, N; Vokes, EE; Wang, X | 1 |
| Katayama, T; Kosaka, T; Matsuo, K; Mitsudomi, T; Sueda, T; Yatabe, Y | 1 |
| Amarshi, N; Billingsley, A; Nair, BA; Thomas, KS | 1 |
| Lam, KC; Mok, TS | 1 |
| Becker, A; Postmus, PE; Smit, EF; van Wijk, A | 1 |
| Allan, S; Baliko, Z; Gridelli, C; Heigener, D; Krzakowski, M; Reck, M; Rischin, D; van Zandwijk, N | 1 |
| Matsuzaki, T; Miyauchi, J; Morishita, T; Naitou, A; Ogawa, R; Terashima, T | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Nishiyama, A; Tomii, K; Yoshioka, H | 1 |
| Au, JS; Mok, T; Park, K; Perng, RP; Wu, YL; Zhang, L; Zhou, C | 1 |
| Abu-Khalaf, M; Gunturu, KS; Saif, MW | 1 |
| Canto, M; Ding, P; Dunbar, KB; Eshleman, JR; Feldmann, G; Goff, D; Haffner, MC; Heckrodt, TJ; Hector, A; Holland, SJ; Hong, SM; Karikari, C; Maitra, A; Marimuthu, A; Meeker, AK; Montgomery, EA; Nelkin, BD; Pandey, A; Riggins, GJ; Roa, JC; Singh, R; Wang, JS; Yu, J; Zhang, J | 1 |
| Chung, KP; Shih, JY; Yu, CJ | 1 |
| Chen, X; Hoffman, L; Lee, TY; Ryan, AJ; Tai, JH; Tessier, J | 1 |
| Alam, N; Dudek, AZ; Gustafson, KS; Kapoor, A; Ladanyi, M; Truskinovsky, AM; Zakowski, MF | 1 |
| Fujiwara, K; Kudo, K; Matsuo, K; Mizuta, M; Sato, T; Tsushima, M; Yonei, T | 1 |
| Chang, CH; Chang, KC; Chu, CY; Kuo, TC; Lu, PH | 1 |
| Cheng, G; Li, L; Wu, XN; Zhang, P; Zhang, ZJ | 1 |
| Arcila, ME; Azzoli, CG; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pietanza, MC; Price, KA; Riely, GJ; Rizvi, NA | 1 |
| Becker, A; Chiappori, A; Haura, EB; Sommers, E; Song, L | 1 |
| Fukuhara, A; Hatachi, Y; Kim, YH; Kubo, T; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Togashi, K; Togashi, Y | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, V; Dennetta, D; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Ugolini, M | 1 |
| Aburatani, H; Fukayama, M; Ishikawa, S; Matsubara, D; Niki, T; Sachiko, O | 1 |
| Hosomi, Y; Iguchi, M; Miyamoto, S; Ohkuma, Y; Okamura, T; Shibuya, M; Shimokawa, T; Takagi, Y | 1 |
| Benlloch, S; Cardenal, F; Molina, MA; Moran, T; Porta, R; Rosell, R; Taron, M; Viteri, S | 1 |
| Chiba, M; Fujiwara, M; Goya, T; Kishino, T; Matsushima, S; Morii, T; Ogura, W; Ohnishi, H; Ohtsuka, K; Watanabe, T | 1 |
| Chang, TH; Huang, CP; Lan, CC; Lin, SB; Shih, JY; Su, KY; Tsai, MF; Wu, CP; Wu, SG; Yang, CH; Yang, PC; Yu, SL; Yu, YL | 1 |
| Ho, CC; Kuo, YW; Shih, JY; Wu, SG | 1 |
| Bahary, N; Bao, PQ; Bartlett, DL; Hughes, SJ; Krasinkas, A; Lee, KK; Lembersky, BC; Moser, AJ; Ramanathan, RK; Zeh, HJ | 1 |
| Chen, YM; Chou, KT; Fan, WC; Hsia, TC; Huang, MS; Huang, SF; Lai, CL; Lee, YC; Perng, RP; Tien, YJ; Tsai, CM; Wu, CH; Yu, CJ | 1 |
| Guan, ZZ; Guo, GF; Wan, DS; Wu, PH; Xia, JC; Xia, LP; Zeng, YX; Zhang, B | 1 |
| Dong, N; Guo, Y; Luan, HL; Sun, BC; Sun, LN; Wang, M; Zang, FL; Zhan, ZL | 1 |
| Asamura, H; Furuta, K; Kohno, T; Kozu, Y; Sekine, I; Suzuki, K; Tamura, T; Tsuda, H; Tsuta, K; Watanabe, S; Yokota, J; Yoshida, A | 1 |
| Azzoli, CG; Brevet, M; Johnson, ML; Ladanyi, M | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Azzoli, CG; D'Angelo, SP; Janjigian, YY; Kris, MG; Ladanyi, M; Pao, W; Park, BJ; Shen, R; Zakowski, MF; Zheng, J | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Iguchi, H; Ioka, T; Ito, T; Komatsu, Y; Nakachi, K; Nakagawa, K; Nakamori, S; Ohkawa, S; Okusaka, T; Yamao, K | 1 |
| Dobashi, Y; Kanai, Y; Koyama, S; Tetsuka, K | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Chang, CC; Chang, HJ; Chi, KH; Hsieh, YS; Hsu, PS; Jiang, JS; Kao, SJ; Tsang, YW; Yeh, YW | 1 |
| Azzoli, CG; Ginsberg, MS; Janjigian, YY; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pereira, LK; Pietanza, MC; Riely, GJ; Rizvi, NA | 1 |
| Beham, A; Bodo, K; Lackner, K; Liegl, B; Martin, D; Tsybrovskyy, O | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Stewart, DJ; Tsai, CM | 1 |
| Ito, K; Kawano, D; Maehara, Y; Morodomi, Y; Shoji, F; Yano, T | 1 |
| Han, JH; Han, JY; Kim, HT; Lee, GK; Lee, JS; Lee, YJ; Park, JH; Yoon, KA; Yoon, SJ; Yun, T | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Asami, K; Atagi, S; Kawaguchi, T; Kawahara, M; Okishio, K | 1 |
| Anthoine, G; Berghmans, T; CsToth, I; Mascaux, C; Meert, AP; Paesmans, M; Sculier, JP | 1 |
| Fujitaka, K; Hamada, A; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Masuda, T; Murai, H; Ohshimo, S | 1 |
| Barlesi, F; Tomasini, P | 1 |
| Galettis, P; Links, M; Luk, PP | 1 |
| Blanchet, B; Goldwasser, F; Mir, O | 2 |
| Bekele, BN; Guo, CC; Marcott, V; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM; Wen, S | 1 |
| Hanagiri, T; Kuwano, M; Ono, M; Shimokawa, H; Uramoto, H | 1 |
| Hureaux, J; Jeanfaivre, T; Le Maignan, L; Mirebeau-Prunier, D; Urban, T; Vervueren, L | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N | 1 |
| Ashton, S; Barry, ST; Blakey, D; Lewis, CE; Murdoch, C; Tazzyman, S; Wood, P | 1 |
| Morio, A; Ninomiya, H; Sunada, K | 1 |
| Armstrong, AJ; Crane, JM; George, DJ; Godley, PA; Grigson, G; Kim, WY; Moore, DT; Morris, K; Pruthi, RS; Rathmell, WK; Wallen, EM; Watkins, CP; Whang, YE | 1 |
| Chen, J; Chu, BB; Deng, J; Fang, HM; Fang, WJ; Mou, HB; Qian, J; Teng, LS; Wu, DP; Xu, N; Zhang, XC | 1 |
| Alcindor, T; Au, HJ; Jarvi, A; MacAlpine, K; Mackay, HJ; McWhirter, E; Oza, AM; Wang, L; Wright, JJ | 1 |
| Blanke, CD; Danenberg, KD; Fenoglio-Preiser, CM; Goldman, B; Iqbal, S; Lenz, HJ; Shibata, SI; Zhang, W | 1 |
| Chen, YM; Chou, KT; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Lee, HM; Tsai, CR; Yang, TY | 1 |
| Boyd, J; Capanu, M; Ilson, DH; Kelsen, D; Klimstra, D; Levine, DA; Miron, B; Schwartz, G; Shah, M | 1 |
| Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A | 1 |
| Nishizawa, S; Saito, T; Soejima, Y; Takahashi, M; Yamamoto, J | 1 |
| Fukuoka, J; Isa, S; Kawaguchi, T; Kitaichi, M; Koh, Y; Kubo, A; Kusunoki, Y; Nakagawa, K; Okamoto, I; Takada, M | 1 |
| Agrogiannis, G; Gamaletsou, MN; Kechagias, G; Papageorgiou, A; Syrios, J; Tsavaris, N; Xynos, ID | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Kern, I; Kovac, V; Rajer, M; Smrdel, U; Vrankar, M; Zwitter, M | 1 |
| Antoine, M; Cadranel, J; Lacave, R; Poulot, V; Ruppert, AM; Wislez, M | 1 |
| Crinò, L; Metro, G | 1 |
| Bagai, R; Fan, W; Flask, CA; Fu, P; Hafez-Khayyata, S; Halmos, B; Howell, S; Huang, H; Jiang, S; Koon, H; Kresak, A; Ma, PC; Morrison, B; Tang, Z; Vasanji, A; Yin, L | 1 |
| Berardi, S; Caravatta, L; Cellini, N; Deodato, F; Di Filippo, L; Fabrizio, G; Ingrosso, M; Macchia, G; Massaccesi, M; Morganti, AG; Pacelli, F; Padula, GD; Picardi, V; Ridolfini, MP; Tambaro, R; Valentini, V | 1 |
| Wang, L; Xiao, F; Zhang, W; Zheng, J | 1 |
| Horai, T; Horiike, A; Kudo, K; Nishio, M; Ohyanagi, F; Yanagitani, N | 1 |
| Fujii, M; Maehara, Y; Mitsudomi, T; Murakami, H; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Antoine, M; Brambilla, E; Busser, B; Cadranel, J; Coll, JL; de Fraipont, F; Dufort, S; Hurbin, A; Moro-Sibilot, D; Rabbe, N; Tenaud, C; Wislez, M | 1 |
| Gruber-Mösenbacher, U; Hilbe, W; Hulla, W; Mohn-Staudner, A; Pirker, R; Ploner, F; Popper, H; Studnicka, M; Wrba, F | 1 |
| Bhattacharyya, A; Kundu, S; Sengupta, S | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Berg, A; Brustugun, OT; Helland, Å; Lund-Iversen, M | 1 |
| Dallas, JL; Jantz, MA; Kaye, FJ; Lightsey, JL; Sonntag, C | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Haro, A; Ito, K; Kawano, D; Maehara, Y; Miura, N; Morodomi, Y; Shoji, F; Takenaka, T; Yano, T; Yoshino, I | 1 |
| Li, Y; Liu, B; Qin, X; You, J; Zhou, Q | 1 |
| Gu, A; Han, B; Shen, J; Shi, C; Xiong, L | 1 |
| Horinouchi, H; Izumi, Y; Kamiya, K; Kawamura, M; Kohno, M; Nomori, H; Shimada, N; Watanabe, M | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Yoon, KA; Yun, T | 1 |
| Shepherd, FA | 1 |
| Armour, AA; Chao, TY; Chu, DT; Duffield, EL; Fukuoka, M; Jiang, H; Leong, SS; Mok, TS; Nakagawa, K; Rukazenkov, Y; Saijo, N; Speake, G; Sriuranpong, V; Sunpaweravong, P; Thongprasert, S; To, KF; Wu, YL; Yang, JC | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Nukiwa, T; Oizumi, S; Saijo, Y; Satoh, H; Yoshizawa, H | 1 |
| Ishida, T; Katsuura, Y; Minemura, H; Misa, K; Munakata, M; Tachihara, M; Uematsu, M | 1 |
| Chanprapaph, K; Pongcharoen, P; Vachiramon, V | 1 |
| Hashimoto, K; Komune, S; Nakano, T; Nakashima, T; Oda, Y; Oyama, M; Shiratsuchi, H; Tamiya, S; Yamamoto, H | 1 |
| Iwamoto, Y; Katakami, N; Kobayashi, M; Matsui, K; Moriyama, A; Nakagawa, K; Sueoka-Aragane, N; Takada, M; Takeda, K; Yoshioka, H | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| He, W; Jiang, G; Liu, M; Song, N; Zhang, P | 1 |
| Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL | 1 |
| Chang, SC; Hsu, SY; Kuo, LC; Lai, JI; Lai, YC; Lin, PC; Wang, WS | 1 |
| Ameshima, S; Asami, K; Atagi, S; Hirai, K; Kawahara, M; Koizumi, T; Morikawa, A; Morozumi, N; Tsukadaira, A | 1 |
| Iida, K; Ishikawa, M; Katagiri, A; Kobayashi, H; Miyazaki, K; Nakayama, K; Nakayama, S; Otsuki, Y; Rahman, M; Rahman, MT; Yeasmin, S | 1 |
| Kagohashi, K; Kawaguchi, M; Kurishima, K; Nakayama, H; Ohara, G; Satoh, H | 1 |
| Belkhiri, A; El-Rifai, W; Zhu, S | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
| de Lima Lopes, G; Do, YK; Finkelstein, EA; Mok, T; Segel, JE; Tan, DS | 1 |
| Dao, KM; DiCarlo, B; Elashoff, R; Hecht, JR; Lin, LS; Park, DJ; Patel, R; Ryba, N; Wainberg, ZA; Wang, HJ | 1 |
| Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T | 1 |
| Barberis, M; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Fumagalli, C; Giovannini, M; Manzotti, M; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Dennie, T; Holen, KD; Mohammed, TA | 1 |
| Kawano, Y; Kawasaki, M; Kitasato, Y; Mizuta, Y; Sakoda, Y; Takata, S | 1 |
| Jou, YS; Ko, JY; Lin, KT; Lin, SC; Tu, PH; Wang, YW | 1 |
| Bonomo, P; Caravatta, L; Cecere, G; Cellini, N; Deodato, F; Di Lullo, L; Macchia, G; Massaccesi, M; Mignogna, S; Morganti, AG; Pacelli, F; Padula, GD; Picardi, V; Piscopo, A; Rotondi, F; Sallustio, G; Sofo, L; Valentini, V | 1 |
| Chang, GC; Chen, HW; Chen, JJ; Hsieh, WY; Lee, JY; Lee, YM; Yang, PC; Yu, SL | 1 |
| Aoki, T; Hanagiri, T; Korogi, Y; Mukae, H; Uramoto, H; Yamashita, Y; Yoshii, C | 1 |
| Chu, QS; de Jonge, MJ; Hamilton, M; Iwata, K; McCarthy, S; Mita, AC; Mita, MM; Papadopoulos, K; Ricart, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Verweij, J; Wacker, B; Witt, K; Wood, L | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Chin, A; Depinho, RA; Dinulescu, DM; Faça, VM; Gazdar, AF; Goodman, G; Hanash, SM; Kelly-Spratt, K; Kemp, CJ; Kucherlapati, R; Lockwood, WW; Park, KS; Pitteri, SJ; Politi, K; Sage, J; Taguchi, A; Varmus, HE; Wong, CH; Zhang, Q | 1 |
| Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK | 1 |
| Cerny, T; De Dosso, S; Koeberle, D; Renggli, V; Saletti, P; Sessa, C | 1 |
| Abe, T; Hayashi, S; Hirai, M; Hosomi, T; Iwanaga, K; Kimura, S; Komiya, K; Nakamura, T; Sato, A; Sueoka, E; Sueoka-Aragane, N; Ureshino, N | 1 |
| Arao, T; Horiike, A; Ikeda, N; Kasahara, K; Kimura, H; Koizumi, F; Matsumoto, K; Nishio, K; Nishio, M; Ohira, T; Saijo, N; Sakai, A; Sakai, K; Sone, T; Yamanaka, T | 1 |
| Dasanu, CA; Kaur, A | 1 |
| Imyanitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Moiseyenko, FV; Moiseyenko, VM; Radzhabova, SA; Suspitsin, EN | 1 |
| Agelaki, S; Georgoulias, V; Giassas, S; Kentepozidis, N; Kotsakis, A; Pallis, AG; Papakotoulas, P; Tryfonidis, K; Vamvakas, L; Vardakis, N; Voutsina, A | 1 |
| Knap, MM; Madsen, HH; Meldgaard, P; Nexo, E; Sorensen, BS; Weber, B | 1 |
| Dainton, M; Lim, E; Min, T; Nicholson, AG; O'Brien, ME; Popat, S; Swansbury, J; Vieira de Araújo, A; Wotherspoon, A | 1 |
| Goya, S; Hatazawa, J; Hirata, H; Inoue, A; Kawase, I; Kida, H; Kijima, T; Kumagai, T; Kumanogoh, A; Nagatomo, I; Okumura, M; Shimosegawa, E; Tachibana, I; Takahashi, R; Takeda, Y; Yoshida, M | 1 |
| Chang, JW; Chen, YR; Chen, YT; Chiu, YT; Hsieh, JJ; Huang, SF; Liu, HP; Wu, HD; Yu, TF | 1 |
| Huang, J; Margolis, J; Nadeau, L; Robertson, JM; Yan, D; Ye, H | 1 |
| Cohen, EE; Faoro, L; Gao, F; Govindan, R; Karrison, T; Kozloff, M; Salgia, R; Subramanian, J; Szeto, L; Vokes, EE | 1 |
| Chang, YL; Chen, YH; Kuo, YW; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Düwel, P; Gehl, HB; Görner, M; Hirnle, P; Müller, F; Riesenberg, H | 1 |
| Chan, WK; Cheng, PN; Cheng, T; Ma, AT; Ma, ES | 1 |
| Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
| Conradt, L; Diersch, S; Eser, S; Godl, K; Kleeff, J; Michalski, CW; Saur, D; Schaab, C; Schmid, RM; Schneider, G; Schnieke, A; Tebbe, A | 1 |
| Guo, H; Kang, Y; Li, Y; Lin, D; Liu, Q; Tian, G; Wan, Y; Yao, Z | 1 |
| Aleknavičius, E; Cicėnienė, A; Drobnienė, M; Grigienė, R; Lachej, N; Steponavičienė, L; Zelvienė, TP | 1 |
| Aranda, E; Arrivi, A; Díaz-Rubio, E; Galán, M; Irigoyen, A; Manzano, JL; Mendez, MJ; Pericay, C; Rivera, F; Safont, MJ; Sastre, J; Valladares-Ayerbes, M | 1 |
| Chen, YM; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Kameda, Y; Koizume, S; Matsukuma, S; Miyagi, Y; Nakamura, Y; Nakayama, H; Sakuma, Y; Yamazaki, Y; Yokose, T; Yoshihara, M | 1 |
| Ishida, T; Iwasaku, M; Korogi, Y; Kunimasa, K; Nagai, H; Nishiyama, A; Yoshioka, H | 1 |
| Aftab, D; Chen, X; Chmielecki, J; Hutchinson, K; Kris, MG; Miller, V; Pao, W; Pietanza, MC; Rizvi, N; Shen, R; Stout, T; Viale, A; Zhao, Z | 1 |
| He, CS; Hu, ZH; Liu, JL; Tian, Y; Xie, M; Xu, F; Zhang, L; Zhao, LP | 1 |
| Arcila, ME; Capelletti, M; Eck, MJ; Ginsberg, MS; He, M; Jänne, PA; Kris, MG; Ladanyi, M; Miller, VA; Nafa, K; Oxnard, GR; Yun, CH; Zhao, B | 1 |
| Abolhoda, A; Ahn, JS; Ahn, MJ; Cui, Z; Kim, Y; Ko, J; Ou, SH; Park, K | 1 |
| Hao, X; Li, J; Shi, Y; Wang, Y; Zhang, X | 1 |
| Chen, Z; Cheng, D; Ding, K; Le Maitre, A; Liu, G; Liu, N; Patel, D; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Chen, LQ; Gao, Q; Wang, KN; Wang, WP | 1 |
| Agatsuma, T; Eda, S; Hachiya, T; Kobayashi, T; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Ohura, N; Tsushima, K; Yasuo, M | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Galdermans, D; Geers, C; In't Veld, P; Schallier, D; Teugels, E; Umelo, I | 1 |
| Asaka, R; Hamanaka, W; Hatano, S; Ishikawa, Y; Lim Choi, Y; Mano, H; Nakagawa, K; Ninomiya, H; Okumura, S; Sakata, S; Satoh, Y; Soda, M; Suzuki, R; Takeuchi, K; Togashi, Y; Uehara, H | 1 |
| Arai, Y; Chiku, S; Enari, M; Furuta, K; Harris, CC; Haugen, A; Hiramoto, M; Ichikawa, H; Iwakawa, R; Kohno, T; Nammo, T; Ogawa, S; Ogiwara, H; Oike, T; Okayama, H; Sakamoto, H; Schetter, AJ; Sekine, I; Shibata, T; Shimada, Y; Skaug, V; Totoki, Y; Tsuda, H; Tsuta, K; Watanabe, S; Yamanaka, I; Yasuda, K; Yokota, J; Yoshida, T | 1 |
| Chen, W; Hu, CP; Liu, JK; Lu, RL; Xiong, Z; Zhou, H; Zhou, ML | 1 |
| Ban, HJ; Kim, KS; Kim, YC; Oh, IJ | 1 |
| Higashino, M; Hiraishi, Y; Hirano, S; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Naka, G; Nakamichi, S; Sugiyama, H; Takeda, Y | 1 |
| Fujiu, K; Kobayashi, N; Miyamoto, H; Suzuki, H | 1 |
| Guo, L; Liu, Z; Meng, Q; Shi, H; Tang, J; Xu, L; Zhu, Y | 1 |
| Böker, B; Grohé, C; Lüders, H | 1 |
| Atagi, S; Fukuoka, M; Ichinose, Y; Ishikura, S; Niho, S; Ohe, Y; Okamoto, H; Saijo, N; Shibata, T; Takeda, K; Tamura, T; Yokoyama, A | 1 |
| Khan, M; Ma, T; Rasul, A; Yang, H; Yu, B; Zhong, L | 1 |
| Ahn, JS; Ahn, MJ; Han, JH; Han, JY; Jo, SJ; Kim, HT; Kim, HY; Kim, SW; Lee, DH; Lee, JS; Lee, JW; Park, K; Suh, C; Yoon, SJ; Yun, T | 1 |
| Fan, Q; Li, P; Ma, Z; Qi, G; Wang, H; Wang, Q; Yan, X; Zhang, G; Zhu, H | 1 |
| Chang, JW; Chang, NJ; Chen, CH; Cheng, HY; Chung, FT; Hou, MM; Hsieh, JJ; Hsu, T; Huang, SF; Kuo, HP; Lin, HC; Lin, YC; Ou, LY; Tsai, YH; Wang, CL; Wang, HM; Yang, CT; Yu, CT | 1 |
| Choi, YH; Han, HS; Kim, ST; Lee, JY; Lee, KH; Lee, OJ; Lim, SN; Shim, YK | 1 |
| Ashai, A; Avital, I; Hassan, R; Kalra, N; Raffeld, M; Xi, L; Zhang, J | 1 |
| Liu, G; Wang, W; Zhang, X; Zhu, X | 1 |
| Bai, CX; Garfield, D; Ge, HY; Song, YL; Wang, X; Wang, XY; Xu, N; Yang, P; Zhang, X | 1 |
| Bunn, PA; Hirsch, FR | 1 |
| Cadranel, J; Chao, TY; Chen, YM; Cong, XJ; Crino, L; Heo, DS; Hirsh, V; Kim, SW; Lorence, RM; Miller, VA; Park, K; Shahidi, M; Su, WC; Sun, Y; Tan, EH; Wang, M; Yang, JC; Zhou, C | 1 |
| Chang, GC; Cong, XJ; Dudek, AZ; Ho, CL; Hsia, TC; Lorence, RM; Miller, VA; Ou, SH; Sequist, LV; Shahidi, M; Shih, JY; Su, WC; Tsai, CM; Yang, JC; Yang, PC; Yu, CJ | 1 |
| Hansen, KH; Hansen, NC; Hansen, O; Kristiansen, C; Olsen, KE | 1 |
| Fujiwara, K; Hamada, N; Horita, N; Hotta, K; Kamei, H; Kiura, K; Segawa, Y; Takata, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Umemura, S; Yamane, H; Yoshioka, H | 1 |
| Schmid-Bindert, G; Wang, YH; Wang, YS; Xia, HP; Zhou, CC; Zhou, SW | 1 |
| Hirata, K; Kimura, T; Kudoh, S; Manabe, M; Mitsuoka, S; Takeda, A; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Dittmann, K; Huber, SM; Mayer, C; Misovic, M; Rodemann, HP | 1 |
| Arango, N; Bonilla, C; Cuello, J; Llinás, N; Rivas, G; Rubiano, J | 1 |
| Ikari, A; Sato, T; Sugatani, J; Watanabe, R; Yamazaki, Y | 1 |
| Aklilu, M; Bernard, SA; Blackstock, AW; Davies, JM; Goldberg, RM; Ivanova, A; O'Neil, BH; Raftery, L; Tepper, JE | 1 |
| Juergens, R; Levine, MN | 1 |
| Capelletti, M; Crawford, J; Edelman, MJ; Gu, L; Jänne, PA; Kratzke, R; Miller, VA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X | 1 |
| Gao, W; Guo, R; Shen, H; Shu, Y; Sun, J; Xu, R | 1 |
| Hamatani, Y; Kim, YH; Masago, K; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Kaneko, F; Oyama, N; Togashi, A; Yamamoto, T | 1 |
| Boehm, JS; Butaney, M; Cheung, HW; Du, J; Engelman, JA; Golub, TR; Hahn, WC; He, F; Jänne, PA; Luo, B; Meyerson, M; Root, DE; Sequist, LV; Wang, X; Weir, BA | 1 |
| Baldotto, CS; da Silveira, JS; de Lima Araújo, LH; Ferreira, CG; Zukin, M | 1 |
| Ando, M; Fukuoka, M; Johkoh, T; Kudoh, S; Nakagawa, K; Ohe, Y; Seki, A; Takemoto, S; Yamazaki, N | 1 |
| Nakamura-Wakatsuki, T; Yamamoto, T | 1 |
| Gerber, DE; Hamann, HA; Lee, SJ; Rasco, DW; Woodruff, S | 1 |
| Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N | 1 |
| Albano, T; Arnovitz, P; Burstein, D; Dhawan, NS; Difeo, A; Farrington, C; Galsky, M; Izadmehr, S; Katz, S; Mazhar, S; Melville, H; Narla, G; Ohlmeyer, M; Okrent, R; Politi, K; Rana, H; Sangodkar, J; Singh, VJ; Yuan, E; Zhang, D | 1 |
| Ahn, JS; Ahn, MJ; Hwang, IG; Jo, SJ; Kim, BS; Kim, HK; Kim, SW; Kim, YH; Lee, DH; Lee, JW; Lee, K; Lee, KH; Min, YJ; Park, K; Song, HS; Sun, JM; Yun, HJ | 1 |
| Adelstein, DJ; Ives, DI; Phillips, BE; Plesec, T; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Tubbs, RR; Videtic, GM | 1 |
| Hashimoto, K; Hayashi, Y; Horinouchi, H; Izumi, Y; Kohno, M; Nomori, H; Ohtsuka, T | 1 |
| Chen, YG; Chian, CF; Lin, CS; Shen, CH | 1 |
| Chen, J; Cui, IH; Gong, Y; Jin, Y; Tang, C; Wu, X; Xu, Z; Zhang, X; Zhang, Y | 1 |
| Keshtgarpour, M; Ma, PC; Pennell, NA; Yin, L | 1 |
| Kołodziejczyk, P; Kulig, J; Kulig, P; Legutko, J | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Ohashi, K; Takata, S; Takeda, H; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Azzoli, CG; Beumer, JH; Dowlati, A; Gadgeel, SM; Kris, MG; Krug, LM; Lynch, TJ; Miller, VA; Mitchell, B; Pietanza, MC; Price, KA; Riely, GJ; Rizvi, NA; Rowland, KM; Salgia, R; Tonda, M; Wertheim, MS | 1 |
| Brown, MP; Cheetham, G; Scott, HS; Sharma, A; Tan, TH | 1 |
| Dietlein, M; Kahraman, D; Kobe, C; Neumaier, B; Nogova, L; Scheffler, M; Thomas, R; Wolf, J; Zander, T | 1 |
| Hsu, CP; Hsu, PY; Lin, JJ; Wu, YL | 1 |
| Cheng, YP; Chiu, HY; Jee, SH; Tsai, TF | 1 |
| Bepler, G; Chen, W; Ghosh, D; Norkin, M; Raghunathan, TE; Sargent, DJ | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Ahn, JS; Ahn, MJ; Cho, SH; Choi, YL; Han, JH; Hwang, DW; Ji, JH; Lee, JY; Park, K; Park, LC; Park, S; Sun, JM | 1 |
| Han, JY; Kim, HT; Kim, SH; Lee, JS; Lee, Y; Yun, T | 1 |
| Cai, DY; Hong, TT; Hua, D; Wu, XH; Zhang, RX | 1 |
| Girard, L; Heymach, JV; Johnson, FM; Lippman, SM; Minna, JD; Peng, S; Saintigny, P; Sen, B; Wistuba, II; Zhang, L | 1 |
| Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC | 1 |
| Chen, M; Hu, P; Li, L; Nie, L; Wang, M; Xiao, Y; Zhang, L; Zhao, J; Zhong, W | 1 |
| Koma, Y; Matsuoka, H; Suzuki, Y; Yoshimatsu, H | 1 |
| Abulafia, O; Fischer, EG; Godwin, AK; Gray, H; Hanjani, P; Lankes, HA; Leslie, KK; Rose, PG; Schilder, RJ; Sill, MW; Tewari, K; Walker, JL | 1 |
| O'Reilly, EM | 1 |
| Jin, C; Li, W; Li, Y; Ren, S; Zhang, D; Zhao, Z | 1 |
| Ali, K; Kumar, I; Saeed, MU; Usman-Saeed, M | 1 |
| Gemma, A; Gemmah, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kobayashi, K; Kudoh, S; Maemondo, M; Minegishi, Y; Morikawa, N; Nukiwa, T; Oizumi, S; Okinaga, S; Tanaka, T | 1 |
| Chua, KT; Lee, CH; Liam, CK; Lim, BK; Pang, YK; Ruthranesan, M | 1 |
| Chu, DT; Duffield, E; Fukuoka, M; Han, B; Jiang, H; Liao, M; Liu, X; Mok, T; Wu, YL; Zhang, L; Zhou, C | 1 |
| Ishikawa, D; Mouri, H; Nanjo, S; Ohtsubo, K; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S | 1 |
| Arcila, ME; de Stanchina, E; Janjigian, YY; Kris, MG; Ladanyi, M; Melnick, MA; Miller, VA; Nebhan, CA; Ohashi, K; Pao, W; Pirazzoli, V; Politi, K; Riely, GJ; Song, X; Spitzler, PJ; Takezawa, K | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK | 1 |
| Barbacid, M; Guerra, C; Hernández-Porras, I; Navas, C; Schuhmacher, AJ; Sibilia, M | 1 |
| Antoine, M; Blons, H; Buisine, MP; Cadranel, J; Chetaille, B; Chouaid, C; Coudert, B; Daniel, C; Danton, G; De Fraipont, F; Faller, M; Foucher, P; Lacroix, L; Longchampt, E; Mauguen, A; Michiels, S; Morin, F; Pignon, JP; Poulot, V; Quoix, E; Solassol, J; Urban, T; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Betticher, D; Brauchli, P; Bubendorf, L; Crowe, S; Droege, C; Froesch, P; Gautschi, O; Hess, T; Mayer, M; Ochsenbein, A; Oppliger Leibundgut, E; Pless, M; Rauch, D; Ribi, K; Schmid, P; Stahel, R; von Moos, R; Zappa, F | 1 |
| Jan, IS; Liao, WY; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Beer, DG; Gotoh, N; Hatanaka, Y; Higuchi, T; Imoto, S; Kohno, T; Miyano, S; Nagasaki, M; Nakata, A; Nomura, M; Saito, A; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yokota, J; Yoshida, R | 1 |
| Hashisako, M; Ikegame, S; Kajiki, A; Kumazoe, H; Nagata, N; Wakamatsu, K | 1 |
| Blackstock, AW; Decker, RH; Gettinger, SN; Khandani, A; Lankford, S; Moore, DT; Morris, DE; Petty, WJ; Schwartz, G; Socinski, MA; Stinchcombe, TE | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Carbone, DP; Ding, K; Grigorieva, J; Roder, H; Roder, J; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Bianchi, L; Lisi, P; Minotti, V; Stingeni, L | 1 |
| Hirano, S; Hojo, M; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Kudo, K; Naka, G; Sano, K; Sugiyama, H; Takeda, Y | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M; Ricar, J | 1 |
| Bevilacqua, S; Botti, G; Caraco, C; Caronna, A; Costanzo, R; De Lutio, E; Montanino, A; Morabito, A; Normanno, N; Pasquale, R; Rocco, G; Sandomenico, C | 1 |
| Cho, YW; Choi, HW; Choi, IS; Choi, JH; Lee, HW; Lee, JY; Lee, KT; Park, JY; Rim, HK | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Abe, K; Ebina, M; Endo, C; Inoue, A; Kobayashi, M; Kondo, T; Kumamoto, H; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nukiwa, T; Sasano, H; Sato, I; Suzuki, T; Yamada-Okabe, H | 1 |
| Bhatt, A; Davison, JM; Foxwell, T; Gibson, MK; Hoppo, T; Hough, B; Jobe, BA; Komatsu, Y; Kosovec, JE; Malhotra, U; Rotoloni, CL; Sanz, AF; Zaidi, AH | 1 |
| Fang, X; Hu, Y; Li, M; Ma, S; Shen, H; Tan, C; Yuan, Y | 1 |
| Ahye, N; Azzoli, CG; Chaft, JE; D'Angelo, SP; Dycoco, J; Janjigian, YY; Kris, MG; Ladanyi, M; Riely, GJ; Rusch, V; Shen, R; Sima, CS; Zakowski, MF; Zheng, J | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Aburatani, H; Endo, S; Fukayama, M; Ishikawa, S; Kanai, Y; Kataoka, H; Matsubara, D; Murakami, Y; Niki, T; Oguni, S; Ohara, S; Sakatani, T; Tamura, T; Yoshimoto, T | 1 |
| Chiu, NT; Chung, WP; Ho, CL; Song, HL; Su, WC | 1 |
| Boursier, C; Bylicki, O; Dot, JM; Peloni, JM | 1 |
| Krug, S; Michl, P | 1 |
| Hou, B; Jiang, WR; Kong, QT; Li, B; Li, J; Liu, ZB; Shen, TZ; Wang, Y; Wang, Z; Wu, XH; Zhu, XX | 1 |
| Jeon, WI; Lee, SY; Ryu, PD | 1 |
| Baik, CS; Chow, LQ; Eaton, KD; Pritchard, CC | 1 |
| Wang, B; Wang, YN; Zhao, Q | 1 |
| Chen, Y; Sun, C; Zhang, X | 1 |
| Li, H; Li, X; Schmid-Bindert, G; Wang, D; Wang, Y; Zhou, C; Zhou, S | 1 |
| Cai, DY; Hua, D; Wu, XH; Zhang, RX | 1 |
| Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S | 1 |
| Gonzalez, D; Nicholson, AG; Nutting, CM; O'Brien, M; Popat, S; Wotherspoon, A | 1 |
| Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Kim, YT; Kim, YW; Lee, SH; Park, JH | 1 |
| Banna, GL; Bellavia, M; Borsellino, N; Ferraù, F; Gebbia, V; Russo, P; Tralongo, P | 1 |
| Chen, Y; Du, XJ; Yang, M; Yu, S; Yuan, X; Zhang, L | 1 |
| Endo, H; Higashiyama, M; Imamura, F; Inoue, M; Kondo, J; Kumagai, T; Nishizawa, Y; Okami, J; Okuyama, H; Takehara, T; Uchida, J | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Bastida, CC; Falchook, GS; Janku, F; Kurzrock, R; Stewart, DJ; Tsao, AS | 1 |
| Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N | 1 |
| Alfieri, R; Ardizzoni, A; Carmi, C; Cavazzoni, A; Dekker, H; Galvani, E; Giovannetti, E; Leon, LG; Mor, M; Peters, GJ; Petronini, PG; Saccani, F | 1 |
| Giuliani, J; Marzola, M | 1 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Barthelemy, P; Becouarn, Y; Bennouna, J; Bertheault-Cvitkovic, F; Conroy, T; Douillard, JY; Fandi, A; François, E; Gamelin, E; Nasca, S; Paillot, B; Raoul, JL; Seitz, JF; Ychou, M | 1 |
| Markó, L; Sárkány, J; Szûcs, M; Tóth, K | 1 |
| Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H | 1 |
| Diasio, R; Gutierrez, J; Kempin, S; Lowery, C; Wilson, E | 1 |
| Grunt, TW | 1 |
| Hedley, DW; Ng, SS; Nicklee, T; Tsao, MS | 1 |
| Binetti, P; La Cesa, A; Massacesi, C; Picardi, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Chung, T; Dent, P; Hagan, MP; Hinman, D; McKinstry, R; Yacoub, A | 1 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Kralidis, E | 1 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Depisch, D; Haider, K; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H; Verena Kornek, G | 1 |
| Beatrix, O; Dumortier, J; Lapalus, MG; Lombard-Bohas, C; Scoazec, JY; Villarejo, J; Vochelle, V | 1 |
| Faessel, HM; Greco, WR; Rustum, YM; Slocum, HK | 1 |
| Goto, H; Hashimoto, E; Ieki, R; Iguchi, M; Moriyama, S; Ohta, T; Okamura, T; Saitoh, E; Shibuya, M; Yuasa, K | 1 |
| Brun, Y; Greco, WR; Slocum, HK; White, DB; Wrzosek, C | 1 |
| Dainichi, T; Furue, M; Noda, K; Tanaka, M; Tsuruta, N | 1 |
| DeGrendele, H | 1 |
| Checkley, D; Kendrew, J; Tessier, JJ; Waterton, JC; Wedge, SR | 1 |
| Alloisio, M; Campagnoli, E; Cavina, R; Ferrari, B; Ginanni, V; Latteri, F; Morenghi, E; Pedicini, V; Ravasi, G; Roncalli, M; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
| Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H | 1 |
| González, A; Guerrero, J; Martínez, J; Santibañez, JF | 1 |
| Nakata, H; Ohsaki, Y; Tuji, T | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; De Vita, F; Melisi, D; Tortora, G; Troiani, T | 1 |
| Haraguchi, N; Kikuchi, N; Kodama, T; Satoh, H; Sekizawa, K | 1 |
| España, A; Fernandez-Galar, M; López-Picazo, JM | 1 |
| Ikejima, T; Onodera, S; Tashiro, S; Wu, LJ; Zhang, QH; Zhang, Y | 1 |
| Fidias, P; Gurubhagavatula, S; Jänne, PA; Johnson, BE; Lucca, J; Lynch, TJ; Ostler, P; Skarin, AT; Yeap, BY | 1 |
| Green, MR | 1 |
| Bell, DW; Brannigan, BW; Christiani, DC; Gurubhagavatula, S; Haber, DA; Haluska, FG; Harris, PL; Haserlat, SM; Louis, DN; Lynch, TJ; Okimoto, RA; Settleman, J; Sordella, R; Supko, JG | 1 |
| Boggon, TJ; Eck, MJ; Fujii, Y; Gabriel, S; Greulich, H; Herman, P; Jänne, PA; Johnson, BE; Kaye, FJ; Lee, JC; Lindeman, N; Meyerson, M; Naoki, K; Paez, JG; Sasaki, H; Sellers, WR; Tracy, S | 1 |
| Argiris, A; Mittal, N | 1 |
| Congleton, J; Harper-Wynne, C; O'Brien, M; Sumpter, K | 1 |
| Ebihara, S; Ohrui, T; Sasaki, H; Takahashi, H; Yamada, M | 1 |
| Gazdar, AF; Herz, J; Minna, JD; Sprang, SR | 1 |
| Campagnoli, E; Cavina, R; Grimaldi, GC; Latteri, F; Morenghi, E; Parra, HS; Roncalli, M; Santoro, A; Zucali, PA | 1 |
| Kodama, T; Kunitoh, H; Kusumoto, M; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Yamamoto, N; Yamamoto, S | 1 |
| Hirano, A; Kawata, N; Kimura, G; Okada, C; Shibayama, T; Soda, R; Tada, A; Takahashi, K; Takigawa, N; Yamadori, I | 1 |
| Li, LY; Mu, XL; Wang, MZ; Wang, SL; Zhang, XT | 1 |
| Doherty, J; Fulton, L; Heelan, R; Kris, M; Kupfer, D; Mardis, E; Miller, V; Pao, W; Politi, K; Rusch, V; Sarkaria, I; Singh, B; Varmus, H; Wilson, R; Zakowski, M | 1 |
| Amano, H; Hoshi, S; Kono, C; Yamada, Y; Yamaguchi, T | 1 |
| Chang, GC; Chen, CY; Hsu, SL; Liang, FP; Lin, SY; Sheu, GT; Tsai, JR | 1 |
| Bencardino, KB; Cappuzzo, F; Ceresoli, GL; Crinò, L; Ferraldeschi, M; Floriani, I; Gregorc, V; Ludovini, V; Mihaylova, Z; Pistola, L; Spreafico, A; Tofanetti, FR; Tonato, M; Torri, V; Villa, E | 1 |
| Ishida, A; Iwamoto, Y; Kanoh, K; Kohno, N; Miyazawa, T; Miyazu, Y; Nishisaka, T | 1 |
| Hansen, M; Jänne, PA; Johnson, BE; Meyerson, M; Mukohara, T; Tracy, S | 1 |
| Chang, GC; Chen, KC; Hsu, JY; Kuo, BI; Lin, CP; Yang, TY; Yin, MC | 1 |
| Goto, K; Ishii, G; Kim, YH; Kodama, T; Nagai, K; Nishiwaki, Y; Nitadori, J; Ochiai, A; Shiono, S; Tsuta, K | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T | 1 |
| Cadranel, J; Madelaine, J; Zalcman, G | 1 |
| Chang, WC; Chen, YR; Chen, YT; Fu, YN; Huang, SF; Ku, YC; Kuo, HP; Li, LH; Lin, YF; Liu, HP; Tsai, HY; Tsai, SF; Wu, YC | 1 |
| Cho, D; Halmos, B; Janne, PA; Kocher, O; Lee, JC; Meyerson, ML; Tenen, DG | 1 |
| Patel, JD | 1 |
| Baetz, T; Berry, S; Brundage, M; Canil, CM; Chi, KN; Douglas, L; Ernst, DS; Fisher, B; McKenna, A; Moore, MJ; Pollak, M; Seymour, L; Winquist, E | 1 |
| Arends, JJ; de Jong, RS; Leys, MB; Nortier, JW; Sleeboom, HP; Smit, JM; Ten Bokkel Huinink, D; Tesselaar, ME | 1 |
| Aikawa, A; Hanawa, Y; Hashizume, M; Itou, S; Katou, K; Kidokoro, T; Kimura, B; Okano, Y; Takano, T; Takaoka, K; Tokimitsu, S; Uchikado, M; Yagi, M; Yamagishi, M | 1 |
| Heelan, RT; Kris, MG; Ladanyi, M; Miller, VA; Pan, Q; Pao, W; Riely, GJ; Varmus, HE; Wang, TY; Zakowski, MF | 1 |
| Ishii, T; Masuda, M; Matsuse, T; Teramoto, S | 1 |
| Boyer, M; Clarke, S; Millward, M; Sharma, R | 1 |
| Caenepeel, P; Demols, A; Houbiers, G; Leleux, A; Peeters, M; Polus, M; Van Cutsem, E; Van Laethem, JL; Van Maele, P; Vermaut, RR; Verslype, C | 1 |
| Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T | 1 |
| Matsuo, K; Tanimoto, M; Uchida, A | 1 |
| Kris, MG; Miller, VA; Pao, W; Politi, KA; Riely, GJ; Somwar, R; Varmus, H; Zakowski, MF | 1 |
| Burdak-Rothkamm, S; Feldmann, K; Ludwig, D; Nguyen, TP; Rübe, C; Rübe, CE; Wiegel, T | 1 |
| Ahn, SJ; Baek, SM; Jeong, JY; Kim, KS; Kim, YC; Kim, YH; Kim, YI; Lim, SC; Na, KJ; Park, CM; Park, CS; Park, KO | 1 |
| Endo, K; Fujii, Y; Fukai, I; Iuchi, K; Kawaguchi, T; Kawahara, M; Konishi, A; Matsumura, A; Okumura, M; Sasaki, H; Shimizu, T; Takada, M; Takeuchi, H; Tanaka, H; Yano, M | 1 |
| Han, JY; Hong, EK; Kim, HK; Kim, HY; Lee, DH; Lee, EK; Lee, HG; Lee, JJ; Lee, JS | 1 |
| Bell, DW; Haber, DA; Louis, DN; Riemenschneider, MJ | 1 |
| Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
| Gemma, A; Kataoka, K; Kokubo, Y; Kudoh, S; Matsuda, K; Minegishi, Y; Noro, R; Okano, T; Seike, M; Shibuya, M; Yoshimura, A | 1 |
| Chang, XY; Cui, QC; Li, LY; Mu, XL; Song, W; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Cui, QC; Feng, RE; Guo, BQ; Li, LY; Mu, XL; Wang, MZ; Zhang, XT; Zhou, HS | 1 |
| Endoh, H; Kosaka, T; Mitsudomi, T; Yatabe, Y | 1 |
| Gatzemeier, U; Reck, M | 1 |
| Brattain, MG; Zhou, Y | 1 |
| Bunn, PA; Crowley, J; Franklin, WA; Gandara, DR; Gumerlock, P; Hirsch, FR; McCoy, J; Varella-Garcia, M; West, H; Xavier, AC | 1 |
| Doi, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakano, H; Soda, H | 1 |
| Cutz, JC; da Cunha Santos, G; Daneshmand, M; Ding, K; Kamel-Reid, S; Lagarde, A; Liu, N; Lorimer, I; Marrano, P; Pater, J; Richardson, F; Sakurada, A; Seymour, L; Shepherd, FA; Squire, J; Tsao, MS; Whitehead, M; Zhang, T; Zhu, CQ | 1 |
| Cheng, AL; Shen, YC; Wan, JP; Yeh, KH; Yeh, SH | 1 |
| Cortese, JF; Eliason, JF; Everson, RB; Gowda, AL; Pass, HI; Wali, A | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Chen, YF; Cohen, MH; Johnson, JR; Pazdur, R; Sridhara, R | 1 |
| Gallmeier, E; Kern, SE | 1 |
| Cantley, LC; Engelman, JA; Halmos, B; Hanna, NH; Jänne, PA; Johnson, BE; Kobayashi, S; Lindeman, N; Mukohara, T; Pearlberg, J; Tenen, DG; Tsuchihashi, Z; Yeap, BY | 1 |
| Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA | 1 |
| Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| Hsue, V; Ichinose, Y; Jablons, D; Jahan, T; Manegold, C; Massuti, B; Mate, JL; Mok, T; Moran, T; Ono, M; Queralt, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Zamora, L | 1 |
| Edakuni, N; Inayama, M; Kakiuchi, S; Muguruma, H; Nakataki, E; Nishikubo, N; Ohtsuka, S; Sone, S; Tomimoto, H; Yano, S | 1 |
| Fukui, T; Hasegawa, Y; Imaizumi, K; Kondo, M; Kume, H; Nagasaka, T; Sekido, Y; Shimokata, K; Yokoi, K; Yokoyama, T; Yoshioka, H | 1 |
| Fujikawa, T; Ito, M; Iwasaki, T; Kawamura, T; Kimura, H; Mori, M; Naka, N; Nakagawa, M; Namba, Y; Niinaka, M; Okada, T; Takeda, Y; Yamaguchi, T; Yokota, S | 1 |
| Matsumori, Y; Muguruma, H; Nakataki, E; Sone, S; Yano, S; Yoshizumi, M; Zheng, R | 1 |
| Chang, YL; Gow, CH; Shih, JY; Yu, CJ | 1 |
| Bradof, JE; Brierre, JE; Burkett, ER; Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Rubinsak, JR; Scullin, DC; Spigel, DR; Thomas, M; Yardley, DA | 1 |
| Garcia-Foncillas, J; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Moreno, M; Perez-Gracia, JL; Zubieta, JL | 1 |
| Ko, AH; Tempero, MA | 1 |
| Dobashi, K; Iijima, H; Ishizuka, T; Minna, JD; Mori, M; Nakajima, T; Otani, Y; Saito, R; Sato, K; Suga, T; Sunaga, N; Takise, A; Tanaka, S; Tomizawa, Y | 1 |
| Allen, W; Galligan, L; Johnston, PG; Longley, DB; McDermott, U; Wilson, T | 1 |
| Höpfner, M; Huether, A; Maaser, K; Scherübl, H; Sutter, AP | 1 |
| Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Maeda, T; Ogino, A; Tabata, M; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T | 1 |
| Ariyama, H; Baba, E; Harada, M; Mitsugi, K; Nakano, S; Qin, B; Tanaka, R | 1 |
| Hotta, K; Kanehiro, A; Kishino, D; Kiura, K; Nishii, K; Notohara, K; Tabata, M; Tanimoto, M; Tanimoto, Y; Ueoka, H; Umemura, S | 1 |
| Berdel, WE; Hoffknecht, P; Lange, T; Müller-Tidow, C; Serve, H; Thomas, M | 1 |
| Hirashima, T; Kawahara, K; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T | 1 |
| Kanazawa, S; Kinoshita, Y; Muramatsu, M; Nomura, S; Yamaguchi, K | 1 |
| Abe, M; Egami, H; Hirota, M; Nozawa, F; Ogawa, M; Tan, X | 1 |
| Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H | 1 |
| Bonner, JA; Clemons, LK; Dobelbower, MC; Posey, J; Raisch, KP; Russo, SM; Seay, LL; Suter, S | 1 |
| Cody, DD; Dackor, J; Fujimoto, N; Hanna, AE; Herbst, R; Iwanaga, K; Kalyankrishna, S; Kurie, JM; Massarelli, E; Minna, JD; Peyton, M; Price, RE; Sato, M; Shay, JW; Tang, X; Threadgill, DW; Wislez, M; Wistuba, II; Zhang, J | 1 |
| Benson, AB; Berlin, JD; Coffey, RJ; LaFleur, B; Levy, DE; Morgan-Meadows, SL; Ramanathan, RK; Rothenberg, ML; Washington, MK | 1 |
| Goto, H; Imao, M; Kato, T; Nakashima, M; Sano, K; Yasuda, S; Yoshimura, K | 1 |
| Choong, NW; Davies, GC; Dietrich, S; Husain, AN; Lipkowitz, S; Ma, PC; Nallasura, V; Salgia, R; Seiwert, TY; Tretiakova, MS | 1 |
| Guan, JY; Hour, TC; Hsieh, MW; Huang, CY; Lin, CC; Lin, SR; Liu, GY; Pu, YS; Wang, CW | 1 |
| Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D | 1 |
| Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S | 1 |
| Chuai, S; Kris, MG; Ladanyi, M; McDonough, T; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rusch, VW; Sarkaria, IS; Singh, B; Venkatraman, ES; Wilson, RK | 1 |
| Clements, DG; Selinger, CP | 1 |
| Abe, S; Harada, K; Inomata, S; Kanai, A; Kitajima, H; Saikai, T; Takahashi, H; Taniguchi, H | 1 |
| Al-Dayel, F; Al-Jommah, N; Al-Kuraya, K; Amr, S; Bavi, P; Ezzat, A; Guido, S; Sheikh, S; Simon, R; Siraj, AK | 1 |
| Aboagye, E; Pillai, RG; Price, P; Yau, K | 1 |
| Demlová, R; Dusek, L; Jarkovský, J; Kiss, I; Kocáková, I; Vyzula, R | 1 |
| Bartralot, R; Bodet, D; García-Patos, V; Heras, C; Mollet, J | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX | 1 |
| Altavilla, G; Rosell, R; Salazar, F; Santarpia, M; Tarón, M | 1 |
| Leow, CH; Liam, CK; Pang, YK | 1 |
| Armstrong, C; Durkin, AJ; Osborne, DA; Rosemurgy, AS; Yeatman, TJ; Zervos, EE | 1 |
| Halgunset, J; Larsson, E; Skogseth, H | 1 |
| Guo, M; Liu, S; Lu, F | 1 |
| Fukumoto, H; Kiura, K; Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Tanimoto, M | 1 |
| Al-Hashem, R; Bronson, RT; Chen, L; Chirieac, LR; Jänne, PA; Ji, H; Johnson, BE; Kim, W; Kobayashi, S; Li, D; Mahmood, U; McNamara, K; Mitchell, A; Padera, R; Shapiro, GI; Sharpless, NE; Shimamura, T; Sun, Y; Tenen, D; Weissleder, R; Wong, KK | 1 |
| Becker, JC; Domschke, W; Muller-Tidow, C; Pohle, T; Serve, H | 1 |
| Mitra, SS; Simcock, R | 1 |
| Avallone, A; Budillon, A; Cascini, LG; Comella, P; Delrio, P; Guida, C; Lastoria, S; Marone, P; Morrica, B; Parisi, V; Petrillo, A; Tatangelo, F | 1 |
| Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F | 1 |
| Laurie, SA; Licitra, L | 1 |
| Chang, JW; Cheung, YC; Chou, WC; Hsieh, JJ; Huang, SF; Liu, MY; Wang, HM; Yeh, KY | 1 |
| Bajpai, A; Mishra, AK; Mishra, P; Pandey, VK; Sharma, RK; Singh, VK; Tiwari, AK | 1 |
| Eguchi, K; Seki, N; Shibakuki, R; Uematsu, K | 1 |
| Hasegawa, Y; Hashimoto, N; Honda, T; Imaizumi, K; Kawabe, T; Nagasaka, T; Shimokata, K | 1 |
| Han, JY; Kim, HT; Lee, DH; Lee, JS | 1 |
| Charoentum, C | 1 |
| Endo, K; Fujii, Y; Haneda, H; Kawano, O; Kobayashi, Y; Sasaki, H; Suzuki, E; Yano, M; Yukiue, H | 1 |
| Hirsch, FR | 1 |
| Chang, WC; Chang, YH; Chen, HC; Chen, YT; Fang, YF; Hsi, BL; Hsieh, MH; Huang, SF; Ku, YC; Kuo, HP; Lin, SY; Liu, CL; Liu, HP; Tsai, SF | 1 |
| Ajani, J; Albert, D; Anthoney, A; Chick, J; Drolet, DW; Eatock, M; Falk, S; Ferry, D; Glen, H; Valle, JW; Van Cutsem, E | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kitahara, N; Kobayashi, Y; Matsumura, A; Okumura, M; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yukiue, H | 1 |
| Nieder, C | 1 |
| Funk, G; Kornek, GV; Oehler, L; Scheithauer, W; Schwarz, C; Urbauer, E; Wenzel, C | 1 |
| Garfield, DH | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Oh, DY | 1 |
| Asada, K; Chida, K; Hasegawa, H; Naito, T; Suda, T | 1 |
| Chang, GC; Chen, KC; Gow, CH; Hsu, C; Lin, CP; Shih, JY; Su, WP; Yang, CH; Yang, PC; Yang, TY; Yu, CJ | 1 |
| Chen, YM; Chiu, CH; Lin, WC; Liou, JL; Perng, RP; Tsai, CM | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Ennishi, D; Hatake, K; Hino, N; Senoo, T; Sezaki, N; Terui, Y | 1 |
| Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX | 1 |
| Asahina, H; Dosaka-Akita, H; Kinoshita, I; Nishimura, M; Yamazaki, K; Yokouchi, H | 1 |
| Heelan, RT; Kris, MG; Miller, VA; Milton, DT; Pao, W; Riely, GJ | 1 |
| Gaya, A; Khorshid, M; Plowman, PN; Walther, JC | 1 |
| Kagohashi, K; Ohtsuka, M; Satoh, H | 1 |
| Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N | 1 |
| Fujiwara, Y; Kasahara, K; Kimura, H; Kunitoh, H; Nishio, K; Sone, T; Tamura, T | 1 |
| Balak, MN; Chiang, A; Gong, Y; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Ouerfelli, O; Pao, W; Riely, GJ; Somwar, R; Yang, G; Zakowski, MF | 1 |
| Balko, JM; Black, EP; Haura, EB; Potti, A; Saunders, C; Stromberg, A | 1 |
| Pujol, JL | 1 |
| Honmura, Y; Komagata, H; Kurimoto, F; Sakai, H; Sudo, J; Yoneda, S | 1 |
| Dragovich, T; Hage, G; Hamilton, M; Huberman, M; Nadler, P; Patnaik, A; Rowinsky, EK; Von Hoff, DD; Wolf, J; Wood, D | 1 |
| Chang, A; Zhang, X | 1 |
| Guan, ZZ; Pan, ZK; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Han, Y; Li, YM; Paradiso, A; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Pühringer-Oppermann, FA; Sarbia, M; Stein, HJ | 1 |
| Ramanarayanan, J; Scarpace, SL | 1 |
| Abe, T; Haraguchi, M; Hayashi, M; Ito, K; Tsutsui, N | 1 |
| Hirano, S; Kitao, H; Kiura, K; Ogino, A; Rai, K; Tabata, M; Takata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Uchida, A | 1 |
| Fujii, K; Gemma, A; Hirohashi, S; Kato, H; Kondo, T; Kudoh, S; Matsuno, Y; Nishimura, T; Ohe, Y; Okano, T; Takano, T; Tsuta, K | 1 |
| Curigliano, G; de Braud, F; De Cobelli, O; De Pas, T; Manzotti, M; Pelosi, G; Renne, G; Spitaleri, G | 1 |
| Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Komaki, R; Langley, RR; O'Reilly, MS; Onn, A; Ryan, AJ; Shibuya, K; Shitani, T; Wu, W | 1 |
| Altiok, S; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Mezzadra, H; Nielsen, ME; Rubio-Viqueira, B; Zhang, X | 1 |
| Ashitani, J; Imai, K; Kodama, T; Kyoraku, Y; Matsumoto, N; Nakazato, M; Sano, A; Yanagi, S | 1 |
| Aoe, M; Date, H; Ichihara, S; Ito, S; Kiura, K; Kobayashi, N; Sano, Y; Soh, J; Suehisa, H; Toyooka, S; Yamane, M | 1 |
| Abbas, M; Aupérin, A; Bedenne, L; Borget, I; Bouché, O; Cassan, P; Clavero-Fabri, MC; Ducreux, M; Mousseau, M; Nasca, S; Pignon, JP; Queuniet, AM; Raoul, JL; Stremsdoerfer, N | 1 |
| Chen, YM; Chou, TY; Liu, JM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Aoki, H; Iijima, H; Imai, H; Ishihara, S; Iwasaki, Y; Mori, M; Saito, R; Sunaga, N; Tomizawa, Y; Watanabe, S | 1 |
| Albert, D; Brock, K; Chick, J; Ciuleanu, T; Diculescu, M; Herrmann, T; Hoepffner, NM; Philip, PA; Roth, A; Sailer, V; Trojan, J; Zalupski, M | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kulke, MH; Loda, M; Meyerhardt, JA; Ogino, S; Ryan, DP; Wolpin, BM | 1 |
| Cho, BK; Choi, HJ; Kim, SY; Lee, JY; Park, HJ | 1 |
| Fujimura, M; Ichikawa, Y; Ishiura, Y; Kasahara, K; Kashii, T; Kimura, H; Kita, T; Kobayashi, M; Kunitoh, H; Mizuguchi, M; Nakao, S; Nakatsumi, Y; Nishio, K; Shiarasaki, H; Shibata, K; Sone, T; Tamura, T; Waseda, Y; Watanabe, K; Yoshimoto, A | 1 |
| Furuyashiki, G; Goya, T; Koshiishi, Y; Matsushima, S; Nogami, H; Ohnishi, H; Ohtsuka, K; Ooide, A; Watanabe, T | 1 |
| Han, JY; Hong, EK; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Nam, BH; Yu, SY | 1 |
| Aburatani, H; Fukayama, M; Goto, A; Ishikawa, S; Morikawa, T; Nakajima, J; Nakamura, Y; Niki, T; Ohara, E; Ota, S; Wang, T | 1 |
| Chen, XQ; Rong, TH; Wei, WD; Wen, ZS; Wu, HY | 1 |
| Sugio, K; Uramoto, H; Yasumoto, K | 1 |
| Li, YL; Li, Z; Wang, ZM; Wei, Z; Wu, C; Zhang, TX | 1 |
| Kohno, H; Maehara, Y; Mori, D; Shoji, F; Yamasaki, F; Yano, T; Yoshino, I | 1 |
| Au, HJ; Campos, D; Clark, G; Ding, K; Figer, A; Gallinger, S; Goldstein, D; Hamm, J; Hecht, JR; Lim, R; Moore, MJ; Murawa, P; Parulekar, W; Ptasynski, M; Voskoglou-Nomikos, T; Walde, D; Wolff, RA | 1 |
| Fischer, JR; Geiger, D; Haffner, UJ; Lahm, H | 1 |
| Esmaili, A; Vahid, B | 1 |
| Battu, S; Bhargava, P; Blaszkowsky, L; Earle, CC; Enzinger, P; Fuchs, CS; Lawrence, C; Mayer, RJ; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX | 1 |
| Hanibuchi, M; Sone, S; Tomimoto, H; Yano, S | 1 |
| Bragg, J; Pomeranz, MK | 1 |
| Date, H; Kiura, K; Takata, M; Toyooka, S; Uchida, A | 1 |
| Bashar, AH; Funai, K; Kazui, T; Mori, H; Sugimura, H; Suzuki, K; Takamochi, K | 1 |
| Eguchi, K; Hisamoto, A; Kiura, K; Kozuki, T; Mandai, K; Nakata, M; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Allan, G; Campbell, MJ; Goldfine, ID; Hodges, L; Kerner, JA; Kushner, P; Maddux, BA; Shiry, L; Youngren, JF; Zavodovskaya, M | 1 |
| Han, Y; Li, YM; Liu, XQ; Song, ST; Xu, JM; Yang, WW; Zhang, Y | 1 |
| Azzoli, CG; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Pizzo, B; Riely, GJ; Rizvi, NA | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Agus, DB; Castellanos, O; Green, E; Gross, M; Higano, C; Nguyen, K; Pantuck, A | 1 |
| Fukui, T; Mitsudomi, T | 2 |
| Hirano, S; Ishiai, M; Kitao, H; Kiura, K; Kozuki, T; Ogino, A; Takata, M; Takigawa, N; Tanimoto, M; Uchida, A | 1 |
| Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C | 1 |
| Abe, S; Chiba, H; Hasegawa, T; Igarashi, Y; Inokuchi, J; Iseki, K; Ishii, A; Kabayama, K; Kaneko, M; Noguchi, M; Saitoh, M; Satoh, M; Shiratori, M; Suzuki, T; Tagami, S; Takahashi, H; Watanabe, A | 1 |
| Hao, HJ; Li, Q; Li, XH; Zhao, YL | 1 |
| Duan, HQ; Han, Y; Liu, XQ; Song, ST; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Boeck, S; Heinemann, V; Wollenberg, A | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK | 1 |
| Almaraz-Pro, C; Colás, B; Colomer, R; Cortés, MA; López-Ruiz, P; Martín-Orozco, RM; Rodríguez-Ubreva, FJ; Ropero, S | 1 |
| Anderson, M; Atherfold, P; Beddard, K; Ferry, DR; Harrison, R; Jankowski, J; Obszynska, J; Tomlinson, S | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Baker, CH; Bekele, N; Fidler, IJ; Herbst, RS; Langley, RR; O'Reilly, MS; Onn, A; Tang, XM; Tsan, RZ; Wu, W | 1 |
| Barbera, F; Bellavita, R; Coco, C; Cosimelli, M; Gambacorta, MA; Genovesi, D; La Torre, G; Lupattelli, M; Maranzano, E; Maurizi-Enrici, R; Minsky, BD; Morganti, AG; Portaluri, M; Trodella, L; Valentini, V | 1 |
| Boelke, E; Budach, W; Enderlein, E; Gerber, PA; Homey, B; Muller, A | 1 |
| Balak, M; Chmielecki, J; Gong, Y; Jiang, X; Pao, W; Politi, K; Somwar, R | 1 |
| Hanaoka, T; Hayano, T; Okada, M; Sone, S; Yamaguchi, S | 1 |
| Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Fekrazad, MH; Jones, DV; Ravindranathan, M | 1 |
| Carrasco, AT; Chaigneau, L; Extra, JM; Fabbro, M; Floquet, A; Gladieff, L; Goncalves, A; Lhommé, C; Viens, P | 1 |
| Gemma, A; Kudoh, S; Matsuda, K; Minegishi, Y; Nara, M; Noro, R; Okano, T; Shibuya, M; Takemura, A; Yoshimura, A | 1 |
| Beale, P; Brennscheidt, U; Bugat, R; Clarke, S; Delord, JP; Fettner, SH; Feyereislova, A; Rakhit, A; Van Cutsem, E; Verslype, C | 1 |
| Okagawa, T; Suyama, M; Uchida, T | 1 |
| Ardizzoni, A; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Crocicchio, F; Labianca, R; Mari, E; Pucci, F; Salvagni, S; Scartozzi, M; Sobrero, A; Tagliaferri, P | 1 |
| Ge, FJ; Luo, WD; Wang, Y; Xu, JM; Yuan, SJ; Zhao, CH | 1 |
| Bell, DW; Brannigan, BW; Morabito, A; Moscato, M; Normanno, N; Zampa, G | 1 |
| Balak, M; Bean, J; Brennan, C; Broderick, S; Chang, WC; Chitale, D; Gazdar, A; Gerald, W; Huang, SF; Ladanyi, M; Miller, V; Motoi, N; Pao, W; Pass, H; Riely, G; Rusch, V; Shih, JY; Szoke, J; Viale, A; Wang, L; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Arai, Y; Kojima, A | 1 |
| Hida, T; Mitsudomi, T; Sugiura, H; Sugiura, T; Yamada, K | 1 |
| Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ | 1 |
| Fang, Z; Li, B; Xia, TB; Xiu, QY; Zang, YS | 1 |
| Johnson, JR; Justice, R; Pazdur, R; Senderowicz, AM; Sridhara, R; Zimmerman, P | 1 |
| Almasi, A; Conte, P; Dominici, M; Eckhardt, S; Jori, B; Kanya, M; Keri, G; Kopper, L; Moldvay, J; Papay, J; Petak, I; Pinter, F; Sapi, Z; Schwab, R; Szabo, E; Szondy, K; Tamasi, A; Varkondi, E | 1 |
| Akamine, S; Akizuki, S; Hijiya, N; Kadota, J; Kawahara, K; Matsuura, K; Miyawaki, M; Moriyama, M; Tsuji, K; Tsukamoto, Y; Uchida, T | 1 |
| Aoe, K; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Kiura, K; Kosaka, T; Matsuo, K; Mitsudomi, T; Ohe, Y; Otani, H; Soh, J; Takano, T; Toyooka, S; Yatabe, Y | 1 |
| Epstein, RJ; Leung, TW | 1 |
| Chang, JW; Chen, YH; Chen, YR; Chen, YT; Chiu, YT; Fang, YF; Hsi, BL; Hsieh, JJ; Hsieh, MH; Hsieh, MS; Hsu, HY; Huang, SF; Liu, HP; Tsai, HY; Tsai, SF | 1 |
| Biffi, R; Chiappa, A; de Braud, F; Dell'Orto, P; Fazio, N; Magni, E; Monfardini, L; Santoro, L; Sonzogni, A; Zampino, MG; Zorzino, L | 1 |
| Carbone, DP; Heelan, RT; Heller, G; Herbst, RS; Johnson, DH; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Patel, JD; Riely, GJ; Sandler, AB; Tsao, A; Zakowski, MF | 1 |
| Barutca, S; Bolaman, Z; Kadikoylu, G; Meydan, N; Yavasoglu, I | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
| Agarwala, A; Breen, T; Bruetman, D; Einhorn, LH; Fisher, W; Hanna, N; Juliar, B; McClean, J; Taber, D; Titzer, M; Yu, M | 1 |
| Advani, S; Aggarwal, S; Babu, G; Bhattacharyya, GS; Chacko, RT; Chang, AY; Digumarti, R; Doval, DC; Hargreaves, L; Jagannathan, R; Nag, S; Parikh, P; Ranade, A; Thatcher, N | 1 |
| Eguchi, K; Fukuoka, M; Jiang, H; Kiura, K; Nakagawa, K; Nishio, K; Ohe, Y; Saijo, N; Seto, T; Shinkai, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Shih, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Chua, YJ; Zalcberg, JR | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
| Saif, MW | 1 |
| Perng, RP; Su, HT; Tsai, CM | 1 |
| Iwasaki, T; Kimura, H; Kitada, S; Maekura, R; Mori, M; Naka, N; Nakagawa, M; Nakazawa, Y; Namba, Y; Niinaka, M; Okada, T; Yano, Y; Yokota, S | 1 |
| Piechocki, MP | 1 |
| Fukuhara, T; Inoue, A; Kanamori, M; Morikawa, N; Nakashima, I; Nukiwa, T; Saijo, Y; Sakakibara, T | 1 |
| Cadranel, J; de Prost, N; Lavolé, A; Taillade, L; Wislez, M | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
| Cruz Hernández, JJ; Delgado Fernández, C; Mezquita Pérez, L; Navarro Martín, M; Rodríguez Sánchez, C | 1 |
| Engelman, JA; Evans, TL; Goldberg, JS; Grunberg, SM; Haber, DA; Han, M; Iafrate, AJ; Jänne, PA; Johnson, BE; Joshi, VA; Kuhlmann, GL; Lynch, TJ; Martins, RG; McCollum, D; Muzikansky, A; Sequist, LV; Settleman, J; Spigel, D; Spira, A | 1 |
| Bagattini, S; Bladou, F; Brunelle, S; Esterni, B; Gonçalves, A; Gravis, G; Marcy, M; Salem, N; Viens, P; Walz, J | 1 |
| Black, JD; Iyer, RV; Javle, MM; Levea, CM; Maddipatla, S; Nwogu, CE; Pande, AU; Rani, A; Yang, GY | 1 |
| Cai, H; Duan, W; Fu, L; Jiang, H; Li, L; Mei, C; Wang, L; Xiong, X | 1 |
| Atassi, G; Brassinne, C; Coune, A; Frühling, J; Ghanem, G; Hildebrand, J; Laduron, C; Ruysschaert, JM; Sculier, JP; Stryckmans, P | 1 |
| Bertino, JR; Cardenas, RM; Fernandes, DJ; Hynes, JB | 1 |
| Harmon, SJ; Hynes, JB; McGill, JE; Washtien, WL; Yang, YC | 1 |
| Bertino, JR; Fernandes, DJ; Hynes, JB | 1 |
| Allegra, CJ | 1 |
| Dev, IK; Dickerson, SH; Duch, DS; Ferone, R; Pendergast, W; Smith, GK | 1 |
| Dev, IK; Dickerson, SH; Duch, DS; Ferone, R; Hall, WR; Humphreys, J; Johnson, JV; Kelly, JM; Pendergast, W; Wilson, DC | 1 |
| Appelt, K; Bacquet, RJ; Bartlett, CA; Booth, CL; Herrmann, SM; Howland, EF; Janson, CA; Jones, TR; Kathardekar, V; Lewis, KK; Marzoni, GP; Matthews, DA; Moomaw, EW; Morse, CA; Palmer, CL; Smith, WW; Varney, MD; Villafranca, JE; Ward, RW; Webber, S; Webber, SE; Welsh, KM; White, J | 1 |
| Arredondo, MA; Matsui, SI; Rustum, YM; Wrzosek, C | 1 |
| Douglass, HO; Kelsen, DP; Meropol, NJ; Pazdur, R; Vincent, M; Willson, JK | 1 |
| Cunningham, D; Harper, P; Kerr, D; Oliver, I; Perez-Manga, G; Rath, U; Seitz, JF; Svensson, C; van Cutsem, E; Zalcberg, JR | 1 |
| Böhmer, FD; Fernández, LE; Greiser, U; Lage, A; Perez, R; Sánchez, B; Suarez Pestana, E | 1 |
| Azizkhan, J; Frank, C; Pajovic, S; Panadero, A; Rustum, YM; Vanhoefer, U; Voigt, W; Yin, MB | 1 |
| Horowitz, RW; Ladner, RD; Schwartz, EL; Wadler, S; Zhang, H | 1 |
| Bertino, JR; Chang, YM; Chou, TC; Gorlick, R; Izzo, J; Longo, GS; Tong, WP; Zielinski, Z | 1 |
| Bauer, B; Benter, T; Daniel, PT; Dietz, R; Dörken, B; Friedrich, M; Köhne, CH; Kretzschmar, A; Thuss-Patience, P | 1 |
| Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G | 1 |
| Albanell, J; Baselga, J; Bos, M; Fry, DW; Kim, YM; Mendelsohn, J | 1 |
| Allal, C; Asslan, R; Favre, G; Le Gaillard, F; Pradines, A; Pratx, C | 1 |
| Greenberg, NM; Kassis, J; Kim, HG; Lo, H; Moellinger, J; Wells, A | 1 |
| Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR | 1 |
| Cunningham, D; Norman, A; Parikh, B; Popescu, RA; Ross, PJ | 1 |
| Anthony, DA; Eatock, MM; El-Abassi, M; Evans, TR; Paul, J; Smith, M; Soukop, M; Wilson, P | 1 |
| Aherne, GW; Benepal, TS; Cunningham, D; Ford, HE; Gruia, G; Massey, A; Price, T; Rao, S; Ross, PJ; Vernillet, L | 1 |
| Ghosh, S; Liu, XP; Myers, DE; Sudbeck, EA; Uckun, FM; Zheng, Y | 1 |
| Artigue, F; Buffet, C; Cassan, P; Flamenbaum, M; Garcia, V; Kemeny, JL | 1 |
| Ganser, A; Reinke, F; Schlichting, C; Schöffski, P; van Gennip, AH; van Kuilenburg, AB; Volk, J | 1 |
| Matsubara, T; Ogasawara, M; Suzuki, H | 1 |
| Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P | 1 |
| Cellini, N; De Santis, M; Doglietto, GB; Morganti, AG; Ratto, C; Smaniotto, D; Sofo, L; Turriziani, A; Valentini, V | 1 |
| Evans, TR; Fullarton, GM; Garcia-Vargas, J; Harris, AL; Lofts, FJ; Mackay, HJ; McDonald, AC; McInnes, A; Paul, J; Raby, N; Soukop, M | 1 |
| Brugger, S; Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M | 1 |
| Barak, V; Eshhar, Z; Gavish, Z; Nagler, A; Pines, M; Pinthus, JH; Ramon, J | 1 |
| Assender, J; Barrow, D; Dewhurst, OL; Dutkowski, CM; Glynne-Jones, E; Goddard, L; Harper, ME; Nicholson, RI; Wakeling, AE | 1 |
| Angelopoulou, A; Fotia, M; Kontos, A; Kosmas, C; Koufos, Ch; Sougioultzis, S; Soulla, M; Tsavaris, N; Vadiaka, M; Vrizidis, N | 1 |
| Aschele, C; Bertino, JR; Nicolin, A; Rosso, R; Sobrero, A | 1 |
| Adkins, DA; Houghton, JA; Houghton, PJ; Rahman, A | 1 |
| Carlson, RW; Doroshow, JH; Flam, MS; Lamborn, KR; Malec, M; Odujinrin, OO | 1 |
| Bertino, JR; McGuire, JJ; Sobrero, AF | 1 |
| Bertino, JR; Nicolin, A; Romanini, A; Rosso, R; Russello, O; Sobrero, A | 1 |
| Bissery, MC; Corbett, TH; Luk, GD; Mucci-LoRusso, P; Plowman, J; Polin, L; Valeriote, F | 1 |
| Bertino, JR; Sobrero, AF | 1 |
| Cassidy, C; Chou, TC; Fanucchi, MP; Fleisher, M; Lokos, G; Niedzwiecki, D; Vidal, P; Walsh, TD; Williams, L; Young, CW | 1 |
| Bertino, JR; McGuire, JJ; Rodenhuis, S; Sawicki, WL | 1 |
| Bertino, JR; Handschumacher, RE; Sobrero, AF | 1 |
| Cantwell, BM; Harris, AL | 1 |
| Atassi, G; Dykes, DJ; Harrison, SD; Kabbe, HJ; Narayanan, VL; Paull, KD; Plowman, J; Yoder, OC | 1 |
| Atassi, G; Dumont, P; Kabbe, HJ; Yoder, O | 1 |
| Hynes, JB; Kumar, A; Tomazic, A; Washtien, WL | 1 |
| Modest, EJ; Rosowsky, A | 1 |
63 review(s) available for quinazolines and Adenocarcinoma
| Article | Year |
|---|---|
Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature review.
Topics: Adenocarcinoma; Benzofurans; Colonic Neoplasms; Humans; Intestine, Small; Male; Middle Aged; Palliative Care; Quinazolines | 2020 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines | 2017 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
[Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Disease Progression; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Quinazolines; Radiography; Spinal Cord Neoplasms | 2013 |
How and when to use genetic markers for nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Brain Neoplasms; Chemoradiotherapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single Nucleotide; Quinazolines | 2013 |
Epidermal growth factor receptor mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2014 |
[Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Stomatitis | 2014 |
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Eyelid Diseases; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2015 |
[Systemic treatment of brain metastases from breast cancer].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Genes, erbB-2; Humans; Lapatinib; Medicine; Molecular Targeted Therapy; Patient Care Team; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autopsy; Critical Care; Diagnosis, Differential; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed | 2015 |
Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Humans; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4 | 2015 |
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
[Case of bilateral pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple pulmonary metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Pneumothorax; Quinazolines | 2008 |
The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Double-Blind Method; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Topics: Acute Disease; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Review Literature as Topic; Treatment Outcome | 2011 |
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Rectal Neoplasms; Treatment Failure | 2010 |
The molecular pathology of cancer.
Topics: Adenocarcinoma; Base Sequence; Breast Neoplasms; Female; Gefitinib; Genes, ras; Genome-Wide Association Study; Humans; Male; Mutation; Neoplasms; Nervous System Neoplasms; Pathology, Molecular; Quinazolines; Signal Transduction | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
Topics: Adenocarcinoma; Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Time Factors | 2010 |
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Targeted therapy: an evolving world of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
[A simple view on lung cancer biology: The EGFR pathway].
Topics: Adenocarcinoma; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Esophageal Neoplasms; Humans; Lapatinib; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines | 2012 |
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
Targeted therapy for gastric cancer--current status.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drugs, Investigational; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2013 |
Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Adjuvant therapy for pancreas adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2013 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2003 |
[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Topics: Adenocarcinoma; Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Quinazolines | 2004 |
Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Translational research on lung cancer--EGFR gene mutation].
Topics: Adenocarcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion; Smoking; Transcription, Genetic | 2005 |
Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Radiography | 2005 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines | 2005 |
From the bench to the bed: individualizing treatment in non-small-cell lung cancer.
Topics: 14-3-3 Proteins; Adenocarcinoma; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; DNA Damage; DNA Repair; Epistasis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Genes, BRCA1; Genes, cdc; Genes, erbB-1; Genes, ras; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines | 2006 |
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms; Trastuzumab | 2006 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
[Is it possible to treat bronchial carcinoma without chemotherapy?].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Neoadjuvant Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Smoking | 2006 |
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Ethnicity; Exons; Female; Gefitinib; Genes, erbB-1; Genes, p53; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Mutagenesis, Insertional; Mutation; Mutation, Missense; Protein Structure, Tertiary; Quinazolines; Randomized Controlled Trials as Topic; Sequence Deletion; Smoking | 2007 |
[Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Smoking | 2007 |
[Gefitinib and epidermal growth factor receptor gene mutation].
Topics: Adenocarcinoma; Antineoplastic Agents; Enzyme Inhibitors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Respiratory Distress Syndrome; Smoking | 2007 |
Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.
Topics: Adenocarcinoma; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Incidence; Lung Diseases, Interstitial; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Liver; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
Epidermal growth factor receptor-directed therapy in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Humans; Incidence; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
Tyrosine kinase inhibitors against EGF receptor-positive malignancies.
Topics: Adenocarcinoma; Amides; Aniline Compounds; Animals; Antineoplastic Agents; Breast Neoplasms; Drug Design; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Genistein; Humans; Leukemia; Macaca fascicularis; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Molecular; Molecular Structure; Neoplasm Proteins; Neoplasms; Nitriles; Protein Conformation; Protein Structure, Tertiary; Quinazolines; Recombinant Fusion Proteins; Sequence Alignment; Species Specificity; Structure-Activity Relationship; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2001 |
Synthesis and biological activity of tricyclic antifolate compounds with fixed geometry.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Chickens; Enterococcus faecalis; Folic Acid Antagonists; Humans; Leukemia L1210; Liver; Malaria; Mammary Neoplasms, Experimental; Mice; Mouth Neoplasms; Pyrimethamine; Quinazolines; Structure-Activity Relationship | 1971 |
249 trial(s) available for quinazolines and Adenocarcinoma
| Article | Year |
|---|---|
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Point Mutation; Quinazolines | 2017 |
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Tandem Mass Spectrometry | 2013 |
N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.
Topics: Adenocarcinoma; Adult; Aged; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Up-Regulation | 2013 |
Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Treatment Outcome | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pemetrexed; Quinazolines | 2013 |
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Treatment Outcome | 2013 |
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Prospective Studies; Quinazolines; Thoracic Duct | 2013 |
Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2013 |
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2014 |
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
Topics: Adenocarcinoma; Adult; Aged; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Survival Rate | 2014 |
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Preoperative Care; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms | 2014 |
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Treatment Outcome | 2014 |
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; Early Detection of Cancer; ErbB Receptors; Gefitinib; Histological Techniques; Humans; Lung Neoplasms; Mutation; Precision Medicine; Quinazolines; Treatment Outcome; Tumor Burden | 2014 |
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Treatment Outcome | 2014 |
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2014 |
A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antimetabolites, Antineoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Glutamates; Guanine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2014 |
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Quinazolinones; Treatment Failure | 2014 |
Phase II study of gefitinib in patients with advanced salivary gland cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Treatment Outcome; Vorinostat | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2011 |
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphopenia; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Quinazolines; Radiography; Severity of Illness Index; Survival Analysis; Tumor Burden | 2014 |
SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis; Quinazolines; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Treatment Outcome | 2014 |
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate | 2014 |
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment | 2014 |
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome | 2014 |
Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.
Topics: Adenocarcinoma; Afatinib; Disease-Free Survival; Health Status; Humans; Longitudinal Studies; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2014 |
A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cecal Neoplasms; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2014 |
Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis | 2014 |
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome | 2014 |
Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Survival Rate; Treatment Outcome; Vorinostat | 2015 |
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Retrospective Studies; Tegafur; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Survival Rate | 2015 |
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Thymidine Phosphorylase; Treatment Outcome | 2015 |
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2015 |
Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tamoxifen | 2015 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate | 2015 |
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; International Cooperation; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Benzodioxoles; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Vascular Endothelial Growth Factor A | 2015 |
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Quinazolines | 2015 |
QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Quality of Life; Quinazolines; Treatment Outcome; Young Adult | 2015 |
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Erysipelas; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2015 |
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Gefitinib; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Neutropenia; Patient Dropouts; Quinazolines; Taxoids | 2015 |
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Lapatinib; Male; MAP Kinase Signaling System; Middle Aged; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms | 2015 |
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Gene Amplification; Humans; Lapatinib; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult | 2016 |
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Rand
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Female; Gefitinib; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Smoking; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult | 2016 |
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorouracil; Humans; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Piperidines; Quinazolines; Treatment Outcome | 2017 |
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Disease-Free Survival; Female; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2016 |
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment | 2017 |
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2016 |
Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; Female; Gefitinib; Humans; Least-Squares Analysis; Lung Neoplasms; Male; Mass Spectrometry; Metabolomics; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea | 2016 |
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome; Tumor Burden | 2017 |
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome; Young Adult | 2017 |
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines | 2017 |
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2017 |
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Endometrial Neoplasms; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2008 |
Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Gefitinib; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prednisone; Prognosis; Prostatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Genes, ras; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Analysis | 2008 |
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Health Surveys; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2008 |
Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Germany; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2008 |
A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2009 |
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to the
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; DNA Mutational Analysis; Female; Gefitinib; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy, Conformal; ras Proteins; Survival Rate | 2009 |
Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Topics: Activities of Daily Living; Adenocarcinoma; Administration, Oral; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Failure | 2009 |
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzodioxoles; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Humans; Lymphopenia; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2009 |
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2009 |
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2009 |
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult | 2009 |
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; Combined Modality Therapy; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Tomography, Emission-Computed; Treatment Outcome; Ultrasonography | 2010 |
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (W
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Rate; Treatment Outcome | 2010 |
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gefitinib; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines | 2010 |
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival; Treatment Outcome | 2011 |
[Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Young Adult | 2010 |
[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Treatment Outcome | 2011 |
[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Smoking; Survival Rate | 2010 |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Topics: Adenocarcinoma; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome | 2010 |
Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Treatment Outcome | 2010 |
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Phosphorylation; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases | 2010 |
Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Cohort Studies; ErbB Receptors; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Sirolimus; Survival Rate; Treatment Outcome | 2010 |
Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Sex Factors; Smoking; Tumor Stem Cell Assay | 2010 |
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Adenosquamous; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Heart Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Male; Middle Aged; Piperazines; Prostatic Neoplasms; Quinazolines; Receptors, Platelet-Derived Growth Factor; Survival Rate | 2011 |
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Castration; ErbB Receptors; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Rate | 2013 |
Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Benzodioxoles; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Stomach Neoplasms | 2012 |
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2011 |
A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Taiwan; Tegafur; Treatment Failure; Uracil | 2011 |
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Mutation; Quinazolines; Retreatment | 2011 |
Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Demography; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Radiography; Radionuclide Imaging; Smoking; Time Factors; Treatment Outcome | 2011 |
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose-escalation study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Quinazolines; Rectal Neoplasms; Thiophenes; Treatment Outcome | 2012 |
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Neoplasm Proteins; Quinazolines; Receptor, IGF Type 1; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2011 |
[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2011 |
Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell-Free System; DNA; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Smoking; Treatment Outcome | 2011 |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Smoking; Treatment Outcome | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetuximab; Cost-Benefit Analysis; ErbB Receptors; Gefitinib; Genetic Testing; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Pharmacogenetics; Quality-Adjusted Life Years; Quinazolines; Singapore; Treatment Outcome | 2012 |
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Protein Kinase Inhibitors; Quinazolines | 2011 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2011 |
Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Radiotherapy; Radiotherapy, Adjuvant; Rectal Neoplasms; Thiophenes | 2011 |
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Piperidines; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate | 2012 |
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines | 2012 |
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Sequence Deletion; Treatment Outcome | 2012 |
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Pneumonia; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Failure | 2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
Topics: Adenocarcinoma; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2013 |
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Smoking | 2012 |
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cohort Studies; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2013 |
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Rate; Tissue Distribution | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Early Detection of Cancer; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; DNA Mutational Analysis; Drug Administration Schedule; Endometrial Neoplasms; Female; Genes, erbB-1; Genetic Markers; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2012 |
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Quality of Life; Quinazolines | 2012 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; ras Proteins; Treatment Outcome | 2012 |
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Esophagitis; Esophagus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy, Conformal; Remission Induction; Tracheoesophageal Fistula; Treatment Failure | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate | 2012 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
[Therapeutic effect of erlotinib in elderly patients with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2012 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Quinazolines; Tegafur | 2013 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pyridines; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2002 |
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Thiophenes; Treatment Outcome; Vomiting | 2003 |
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Time Factors; Treatment Outcome | 2003 |
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Epidermal Growth Factor; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Survival Analysis | 2004 |
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis | 2004 |
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Topics: Acne Vulgaris; Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Remission Induction; Stomatitis; Treatment Outcome | 2004 |
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2005 |
A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Survival Rate; Thiophenes | 2005 |
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2004 |
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin Diseases; Smoking; Survival Analysis; Treatment Outcome | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gefitinib; Health Status; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Function Tests; Retrospective Studies; Sex Factors; Survival Analysis; Treatment Outcome | 2005 |
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
FDA drug approval summary: erlotinib (Tarceva) tablets.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Psychomotor Performance; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis | 2005 |
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Rectal Neoplasms | 2006 |
Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis | 2006 |
Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Digestive System Surgical Procedures; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Quinazolines; Thiophenes | 2006 |
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Thiophenes | 2006 |
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Glutarates; Humans; Isoindoles; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2006 |
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Quinazolines; Survival Analysis | 2006 |
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Male; Mutation; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2007 |
Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost of Illness; Cost-Benefit Analysis; Disease-Free Survival; Female; Fluorouracil; France; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2006 |
Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Polymerase Chain Reaction; Quinazolines; Vinblastine; Vinorelbine | 2007 |
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Female; Fluorouracil; Glutarates; Humans; Isoindoles; Leucovorin; Male; Middle Aged; Quinazolines; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2007 |
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines | 2006 |
The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Korea; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Quality of Life; Quinazolines; Risk Assessment; Single-Blind Method; Smoking; Survival Rate; Treatment Outcome | 2006 |
[Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quality of Life; Quinazolines; Remission Induction | 2007 |
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Quinazolines; Survival Analysis | 2007 |
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Quinazolines | 2007 |
[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease Progression; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Sex Factors; Treatment Outcome | 2007 |
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Survival Rate; United States | 2007 |
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Erlotinib Hydrochloride; Humans; Male; Prostatic Neoplasms; Quality of Life; Quinazolines; Survival Rate; Taxoids | 2007 |
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2008 |
A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Middle Aged; Models, Biological; Quinazolines; Treatment Outcome | 2007 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms; Thiophenes | 2008 |
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Uterine Cervical Neoplasms | 2008 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Gene Dosage; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Leucovorin; Male; Middle Aged; NF-kappa B; Organoplatinum Compounds; Quinazolines; Survival Rate | 2008 |
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms | 2008 |
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Prognosis; Quinazolines; Treatment Outcome | 2008 |
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2008 |
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles; Quinazolines; Sulfonamides; Survival Rate | 2008 |
Clinical experience with gefitinib in Indian patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; India; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Prognosis; Quinazolines | 2008 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of ZD1694 in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Asthenia; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Mucous Membrane; Nausea; Neoplasm Staging; Quinazolines; Remission Induction; Stomach Neoplasms; Thiophenes; Thrombocytopenia; Thymidylate Synthase; Vomiting | 1996 |
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Longitudinal Studies; Male; Middle Aged; Quinazolines; Thiophenes | 1996 |
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Quality of Life; Quinazolines; Survival Analysis; Thiophenes | 1998 |
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Prognosis; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 1999 |
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Thiophenes; Treatment Outcome | 2000 |
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2000 |
Preoperative chemoradiation with raltitrexed ('Tomudex') for T2/N+ and T3/N+ rectal cancers: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Female; Humans; Leukopenia; Male; Middle Aged; Quinazolines; Radiotherapy, Adjuvant; Rectal Neoplasms; Thiophenes | 2001 |
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Hypersensitivity; Enteritis; Epirubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pulmonary Embolism; Quinazolines; Sepsis; Stomach Neoplasms; Survival Analysis; Thiophenes; Treatment Outcome | 2001 |
Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Survival Rate; Thiophenes | 2002 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Salvage Therapy; Secondary Prevention; Thiophenes; Treatment Outcome | 2002 |
Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Quinazolines; Thiophenes; Thymidylate Synthase | 2002 |
Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Evaluation; Drugs, Investigational; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Trimetrexate | 1990 |
839 other study(ies) available for quinazolines and Adenocarcinoma
| Article | Year |
|---|---|
A multidimensional biosensor system to guide LUAD individualized treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biosensing Techniques; Biphenyl Compounds; Cell Culture Techniques; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lignans; Lung Neoplasms; Male; Mice; Mice, Nude; Piperidines; Precision Medicine; Quinazolines; Tumor Cells, Cultured | 2021 |
Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Mutation; Natural Killer T-Cells; Protein Kinase Inhibitors; Quinazolines | 2022 |
A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; ErbB Receptors; Glomerulonephritis; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Renal Dialysis | 2023 |
[Gefitinib Monotherapy Afforded Long-Term Survival of an Octogenarian Patient with a Postoperative Recurrence of a Pulmonary Adenocarcinoma-A Case Report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Octogenarians; Quinazolines | 2023 |
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Small; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Quinazolines; Registries; Retrospective Studies; Survival Rate | 2019 |
Acceleration of interstitial lung disease induced by raltitrexed.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Humans; Lung Diseases, Interstitial; Male; Quinazolines; Thiophenes | 2020 |
Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Docetaxel; Gamma Rays; Gene Expression Regulation; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor | 2020 |
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Synergism; Female; Humans; Irinotecan; Male; Mutation; Pancreatic Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Rate; Tumor Suppressor Protein p53 | 2021 |
Tryptanthrin exerts anti-breast cancer effects both in vitro and in vivo through modulating the inflammatory tumor microenvironment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Quinazolines; Tumor Microenvironment | 2021 |
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
Topics: Adenocarcinoma; Female; Humans; Mutation; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Isotope Labeling; Lung Neoplasms; Mass Spectrometry; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Tyrosine | 2017 |
Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Real-Time Polymerase Chain Reaction | 2017 |
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.
Topics: Adenocarcinoma; Afatinib; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Remission Induction; Xenograft Model Antitumor Assays | 2017 |
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phloretin; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Withanolides; Xenograft Model Antitumor Assays | 2017 |
Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Movement; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Molecular Targeted Therapy; Neoplasm Invasiveness; Ovarian Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; src-Family Kinases; Tumor Cells, Cultured | 2017 |
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2017 |
Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Gene Fusion; Humans; Lung Neoplasms; Male; Middle Aged; Neuregulin-1; Quinazolines | 2017 |
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; ErbB Receptors; Exons; Female; Humans; INDEL Mutation; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Quinazolines; Treatment Outcome | 2017 |
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Duodenal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Pyrimidines; Quinazolines; Treatment Outcome | 2017 |
Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines | 2017 |
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfones | 2017 |
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Urine | 2017 |
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Bile Duct Neoplasms; Cholangiocarcinoma; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Neuregulin-1; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Syndecan-4 | 2017 |
Murine breast cancer mastectomy model that predicts patient outcomes for drug development.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Luminescent Measurements; Lung; Lung Neoplasms; Mammary Neoplasms, Experimental; Mastectomy, Radical; Mice, Inbred BALB C; Neoplasm Metastasis; Quinazolines | 2017 |
PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Survival Analysis; Thiazolidinediones | 2017 |
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2018 |
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2017 |
Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Female; Humans; Lung Neoplasms; Middle Aged; Neuregulin-1; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2018 |
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Cell Nucleus; Cell Proliferation; Cisplatin; Claudin-2; Doxorubicin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Quinazolines; Spheroids, Cellular | 2018 |
Lung Cancer with Concomitant Double Gene Mutation.
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Biopsy; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Nivolumab; Pemetrexed; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Mutation, Missense; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2018 |
Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Biopsy; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutagenesis, Insertional; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed | 2017 |
Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Exons; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Survival Analysis; Time Factors | 2018 |
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Male; Microarray Analysis; Middle Aged; Mutation; Nanofibers; Neoplastic Cells, Circulating; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Reproducibility of Results | 2018 |
Mandibular metastasis as the first clinical indication of occult lung adenocarcinoma with multiple metastases: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Immunohistochemistry; Lung; Lung Neoplasms; Mandible; Mandibular Neoplasms; Neoplasm Grading; Neoplasm Staging; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid | 2018 |
Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2018 |
PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Apoptosis; B7-H1 Antigen; Bcl-2-Like Protein 11; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Vascular Endothelial Growth Factor A | 2018 |
Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Remission Induction | 2018 |
Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Annexin A5; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines | 2018 |
[Expression of Acetaldehyde Dehydrogenase in Gefitinib-resistant Human Lung Adenocarcinoma HCC-827/GR Cells].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aldehyde Oxidoreductases; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines | 2018 |
PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Survivin | 2018 |
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cesarean Section; China; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate; Thiophenes | 2018 |
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2018 |
Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers, Pharmacological; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Telomere | 2018 |
Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreas; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; STAT3 Transcription Factor | 2019 |
Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycerol Kinase; Humans; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2019 |
Synergistic Effect of Novel EGFR Inhibitor AZD8931 and p38α siRNA in Lung Adenocarcinoma Cancer Cells.
Topics: A549 Cells; Adenocarcinoma; Apoptosis; Cell Proliferation; ErbB Receptors; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 14; Quinazolines; RNA, Small Interfering | 2019 |
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult | 2019 |
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Endodeoxyribonucleases; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; LIM Domain Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult | 2013 |
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib-induced hair repigmentation.
Topics: Adenocarcinoma; Aged; Erlotinib Hydrochloride; Female; Hair Color; Humans; Lung Neoplasms; Pigmentation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Diagnostic Tests, Routine; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; CD56 Antigen; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Ki-67 Antigen; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2 | 2013 |
Two rare exon 21 EGFR mutations in patients treated with gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
[Primary lateral sclerosis and lung adenocarcinoma].
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Causality; Diagnosis, Differential; Dysarthria; Electromyography; Fatal Outcome; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Motor Neuron Disease; Motor Neurons; Multimodal Imaging; Paraneoplastic Syndromes, Nervous System; Pemetrexed; Pleural Effusion, Malignant; Positron-Emission Tomography; Quadriplegia; Quinazolines; Tomography, X-Ray Computed | 2013 |
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Sex Factors; Treatment Outcome | 2012 |
[Erlotinib-induced acneiform eruption].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Erlotinib Hydrochloride; Fluoroquinolones; Humans; Lung Neoplasms; Male; Methylprednisolone; Quinazolines; Quinolizines; Treatment Outcome | 2013 |
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Systematic Reviews as Topic | 2013 |
Influence of gefitinib and erlotinib on apoptosis and c-MYC expression in H23 lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeletal Proteins; Down-Regulation; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Phosphorylation; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Quinazolines; RNA, Messenger; Signal Transduction; Transcriptome | 2013 |
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
Topics: Adenocarcinoma; Antineoplastic Agents; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2013 |
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; France; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutagenesis, Insertional; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Spain; Switzerland; Trastuzumab; Treatment Outcome | 2013 |
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crown Ethers; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cytochrome P-450 CYP2D6; Female; Follow-Up Studies; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases | 2013 |
[Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Signal Transduction | 2013 |
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cytodiagnosis; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Antigens, Differentiation, B-Lymphocyte; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Frequency; Gene Rearrangement; Glutamates; Guanine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Pyrimidines; Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Smoking; Treatment Outcome | 2013 |
Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Ethnicity; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2013 |
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Docetaxel; Erlotinib Hydrochloride; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2013 |
[A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Time Factors | 2013 |
[Clinical observation of icotinib hydrochloride in first-line therapy for pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Crown Ethers; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Financing, Government; Follow-Up Studies; Gefitinib; Health Plan Implementation; Health Services; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Protein v-akt; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines | 2013 |
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2013 |
Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Salvage Therapy | 2013 |
Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2013 |
Afatinib monotherapy in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smad4 Protein; Treatment Outcome | 2013 |
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line.
Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD24 Antigen; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Hyaluronan Receptors; Hypoglycemic Agents; Lung Neoplasms; Metformin; Mice; Mice, SCID; Neoplasm Transplantation; Peptides; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Animals; Biological Transport; Cholinergic Antagonists; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Microtomy; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Scopolamine Derivatives; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tiotropium Bromide; Tissue Culture Techniques; Tumor Microenvironment | 2013 |
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2014 |
[Assessing the usefulness of erlotinib in patients with unknown or negative epidermal growth factor receptor mutation status].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Guanylate Kinases; Humans; Lung Neoplasms; Membrane Proteins; MicroRNAs; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1 | 2014 |
Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival; Treatment Outcome | 2013 |
Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Pancreatic Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Survival Analysis; Time Factors; Transcriptome | 2014 |
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2014 |
[Effects of AG1478 on the expression of FOXM1 gene via FOXO3a in non-small cell lung cancer cells].
Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Lung Neoplasms; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transfection; Tyrphostins | 2013 |
Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction | 2013 |
Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Topics: Adenocarcinoma; Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Matrix Metalloproteinase 9; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Prognosis; Quinazolines; Republic of Korea; Retrospective Studies; Sequence Deletion; Survival Analysis; Treatment Outcome | 2013 |
Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crown Ethers; Docetaxel; Drug Dosage Calculations; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2014 |
The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Topics: Acetylation; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Histone Deacetylase 1; Humans; Immunoenzyme Techniques; Immunoprecipitation; Ku Autoantigen; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Neoplasm Metastasis; Phosphatidylinositol 3-Kinase; Phosphorylation; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, IGF Type 1; Tumor Cells, Cultured | 2014 |
[Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lung; Lung Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Transforming Growth Factor alpha; Tumor Microenvironment; Vimentin | 2013 |
An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Middle Aged; Mutagenesis, Insertional; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Salvage Therapy | 2013 |
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2014 |
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
[Radiosensitizing effect of erlotinib on human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Particle Accelerators; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2013 |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Phosphatidylinositol 3-Kinases; Precision Medicine; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2014 |
Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Luteolin; Male; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Afatinib-related nonhematologic adverse events: is common evaluation enough for now?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Reply to F. De Marinis et al.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
Reply to E.R. Haspinger et al.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured | 2014 |
Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Lung Neoplasms; Piperazines; Quinazolines | 2014 |
Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Empyema, Pleural; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Node Excision; Mutation; Neoadjuvant Therapy; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Neoplasm | 2014 |
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deglutition Disorders; Drug Administration Routes; Female; Gastrostomy; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2014 |
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Pemetrexed; Quinazolines; Radiography; Treatment Outcome | 2014 |
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Brain Neoplasms; Cranial Irradiation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2014 |
Reossification of osteolytic metastases at the acetabulum following gefitinib and multidisciplinary treatment for lung cancer: a case report with autopsy findings.
Topics: Acetabulum; Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Autopsy; Biopsy; Bone Neoplasms; Disease Progression; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Ossification, Heterotopic; Quinazolines; Tomography, X-Ray Computed | 2015 |
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines | 2014 |
Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Quinazolines; Retrospective Studies; Ribonuclease III; RNA, Messenger | 2014 |
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Large Cell; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Molecular Sequence Data; Mutagenesis, Insertional; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mice, Transgenic; Mutation; Neoplasms, Experimental; Quinazolines; SOXB1 Transcription Factors | 2014 |
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutant Proteins; Mutation; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cytoplasm; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphoproteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Survival Rate; Transcription Factors; YAP-Signaling Proteins; Young Adult | 2014 |
Case of erlotinib-induced photosensitivity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Dermatitis, Photoallergic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Patch Tests; Protein Kinase Inhibitors; Quinazolines | 2014 |
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Mice, Transgenic; Multiprotein Complexes; Mutation; Quinazolines; Random Allocation; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Quinolines; Thiourea; Vascular Endothelial Growth Factor A | 2014 |
A complex deletion/insertion on exon 19 of the EGFR gene predicts response to gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Exons; Female; Gefitinib; Humans; INDEL Mutation; Lung Neoplasms; Quinazolines | 2014 |
Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; ErbB Receptors; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2 | 2014 |
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2014 |
[Efficacy of gefitinib for young patients with unknown EGFR gene mutation
in advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Fluorescent Antibody Technique; G2 Phase Cell Cycle Checkpoints; Humans; In Situ Nick-End Labeling; M Phase Cell Cycle Checkpoints; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Stomach Neoplasms | 2014 |
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Female; Fibroblasts; Humans; Interleukin-6; Lung Neoplasms; Mice; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Serine; STAT3 Transcription Factor; Tyrosine | 2014 |
Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Copy Number Variations; Drug Resistance, Neoplasm; Electrophoresis, Capillary; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Metabolome; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2014 |
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2014 |
Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; EGF Family of Proteins; Endothelial Growth Factors; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Signal Transduction; Snail Family Transcription Factors; Stomach Neoplasms; Transcription Factors; Tyrphostins; Vimentin | 2014 |
Gefitinib for oesophageal cancer: a cog in need of a wheel?
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Quinazolines | 2014 |
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Tandem Mass Spectrometry | 2015 |
Increased INR after gefitinib and acenocoumarol co-administration.
Topics: Acenocoumarol; Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Heart Failure; Humans; International Normalized Ratio; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2014 |
Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy.
Topics: Adenocarcinoma; Anti-Infective Agents; Atovaquone; Chorioretinitis; ErbB Receptors; Erlotinib Hydrochloride; Female; Food Parasitology; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Toxoplasma; Toxoplasmosis, Ocular | 2014 |
Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain; Cetuximab; ErbB Receptors; Fatal Outcome; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Meningeal Neoplasms; Mutation; Neoplasms, Second Primary; Quinazolines | 2014 |
Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy.
Topics: Adenocarcinoma; Aged; Autoantibodies; Autoantigens; Electroretinography; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Infusions, Intravenous; Isoxazoles; Lung Neoplasms; Male; Night Blindness; Paraneoplastic Syndromes, Ocular; Phosphopyruvate Hydratase; Quinazolines; Resorcinols; Retina; Tomography, Optical Coherence; Visual Acuity | 2014 |
[Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bronchial Neoplasms; Disease Progression; Docetaxel; ErbB Receptors; Exons; Female; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; Molecular Targeted Therapy; Quinazolines; Remission Induction; Retreatment; Taxoids; Treatment Outcome | 2014 |
Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Carcinogenesis; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Oncogene Proteins, Fusion; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2014 |
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Interleukin-6; Janus Kinase 1; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, SCID; Mutation; Nitriles; Oncogenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; ras Proteins; Receptors, Fibroblast Growth Factor; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
Topics: Adenocarcinoma; Cell Line, Tumor; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Quinazolines | 2014 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Intensive Care Units; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Respiration, Artificial; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib-resistant lung adenocarcinoma cells.
Topics: Acridine Orange; Adenocarcinoma; Adenocarcinoma of Lung; Annexin A5; Antineoplastic Agents, Phytogenic; Autophagy; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cupressaceae; DNA Damage; Drug Resistance, Neoplasm; ErbB Receptors; Gas Chromatography-Mass Spectrometry; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Monoterpenes; Oils, Volatile; Quinazolines; Real-Time Polymerase Chain Reaction; Taiwan; Tropolone; Tumor Stem Cell Assay | 2014 |
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cohort Studies; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis | 2014 |
Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Treatment Failure; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Outcome | 2014 |
Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pakistan; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction | 2014 |
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Animals; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Heparin-binding EGF-like Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Matrix Metalloproteinase 1; Mice, Nude; Middle Aged; Neoplasm Staging; Neuregulin-1; Neurotensin; Paracrine Communication; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Cysts; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Pneumothorax; Protein Kinase Inhibitors; Quinazolines; Rupture, Spontaneous | 2014 |
Crotoxin suppresses the tumorigenic properties and enhances the antitumor activity of Iressa® (gefinitib) in human lung adenocarcinoma SPCA‑1 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Crotoxin; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines | 2014 |
Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; ErbB Receptors; Estradiol; Estrogen Receptor beta; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Osteopontin; Pleural Effusion, Malignant; Prognosis; Prospective Studies; Quinazolines; Transcriptional Activation | 2015 |
MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Computational Biology; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2015 |
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Proto-Oncogene Proteins c-cbl; Quinazolines; RNA, Small Interfering | 2015 |
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Amplification; Gene Expression; Gene Silencing; Genes, src; Humans; Lapatinib; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; Stomach Neoplasms | 2014 |
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fibroblasts; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Mutation; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Risk Factors; Treatment Outcome; Tumor Microenvironment | 2015 |
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Mass Spectrometry; Phosphopeptides; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2015 |
[Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Molecular; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2015 |
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2015 |
Icotinib hydrochloride enhances the effect of radiotherapy by affecting DNA repair in colorectal cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Survival; Colorectal Neoplasms; Crown Ethers; DNA Repair; Flow Cytometry; Fluorescent Antibody Technique; HCT116 Cells; Heterografts; HT29 Cells; Humans; Mice; Mice, Nude; Quinazolines; Radiation-Sensitizing Agents | 2015 |
Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Epidemiologic Methods; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
LUX-Lung: determining the best EGFR inhibitor in NSCLC?
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2015 |
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Targeted therapies: LUX-Lung trials-not all mutations are created equal.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2015 |
Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cell Survival; Cytoplasm; Enzyme Activation; Extracellular Fluid; Gefitinib; HMGB1 Protein; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor for Advanced Glycation End Products; RNA Interference; RNA, Small Interfering; Stomach Neoplasms; Transfection | 2015 |
A 'shock-ing' endoscopic finding on esophagogastroduodenoscopy.
Topics: Adenocarcinoma; Antineoplastic Agents; Endoscopy, Digestive System; Erlotinib Hydrochloride; Esophagus; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Multiple Organ Failure; Necrosis; Quinazolines | 2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2015 |
Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; Treatment Outcome | 2015 |
Disease flare after gefitinib discontinuation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Withholding Treatment | 2015 |
Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique, Indirect; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Quinazolines | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
[Brain metastases in pulmonary adenocarcinoma with EGFR mutation: how important is therapy with erlotinib compared to radiotherapy?].
Topics: Adenocarcinoma; Brain Neoplasms; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2015 |
Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crown Ethers; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines | 2015 |
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Topics: Adenocarcinoma; Androgen Receptor Antagonists; Animals; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lapatinib; Male; Mice; Mice, Nude; Neoplasm Proteins; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Signal Transduction; Y-Box-Binding Protein 1 | 2015 |
Current two EGFR mutations in lung adenocarcinoma - case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography | 2015 |
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines | 2015 |
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cytoskeletal Proteins; Drug Delivery Systems; ErbB Receptors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Essential; Humans; Lung Neoplasms; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; RNA; Sequence Analysis, RNA; Single-Cell Analysis; Transcriptome | 2015 |
Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; ROC Curve; Tissue Distribution; Tomography, X-Ray Computed; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Mutation; Proportional Hazards Models; Quinazolines; Sequence Analysis, DNA | 2015 |
The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Down-Regulation; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; RNA, Long Noncoding; Transfection; Xenograft Model Antitumor Assays | 2015 |
[Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines | 2015 |
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
[Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation | 2015 |
Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Exons; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Pemetrexed; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2015 |
Assessment of Proliferation and Cytotoxicity in a Biomimetic Three-Dimensional Model of Lung Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomimetics; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2015 |
[A Case of Pneumatosis Cystoides Intestinalis Secondary to Gefitinib Therapy for Lung Adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Diarrhea; Gefitinib; Humans; Lung Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed; Vomiting | 2015 |
An unusual bowel complication during molecularly-targeted therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Emphysema; Female; Gefitinib; Humans; Intestinal Diseases; Lung Neoplasms; Pneumoperitoneum; Quinazolines; Tomography, X-Ray Computed | 2015 |
Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quinazolines; Rectal Neoplasms; Retrospective Studies; Survival Rate; Thiophenes; Young Adult | 2015 |
Invited Commentary.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomimetics; Cell Culture Techniques; Cisplatin; Humans; Lung Neoplasms; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2015 |
Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; beta Catenin; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Sequence Data; Molecular Targeted Therapy; Mutation, Missense; Protein Transport; Quinazolines; Transcription, Genetic; Transcriptional Activation; Up-Regulation; Wnt Signaling Pathway | 2015 |
Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Membrane Proteins; Proteomics; Quinazolines; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neurons; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Mice, SCID; Molecular Docking Simulation; Molecular Structure; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; Structure-Activity Relationship; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Lung cancer in China: The new frontier?
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Humans; Male; Molecular Targeted Therapy; Quinazolines; Smoking | 2015 |
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; China; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cetuximab; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines | 2016 |
[Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Brain Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
Topics: Adenocarcinoma; Afatinib; Brain Neoplasms; Diagnostic Imaging; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Ligands; Liver X Receptors; Lung Neoplasms; Mutation; Orphan Nuclear Receptors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
[Sequence-dependent Effect of Triptolide with Gefitinib on the Proliferation
and Apoptosis of Lung Adenocarcinoma Cell H1975].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diterpenes; Epoxy Compounds; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phenanthrenes; Protein Kinase Inhibitors; Quinazolines | 2015 |
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; MCF-7 Cells; Metformin; Neoplasm Proteins; Neuregulin-1; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Tamoxifen; Tumor Stem Cell Assay | 2016 |
Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Enzyme Assays; ErbB Receptors; Humans; Lung Neoplasms; Mass Spectrometry; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Real-Time Polymerase Chain Reaction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; ErbB Receptors; Europe; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2016 |
Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.
Topics: Adenocarcinoma; Afatinib; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Signal Transduction | 2016 |
Overexpression of BRCA1 attenuates the sensitivity of PC9 cells to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Signal Transduction | 2015 |
5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Line, Tumor; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; Quinazolines | 2015 |
Quinalizarin, a specific CK2 inhibitor, reduces cell viability and suppresses migration and accelerates apoptosis in different human lung cancer cell lines.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Large Cell; Casein Kinase II; Cell Movement; Cell Proliferation; Flow Cytometry; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2015 |
Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
Topics: Acrylamides; Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mutation; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Case Report: Bazex Syndrome Associated With Pulmonary Adenocarcinoma.
Topics: Acitretin; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Biopsy, Needle; Bone Neoplasms; Carcinoma, Basal Cell; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Gefitinib; Humans; Hypotrichosis; Immunohistochemistry; Lung Neoplasms; Lymph Nodes; Male; Paraneoplastic Syndromes; Quinazolines; Radiography; Rare Diseases; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2016 |
An unusual cause of early aortic bioprosthetic valve failure.
Topics: Adenocarcinoma; Antineoplastic Agents; Aortic Valve; Aortic Valve Stenosis; Bioprosthesis; Echocardiography; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prosthesis Failure; Quinazolines | 2016 |
Paris Saponins enhance radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Saponins | 2016 |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Signal Transduction | 2016 |
NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
[The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Analysis of Variance; Anthraquinones; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lung Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2016 |
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2016 |
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Topics: Adenocarcinoma; Afatinib; Aged; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mutagenesis, Insertional; Neoplasm Staging; Prognosis; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tumor Cells, Cultured | 2016 |
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Cisplatin; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lung Neoplasms; Metformin; Mutation; Purines; Quinazolines; Transforming Growth Factor beta | 2016 |
Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Drug Resistance, Neoplasm; Female; Fever; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nivolumab; Quinazolines | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Choroidal metastasis as a presenting manifestation of a lung adenocarcinoma with response to afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Signal Transduction | 2016 |
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Swine; Tissue Engineering; Transforming Growth Factor beta1 | 2016 |
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cadherins; Down-Regulation; ErbB Receptors; Female; Gefitinib; Humans; Hyaluronan Receptors; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.
Topics: Adenocarcinoma; Afatinib; Aged; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2 | 2016 |
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Line; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; NIH 3T3 Cells; Oncogene Proteins, Fusion; Piperidines; Protein Isoforms; Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous | 2016 |
Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Drug Eruptions; Female; Humans; Lung Neoplasms; Quinazolines | 2016 |
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2016 |
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Gain of Function Mutation; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2016 |
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Autophagy-Related Protein-1 Homolog; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Survival; Dasatinib; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; MicroRNAs; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; src-Family Kinases | 2017 |
A genetic cell context-dependent role for ZEB1 in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Mice, Nude; MicroRNAs; Promoter Regions, Genetic; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-3; Receptor, Notch1; Reproducibility of Results; Smoking; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Feedback, Physiological; Forkhead Box Protein M1; Gefitinib; Humans; Indoles; Lung Neoplasms; Morpholines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Small Interfering; Signal Transduction; Sulfones | 2016 |
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed | 2016 |
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, IGF Type 1; Receptors, Death Domain; Receptors, Somatomedin; Signal Transduction; Smad2 Protein; Smad3 Protein; Somatomedins | 2016 |
Neighbors' death is required for surviving human adenocarcinoma PC-9 cells in an early stage of gefitinib treatment.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Quinazolines; Receptors, Fibroblast Growth Factor; Signal Transduction; Treatment Outcome | 2016 |
Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Precision Medicine; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; White People | 2016 |
Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antigens, Neoplasm; B7-H1 Antigen; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; ErbB Receptors; Galectins; Humans; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2016 |
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment | 2017 |
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop.
Topics: 3' Untranslated Regions; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Movement; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Models, Biological; Neoplastic Stem Cells; NF-kappa B; Quinazolines; RNA Interference; Signal Transduction; Tumor Necrosis Factor alpha-Induced Protein 3 | 2017 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2017 |
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Rate | 2017 |
An autopsy case of bronchiolitis obliterans as a previously unrecognized adverse event of afatinib treatment.
Topics: Adenocarcinoma; Afatinib; Autopsy; Bronchiolitis Obliterans; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2017 |
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Osteogenesis; Pelvic Bones; Quinazolines; Spine | 2016 |
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2017 |
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Circulating Tumor DNA; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Genome; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Neoplasm Metastasis; Oncogene Proteins, Fusion; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; Recurrence | 2017 |
Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Proto-Oncogene Proteins; Quinazolines; Signal Transduction; Smad3 Protein; STAT3 Transcription Factor | 2017 |
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Quinazolines | 2017 |
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
Topics: Adenocarcinoma; Aged; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Dyspnea; ErbB Receptors; Exons; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines | 2017 |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Quinazolines; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2017 |
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Circulating Tumor DNA; ErbB Receptors; Female; High-Throughput Nucleotide Sequencing; Humans; Liquid Biopsy; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines | 2017 |
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
Topics: Adenocarcinoma; Aged; Biomarkers; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Financing, Government; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Audit; Middle Aged; New Zealand; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2017 |
HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
Topics: Acrylamides; Adenocarcinoma; Antimetabolites; Antineoplastic Agents; Biomarkers, Tumor; Diagnostic Tests, Routine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glucose; Humans; Lapatinib; Quinazolines; Theranostic Nanomedicine; Therapeutic Uses; Uterine Cervical Neoplasms | 2017 |
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Topics: Adenocarcinoma; Cerebrospinal Fluid; Diagnosis, Differential; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2008 |
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Letrozole; Lung Neoplasms; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Skin Neoplasms; Triazoles | 2008 |
EGFR polymorphism of the kinase domain in Japanese lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Polymorphism, Genetic; Prognosis; Quinazolines | 2008 |
Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter.
Topics: Adenocarcinoma; Animals; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Peptides; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein C; Quinazolines | 2008 |
Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; Dose-Response Relationship, Drug; Female; Gefitinib; Glomerulonephritis, IGA; Humans; Kidney; Lung Neoplasms; Middle Aged; Nephritis, Interstitial; Quinazolines | 2008 |
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organoplatinum Compounds; Quinazolines; Retroperitoneal Neoplasms; Sacrum; Thiophenes; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
Prolonged response to gefitinib in bone metastasis.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Back Pain; Carboplatin; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Spinal Neoplasms; Time Factors | 2009 |
Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Dizziness; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Hearing; Hearing Loss, Sensorineural; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Tinnitus; Treatment Failure | 2008 |
Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Survival Rate; Treatment Outcome | 2009 |
Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.
Topics: Adenocarcinoma; Adult; Back Pain; Diagnosis, Differential; Drug Resistance, Neoplasm; Fractures, Compression; Gefitinib; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Radiography; Sequence Deletion; Spinal Fractures; Thoracic Vertebrae | 2008 |
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Drug interaction between complementary herbal medicines and gefitinib.
Topics: Adenocarcinoma; Adult; ErbB Receptors; Female; Gefitinib; Herb-Drug Interactions; Herbal Medicine; Humans; Lung Neoplasms; Plants, Medicinal; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.
Topics: Adenocarcinoma; Adult; Aged; Cell Line, Tumor; Cell Proliferation; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mesoderm; Microfilament Proteins; Middle Aged; Pancreatic Neoplasms; Phenotype; Quinazolines | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy; Xenograft Model Antitumor Assays | 2008 |
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pilot Projects; Postmenopause; Prognosis; Quinazolines; Safety; Survival Rate; Treatment Outcome | 2009 |
Trichomegaly induced by erlotinib.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Lymphatic Metastasis; Protein Kinase Inhibitors; Quinazolines | 2008 |
Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation.
Topics: Adenocarcinoma; Animals; Gefitinib; Gene Expression; Humans; In Vitro Techniques; Lipopolysaccharides; Lung Diseases, Interstitial; Mice; Pneumonia; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein A; Quinazolines; Signal Transduction | 2008 |
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2008 |
Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2008 |
An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Quinazolines | 2008 |
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunoenzyme Techniques; Introns; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Radiography, Thoracic; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Up-Regulation | 2008 |
A population-based study of gefitinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Demography; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking | 2009 |
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate | 2008 |
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Prolonged response to first-line erlotinib for advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2008 |
Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor.
Topics: Adenocarcinoma; Amphiregulin; Autoantibodies; Cell Line, Tumor; Cell Proliferation; EGF Family of Proteins; ErbB Receptors; Esophageal Neoplasms; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Leptin; Matrix Metalloproteinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transcriptional Activation; Transforming Growth Factor alpha; Tyrphostins | 2008 |
[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorine Radioisotopes; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; ROC Curve; Thymidine; Time; Tomography, X-Ray Computed | 2008 |
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Protein Structure, Quaternary; Quinazolines; Sequence Alignment | 2008 |
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
Topics: Adenocarcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor | 2008 |
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Reproducibility of Results; Tumor Cells, Cultured | 2009 |
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Wood-smoke exposure (WSE) as a predictor of response and survival in erlotinib-treated non-small cell lung cancer (NSCLC) patients.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhalation Exposure; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2009 |
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antineoplastic Agents; Cell Proliferation; Cone-Beam Computed Tomography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, p53; Genes, ras; Lung Neoplasms; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; Quinazolines; Tumor Burden | 2009 |
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Risk Factors; Smoking | 2009 |
Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2009 |
A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Risk Assessment | 2009 |
Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fatal Outcome; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Multiple Primary; Quinazolines; Sequence Deletion; Treatment Outcome | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking | 2009 |
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rad51 Recombinase; Sulfonamides | 2009 |
Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzo(a)pyrene; Cell Culture Techniques; Cell Division; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Signal Transduction | 2009 |
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome | 2009 |
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer.
Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Metformin; Quinazolines | 2009 |
Histoculture drug response assay for gefitinib in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Smoking; Tissue Culture Techniques | 2009 |
Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Enzyme Induction; Female; Glutathione S-Transferase pi; Humans; JNK Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Quinazolines | 2009 |
Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Hair; Hair Color; Humans; Hypertrichosis; Lung Neoplasms; Neoplasm Proteins; Paronychia; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2009 |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2009 |
Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Caveolin 1; Cell Division; Cell Line, Tumor; Cell Movement; Enzyme Activation; Enzyme Induction; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; MAP Kinase Signaling System; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2009 |
Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adenocarcinoma; Aged; Artifacts; Biopsy; Bone and Bones; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radionuclide Imaging; Retrospective Studies | 2009 |
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Phosphorylation; Piperidines; Polymerase Chain Reaction; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2009 |
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate | 2009 |
Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Quinazolines; Treatment Outcome; Ventriculoperitoneal Shunt | 2009 |
[Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2009 |
[A case of lung cancer combined with pregnancy; dramatically deteriorating condition after caesarian section].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cesarean Section; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Quinazolines | 2009 |
Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Lung Neoplasms; Methylprednisolone; Muscular Diseases; Prednisolone; Quinazolines | 2010 |
Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Models, Animal; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Phosphorylation; Promoter Regions, Genetic; Pulmonary Surfactant-Associated Protein C; Quinazolines; Receptor, ErbB-3; Smoking | 2009 |
[A case of lung adenocarcinoma successfully treated with dose-reescalated gefitinib after resistance was acquired].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2009 |
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking | 2009 |
Three cases of severe hepatic impairment caused by erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Biopsy; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Failure; Liver Function Tests; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Liver Cirrhosis; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Development of rheumatoid arthritis during the course of gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prednisolone; Quinazolines; Sulfasalazine | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inflammation; Lung Neoplasms; Male; Mesoderm; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction | 2009 |
[A case of non-small cell lung cancer treated safely by whole brain radiation therapy and erlotinib].
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Biopsy, Fine-Needle; Endosonography; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2009 |
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
Massive hematuria from the bilateral upper urinary tract in a patient treated for advanced lung cancer with gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Hematuria; Humans; Lung Neoplasms; Prognosis; Quinazolines; Treatment Outcome; Urinary Tract | 2010 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2009 |
A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Biopsy; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Endoscopy; ErbB Receptors; Esophageal Neoplasms; Exons; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2010 |
A case of bullous dermatitis induced by erlotinib.
Topics: Adenocarcinoma; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases, Vesiculobullous | 2009 |
Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Meningeal Neoplasms; Mutation; Paclitaxel; Quinazolines | 2009 |
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Chimera; Disease Models, Animal; Embryonic Stem Cells; ErbB Receptors; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Phenotype; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines; Respiratory Insufficiency; Signal Transduction | 2010 |
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy, Needle; Clinical Trials, Phase II as Topic; DNA Mutational Analysis; ErbB Receptors; Female; Fluoroscopy; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiography, Interventional; ras Proteins; Tomography, X-Ray Computed | 2010 |
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
[Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Remission Induction; Survival Rate | 2010 |
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors | 2009 |
Treatment of lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Paclitaxel; Proportional Hazards Models; Quinazolines | 2009 |
Trichomegaly secondary to erlotinib.
Topics: Adenocarcinoma; Aged; ErbB Receptors; Erlotinib Hydrochloride; Eyebrows; Eyelashes; Humans; Hypertrichosis; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2010 |
First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Biomarkers, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
Topics: Adenocarcinoma; Alopecia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines | 2011 |
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
[Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report].
Topics: Adenocarcinoma; Aged; Erlotinib Hydrochloride; Female; Humans; IgA Vasculitis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
Topics: Adenocarcinoma; Apoptosis; Cell Fractionation; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatic Neoplasms; Quinazolines; Taxoids; Transcription Factors; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2010 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2010 |
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2010 |
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Topics: Adenocarcinoma; Amino Acid Substitution; Animals; Antineoplastic Agents; Aspartic Acid; Cyclin-Dependent Kinases; Diagnostic Imaging; Disease Models, Animal; Drug Evaluation, Preclinical; Genes, ras; Glycine; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutant Proteins; Pyrazoles; Quinazolines; Treatment Outcome | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p16; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Prevalence; Quinazolines; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53 | 2010 |
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Renal Dialysis; Tissue Distribution; Treatment Outcome | 2010 |
Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; DNA Mutational Analysis; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Pneumonectomy; Quinazolines; Radiography, Thoracic | 2010 |
Stromal depletion goes on trial in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Hedgehog Proteins; Humans; Off-Label Use; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Survival Analysis; United States | 2010 |
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.
Topics: Adenocarcinoma; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Osteoblasts; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib.
Topics: Adenocarcinoma; Adult; Animals; Cell Line, Tumor; Cell Proliferation; Chromosomes; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Quinazolines | 2010 |
Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms; Remission Induction; Thiophenes; Thymidylate Synthase; Treatment Outcome; Vitamin B Complex | 2011 |
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Russia; Treatment Outcome | 2010 |
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cadherins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Gallbladder cancer with tumor thrombus in the superior vena cava.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Female; Fibrinolytic Agents; Gallbladder Neoplasms; Gefitinib; Humans; Incidental Findings; Middle Aged; Neoplastic Cells, Circulating; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Superior | 2010 |
Trastuzumab in gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Forecasting; Genes, erbB-2; Humans; Lapatinib; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2010 |
Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment.
Topics: Adenocarcinoma; Aged; Biopsy, Needle; Chemotherapy, Adjuvant; Female; Gefitinib; Genes, erbB-1; Humans; Infant; Lung Neoplasms; Mutation; Neoadjuvant Therapy; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2010 |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
Topics: Adenocarcinoma; Automation; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Electrophoresis, Capillary; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Nucleic Acid Denaturation; Pharmacogenetics; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Treatment Outcome | 2010 |
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Modulation of P-gp expression by lapatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome | 2010 |
Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome | 2010 |
Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Face; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinogens; Chemoprevention; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Piperidines; Protein Kinase Inhibitors; Quinazolines; Urethane; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Morpholines; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mesoderm; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Analysis; Treatment Outcome | 2010 |
Elevated international normalized ratio associated with concomitant warfarin and erlotinib.
Topics: Adenocarcinoma; Anticoagulants; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; International Normalized Ratio; Lung Neoplasms; Male; Middle Aged; Quinazolines; Thromboembolism; Warfarin | 2010 |
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Folliculitis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2010 |
[A case of advanced adenocarcinoma of the lung which maintained complete response for 5 years by treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Sequence Deletion | 2010 |
Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Fatal Outcome; Hepatorenal Syndrome; Humans; Liver Failure; Male; Pancreatic Neoplasms; Quinazolines | 2010 |
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Axl Receptor Tyrosine Kinase; Barrett Esophagus; Benzocycloheptenes; Cell Movement; Esophageal Neoplasms; Female; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lapatinib; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; ral GTP-Binding Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Survival Rate; Triazoles | 2010 |
Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chemotherapy, Adjuvant; Cholecystitis; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Incidental Findings; Lung Neoplasms; Mutation; Neoplasm Staging; Pedigree; Pneumonectomy; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vinorelbine | 2010 |
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Contrast Media; Humans; Image Enhancement; Kinetics; Male; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Nude; Time Factors; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2010 |
Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Mutation; Quinazolines | 2010 |
Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Hypertrichosis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoblotting; Keratinocytes; Lung Neoplasms; Quinazolines; Signal Transduction | 2011 |
[Feasibility of erlotinib after gefitinib failure in patients with advanced pulmonary adenocarcinoma previously responding to gefitinib].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Tolerance; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Phosphorylation; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Tissue Distribution; Tyrosine | 2010 |
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed | 2011 |
Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cluster Analysis; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2 | 2010 |
[Re-treatment with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)for lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2010 |
Predictive biomarkers in the management of EGFR mutant lung cancer.
Topics: Adenocarcinoma; Aged; Apoptosis; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; White People | 2010 |
Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Topoisomerases, Type I; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Genotype; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Polymerase Chain Reaction; Protein Tyrosine Phosphatases; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Tyrphostins | 2010 |
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockout Techniques; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion; Quinazolines | 2010 |
Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2011 |
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Catheter Ablation; Cetuximab; Cytokine-Induced Killer Cells; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Oxaloacetates; Positron-Emission Tomography; Quality of Life; Quinazolines; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2010 |
[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking; Young Adult | 2010 |
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antibody Specificity; ErbB Receptors; Female; Gefitinib; Genetic Association Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Point Mutation; Quinazolines; Sequence Deletion | 2011 |
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Mutation, Missense; Quinazolines; Sequence Deletion | 2011 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Microcystic/reticular schwannoma of the pancreas: a potential diagnostic pitfall.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Deoxycytidine; Diagnostic Errors; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neurilemmoma; Pancreatectomy; Pancreatic Neoplasms; Quinazolines | 2011 |
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure; Tumor Cells, Cultured | 2011 |
Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quinazolines | 2011 |
DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; DNA-Binding Proteins; Endonucleases; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Smoking; X-ray Repair Cross Complementing Protein 1 | 2011 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Failure | 2011 |
C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Survival Rate | 2011 |
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines | 2011 |
[Pleural metastases from bronchial carcinoma: is a cure possible?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperidines; Pleural Neoplasms; Quinazolines; Radiotherapy; Receptor Protein-Tyrosine Kinases; Retreatment; Survivors; Thoracotomy | 2011 |
ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Mutation; Nitriles; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; RNA, Small Interfering; Tyrphostins | 2011 |
More on aprepitant for erlotinib-induced pruritus.
Topics: Adenocarcinoma; Aprepitant; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2011 |
Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cadherins; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Fibronectins; gamma Catenin; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins | 2011 |
First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Middle Aged; Mutation; Polymerase Chain Reaction; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Proliferation; Chemotaxis; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Humans; Immunoenzyme Techniques; In Vitro Techniques; Lung Neoplasms; Melanoma; Mice; Mice, Inbred BALB C; Mice, SCID; Neutrophil Infiltration; Quinazolines; Receptors, Interleukin-8B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spheroids, Cellular; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2011 |
Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Base Sequence; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Salvage Therapy | 2011 |
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
Focal leptomeningeal metastasis following curative surgery for lung cancer: case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Quinazolines | 2011 |
Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Apoptosis; Drainage; Gefitinib; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Quinazolines; Treatment Outcome | 2011 |
Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymyositis; Quinazolines; Radionuclide Imaging | 2011 |
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; bcl-X Protein; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mice; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Transplantation, Heterologous | 2011 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Taxoids | 2011 |
[A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib].
Topics: Adenocarcinoma; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Embolism; Quinazolines | 2011 |
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Topics: Adenocarcinoma; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Proliferation; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Oligonucleotide Array Sequence Analysis; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
[Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer].
Topics: Adenocarcinoma; Algorithms; Austria; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride.
Topics: Adenocarcinoma; Antineoplastic Agents; Cadmium Chloride; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Environmental Pollutants; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Lethal Dose 50; Lung Neoplasms; Microscopy, Acoustic; Proliferating Cell Nuclear Antigen; Quinazolines; Up-Regulation | 2011 |
Palmar bullous blistering induced by erlotinib.
Topics: Adenocarcinoma; Blister; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hand Dermatoses; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Retreatment; Treatment Outcome | 2011 |
The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Quinazolines; Signal Transduction | 2011 |
[Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Quinazolines | 2011 |
Molecular selection trumps clinical selection.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Paclitaxel; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Ascites; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Prednisolone; Quinazolines | 2011 |
Papulopustular eruptions in a 32-year-old woman after lung cancer treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Metronidazole; Mupirocin; Quinazolines | 2011 |
Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Combined Modality Therapy; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2011 |
Surgical resection of locally advanced pulmonary adenocarcinoma after gefitinib therapy.
Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Quinazolines; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA | 2012 |
Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Alanine Transaminase; Anti-Inflammatory Agents; Antineoplastic Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Function Tests; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Muscle Weakness; Quinazolines; Radiography, Thoracic | 2011 |
EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Squamous Cell; Child; Child, Preschool; ErbB Receptors; Female; Gene Amplification; Genes, erbB-1; Humans; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Mutation; Quinazolines; Tyrphostins; Up-Regulation; Uterine Cervical Neoplasms | 2011 |
Recovery from carcinomatous meningitis by erlotinib.
Topics: Adenocarcinoma; Aged; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms | 2011 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Drug-induced effects on erlotinib metabolism.
Topics: Adenocarcinoma; Aged; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2011 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome | 2011 |
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Review Literature as Topic; Treatment Outcome | 2011 |
[A case of alveolar hemorrhage caused by gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Pulmonary Alveoli; Quinazolines | 2011 |
Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Metastasis; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2011 |
Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Intestinal Mucosa; Intestines; Lung Neoplasms; Mice; Mice, SCID; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Ubiquitination; Xenograft Model Antitumor Assays | 2011 |
Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Osteosclerosis; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Middle Aged; Molecular Sequence Data; Neuroendocrine Cells; Nuclear Proteins; Proteins; Proteome; Proteomics; Quinazolines; RNA Interference; RNA, Small Interfering; Small Cell Lung Carcinoma; Thyroid Nuclear Factor 1; Transcription Factors | 2011 |
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.
Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth | 2011 |
A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Heparitin Sulfate; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Failure | 2011 |
Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; DNA Mutational Analysis; Down-Regulation; ErbB Receptors; Female; Gefitinib; Humans; Inflammation Mediators; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Tomography, X-Ray Computed | 2011 |
Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Topics: Adenocarcinoma; Adult; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Rearrangement; Humans; Lung Neoplasms; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2011 |
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2012 |
Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Real-Time Polymerase Chain Reaction | 2011 |
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Area Under Curve; Combined Modality Therapy; Deoxycytidine; Duodenum; Erlotinib Hydrochloride; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Quinazolines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Risk Factors | 2012 |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Cell Cycle Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Mutation Rate; Oncogene Proteins, Fusion; Pleural Effusion, Malignant; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Smoking; Translocation, Genetic | 2012 |
[Complete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain Neoplasms; Cranial Irradiation; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2011 |
Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mutation; Prognosis; Quinazolines; Small Cell Lung Carcinoma | 2012 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Transfection; Tumor Cells, Cultured | 2011 |
EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoembryonic Antigen; Drainage; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleura; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tissue Polypeptide Antigen; Treatment Outcome | 2012 |
Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2011 |
WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Topics: Acrylamides; Adenocarcinoma; Aged; Aged, 80 and over; Aniline Compounds; Anoikis; Benzodioxoles; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Quinazolines; src-Family Kinases; Sulfonamides | 2012 |
Pneumatosis cystoides intestinalis after gefitinib therapy for pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Quinazolines; Radiography | 2012 |
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azabicyclo Compounds; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2012 |
Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anoikis; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, Notch1; RNA, Small Interfering; Signal Transduction; Tumor Stem Cell Assay | 2012 |
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2012 |
The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
Topics: Adenocarcinoma; Adult; Afatinib; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2012 |
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate | 2012 |
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Prognosis; Protein Kinases; Quinazolines; Receptor, ErbB-2; Sequence Homology, Amino Acid | 2012 |
RET, ROS1 and ALK fusions in lung cancer.
Topics: 3T3 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cytoskeletal Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Neoplasm Staging; Oncogene Proteins, Fusion; Piperidines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors | 2012 |
KIF5B-RET fusions in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Animals; Cell Transformation, Neoplastic; ErbB Receptors; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Japan; Kinesins; Lung Neoplasms; Mice; NIH 3T3 Cells; Norway; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; United States | 2012 |
[Evaluating the short-term effect of gefitinib in advanced lung adenocarcinoma with positive EGFR-mutant by dual source volume perfusion CT].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cone-Beam Computed Tomography; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2011 |
[Efficacy of combination therapy with EGFR-TKI and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKI].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2012 |
A case of choroidal metastasis of lung cancer successfully treated with erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Choroid Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis | 2012 |
Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; bcl-2-Associated X Protein; Beclin-1; Cell Cycle; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Stomach Neoplasms | 2012 |
Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aging; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Retrospective Studies; Software; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis | 2012 |
Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Embolism, Air; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Portal Vein; Protein Kinase Inhibitors; Quinazolines | 2012 |
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Mutation; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2012 |
FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Forkhead Box Protein M1; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors | 2012 |
A new generation of EGFR tyrosine-kinase inhibitors in NSCLC.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multimodal Imaging; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2012 |
MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Mutation; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2012 |
[Carcinomatous meningitis in a post-operative patient with lung adenocarcinoma for which erlotinib was effective - a case report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Membrane Potentials; Patch-Clamp Techniques; Phlorhizin; Protein-Tyrosine Kinases; Quinazolines; Radiation Dosage; Sodium-Glucose Transport Proteins; Tumor Cells, Cultured | 2012 |
Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Binding Sites; Butadienes; Cell Line, Tumor; Claudins; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Nitriles; Promoter Regions, Genetic; Protease Inhibitors; Protein Binding; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transcription Factor AP-1; Tyrphostins | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Receptors, Estrogen; Signal Transduction; Up-Regulation | 2012 |
A case of rapid improvement of severe psoriasis during molecular-targeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Comorbidity; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Cell Death; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 22; Epithelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Neurofibromin 1; Nuclear Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; raf Kinases; Shelterin Complex; Signal Transduction; SOS1 Protein; Telomere-Binding Proteins | 2011 |
Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Survival Rate; Young Adult | 2012 |
Purpuric drug eruption and alopecia induced by erlotinib.
Topics: Adenocarcinoma; Aged; Alopecia; Dermis; Drug Eruptions; Erlotinib Hydrochloride; Humans; Leg; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comprehension; Female; Focus Groups; Health Knowledge, Attitudes, Practice; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Patient Preference; Perception; Qualitative Research; Quality of Life; Quinazolines; Texas; Treatment Outcome | 2012 |
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt | 2012 |
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Transcription, Genetic; Trifluoperazine; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Neoplasm, Residual; Quinazolines; Salvage Therapy | 2012 |
Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Femoral Vein; Humans; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis | 2012 |
Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival Rate | 2012 |
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Genes, erbB-1; Humans; Janus Kinase 2; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Prognosis; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dideoxynucleosides; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Sequence Deletion | 2012 |
Detecting the effect of targeted anti-cancer medicines on single cancer cells using a poly-silicon wire ion sensor integrated with a confined sensitive window.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Gefitinib; Humans; Ions; Lung Neoplasms; Propylamines; Quinazolines; Silanes; Silicon; Single-Cell Analysis; Staurosporine | 2012 |
Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Eruptions; Eczema; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
On Bayesian methods of exploring qualitative interactions for targeted treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Carboplatin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Computer Simulation; ErbB Receptors; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pharmacogenetics; Quinazolines; Regression Analysis; Survival Analysis | 2012 |
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies | 2012 |
[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Rate | 2012 |
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Ephrins; Epithelial Cells; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multivariate Analysis; Mutation, Missense; Neoplasm Invasiveness; Occludin; Proportional Hazards Models; Quinazolines; Receptor, EphA4 | 2012 |
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tandem Mass Spectrometry | 2013 |
Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Follow-up of erlotinib related uveitis.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Uveitis; Visual Acuity | 2012 |
Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Malaysia; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2012 |
[Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective].
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasms, Unknown Primary; Quinazolines; Tomography, X-Ray Computed | 2012 |
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine | 2012 |
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering | 2012 |
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors | 2012 |
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cells, Cultured; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; STAT3 Transcription Factor; Tumor Suppressor Protein p53 | 2012 |
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Factors; Survival Rate | 2012 |
Survival of lung adenocarcinoma patients with malignant pleural effusion.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Prospective Studies; Quinazolines; Sequence Analysis, DNA; Time Factors; Treatment Outcome | 2013 |
Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma.
Topics: Adenocarcinoma; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Reproducibility of Results | 2012 |
Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polyphosphates; Quinazolines; Radionuclide Imaging; Technetium Compounds; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Erlotinib-induced bullous pemphigoid.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Pemphigoid, Bullous; Quinazolines | 2012 |
The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2012 |
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2013 |
Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Prognosis; Quinazolines | 2012 |
T-type Ca2+ channel blocker, KYS05047 induces G1 phase cell cycle arrest by decreasing intracellular Ca2+ levels in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Quinazolines; Transplantation, Heterologous | 2012 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease.
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Benzamides; Caspase 3; Disease Models, Animal; Esophageal Neoplasms; Gastroesophageal Reflux; Gene Expression; Hedgehog Proteins; Immunoenzyme Techniques; Ki-67 Antigen; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, G-Protein-Coupled; RNA, Messenger; Smoothened Receptor | 2013 |
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Middle Aged; Mutation, Missense; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cytoskeletal Proteins; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Proteins, Fusion; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
Gastric perforation secondary to regression of lung adenocarcinoma after gefitinib treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Remission Induction; Stomach Rupture; Tomography, X-Ray Computed | 2013 |
[Perforation of the nasal septum: a rare complication of bevacizumab].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Nasal Septal Perforation; Neoplasm Proteins; Pemetrexed; Quinazolines; Respiratory Insufficiency; Salvage Therapy; Vascular Endothelial Growth Factor A | 2012 |
Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Kv1.1 Potassium Channel; Lung Neoplasms; Male; Mice; Mice, Nude; Peptides; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2012 |
EGFR mutations in squamous cell lung cancer in never-smokers.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Epidural Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Smoking; Thoracic Vertebrae | 2013 |
Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
Topics: Acneiform Eruptions; Adenocarcinoma; Adenocarcinoma of Lung; Antigens, CD1; Antineoplastic Agents; Biopsy; Blister; Chemotherapy, Adjuvant; Crown Ethers; Dose Fractionation, Radiation; Down-Regulation; Drug Eruptions; Enzyme Inhibitors; ErbB Receptors; Face; Folliculitis; Humans; Immunohistochemistry; Ki-67 Antigen; Langerhans Cells; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Skin; Thoracic Wall | 2013 |
Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; MAP Kinase Kinase Kinases; Membrane Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Tumor Cells, Cultured | 2013 |
[Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Taxoids | 2012 |
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Neuroendocrine; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2013 |
Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Survival Rate; Tumor Burden | 2013 |
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Follow-Up Studies; Health Plan Implementation; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate | 2013 |
Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.
Topics: Adenocarcinoma; Animals; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Exons; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2013 |
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Adenocarcinoma; Amides; Animals; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
[The rare manifestation of soft tissue metastasis in colorectal cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fatal Outcome; Humans; Male; Quinazolines; Soft Tissue Neoplasms; Thiophenes | 2002 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Colorectal Neoplasms; Cross-Sectional Studies; Fatigue; Female; Fever; Fluorouracil; Humans; Inflammation; Interleukin-6; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Necrosis Factor-alpha | 2002 |
Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Colonic Diseases; Drug Hypersensitivity; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Middle Aged; Quinazolines; Thiophenes; Thymidylate Synthase | 2002 |
Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells.
Topics: Adenocarcinoma; Apoptosis; Benzothiazoles; Cell Division; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Humans; Neoplasm Proteins; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Tretinoin; Tumor Cells, Cultured; Tyrphostins | 2003 |
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique, Indirect; Gemcitabine; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Wortmannin | 2002 |
Severe liver dysfunction after raltitrexed administration in an HCV-positive colorectal cancer patient.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Chemical and Drug Induced Liver Injury; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Viremia | 2003 |
Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling.
Topics: Adenocarcinoma; Autocrine Communication; Cobalt Radioisotopes; DNA Damage; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Flavonoids; Gamma Rays; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Prostatic Neoplasms; Protein Biosynthesis; Proteins; Quinazolines; Tumor Cells, Cultured; Tyrphostins; X-ray Repair Cross Complementing Protein 1 | 2003 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
[Severe acute cytomegalovirus colitis after administration of irinotecan and raltitrexed chemotherapy].
Topics: Acute Disease; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Camptothecin; Colitis; Cytomegalovirus Infections; Ganciclovir; Humans; Immunocompromised Host; Irinotecan; Male; Quinazolines; Rectal Neoplasms; Sigmoid Neoplasms; Thiophenes | 2003 |
Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Cell Division; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Folic Acid; Glutamates; Hematinics; Humans; Hydroxymethyl and Formyl Transferases; Hypoxanthine; Ileal Neoplasms; Peptide Synthases; Phosphoribosylglycinamide Formyltransferase; Pyrimidines; Quinazolines; Thiophenes; Thymidine; Thymidylate Synthase; Trimetrexate; Tumor Cells, Cultured | 2003 |
[Alveolar hemorrhage as a possible adverse drug reaction by gefitinib (ZD1839, Iressa)].
Topics: Adenocarcinoma; Antineoplastic Agents; Gefitinib; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Pulmonary Alveoli; Quinazolines; Respiratory Insufficiency | 2003 |
A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example.
Topics: Adenocarcinoma; Algorithms; Antimetabolites; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Hydroxymethyl and Formyl Transferases; Intestinal Neoplasms; Models, Biological; Nonlinear Dynamics; Phosphoribosylglycinamide Formyltransferase; Quinazolines; Tetrahydrofolates; Thiophenes; Trimetrexate | 2003 |
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Nail Diseases; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index | 2003 |
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.
Topics: Adenocarcinoma; Animals; Capillary Permeability; Contrast Media; Dose-Response Relationship, Drug; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasms, Experimental; Piperidines; Prostatic Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2003 |
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2004 |
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids | 2004 |
EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; ErbB Receptors; Female; Genes, src; Humans; Kinetics; Matrix Metalloproteinases; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Peptide Fragments; Phosphorylation; Quinazolines; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Transcriptional Activation; Tyrphostins; Urokinase-Type Plasminogen Activator | 2004 |
[A case of peritonitis carcinomatosa of pulmonary adenocarcinoma in which gefitinib was effective].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Ascitic Fluid; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Peritonitis; Quinazolines | 2004 |
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Topics: Adenocarcinoma; Agar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Membrane; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Piperidines; Precipitin Tests; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors | 2004 |
Response to gefitinib in pericardial effusion due to lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Pericardial Effusion; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
Topics: Acneiform Eruptions; Adenocarcinoma; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa.
Topics: Adenocarcinoma; Animals; Apoptosis; Breast Neoplasms; Cell Survival; Evodia; Female; Fibrosarcoma; Fruit; Humans; Leukemia, Monocytic, Acute; Leukocytes, Mononuclear; Melanoma; Mice; Plant Extracts; Quinazolines; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2004 |
Targeting targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2004 |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2004 |
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Topics: Adenocarcinoma; Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Controlled Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Mutation, Missense; Phosphorylation; Protein Conformation; Protein Structure, Tertiary; Quinazolines; Sequence Deletion; Treatment Outcome; United States | 2004 |
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
Severe acute interstitial pnuemonia and gefitinib.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Agents; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Effect of gefitinib (ZD1839) on metastatic brain tumour.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Treatment Outcome | 2004 |
Cancer. A bull's eye for targeted lung cancer therapy.
Topics: Adenocarcinoma; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Japan; Ligands; Lung Neoplasms; Mutation; Phosphorylation; Protein Structure, Tertiary; Quinazolines; Sequence Deletion; Smoking; Treatment Outcome; United States | 2004 |
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Membrane; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
[Interstitial pneumonia due to gefitinib followed in detail by high-resolution CT in a patient with adenocarcinoma of the lung].
Topics: Adenocarcinoma; Aged; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2004 |
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2004 |
[Recurrence of non-small cell lung cancer after successful treatment with gefitinib--report of three cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Caspases; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Enzyme Activation; fas Receptor; G1 Phase; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2004 |
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Time Factors; Treatment Outcome | 2004 |
Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Enzyme Inhibitors; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2005 |
Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Quinazolines; Time Factors; Treatment Outcome | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gefitinib; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2004 |
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Phosphorylation; Quinazolines; Sequence Homology, Nucleic Acid; Taiwan | 2004 |
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2005 |
[A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Postoperative Period; Quality of Life; Quinazolines; Respiratory Insufficiency | 2005 |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
The effects of S-phase kinase-associated protein 2 (SKP2) on cell cycle status, viability, and chemoresistance in A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cisplatin; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Quinazolines; S-Phase Kinase-Associated Proteins; Tyrphostins | 2004 |
Gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2005 |
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Adenocarcinoma; Amphiregulin; Antineoplastic Agents; Camptothecin; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Metalloproteases; Phosphorylation; Quinazolines; Reactive Oxygen Species; Stomach Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |
APL during gefitinib treatment for non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines | 2005 |
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa).
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance | 2005 |
Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Frequency; Genotype; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation, Missense; Polymerase Chain Reaction; Quinazolines | 2005 |
Pulmonary adenocarcinomas with mutant epidermal growth factor receptors.
Topics: Adenocarcinoma; Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation, Missense; Quinazolines; Sequence Deletion; Stromal Cells; Transforming Growth Factor alpha | 2005 |
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Molecular Sequence Data; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Phosphorylation; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2005 |
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Treatment Outcome | 2005 |
Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Humans; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tyrphostins | 2005 |
Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mucin 5AC; Mucins; Oncogene Protein v-akt; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured | 2005 |
Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Polymerase Chain Reaction; Quinazolines | 2005 |
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.
Topics: Adenocarcinoma; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Mesothelioma; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition.
Topics: Adenocarcinoma; Apoptosis; Benzamides; BRCA2 Protein; Enzyme Inhibitors; Frameshift Mutation; Humans; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2005 |
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Genotype; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Asian People; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dinucleotide Repeats; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Survival Analysis; Treatment Outcome; White People | 2005 |
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion; Quinazolines; Recurrence; Retreatment; Time Factors | 2005 |
Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Sex Characteristics | 2005 |
Simultaneous bilateral spontaneous pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple lung metastases.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Pneumothorax; Quinazolines; Radiography | 2005 |
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; In Vitro Techniques; Injections, Subcutaneous; Lung Neoplasms; Male; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Piperidines; Proto-Oncogene Mas; Quinazolines; src-Family Kinases; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
Topics: Adenocarcinoma; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; DNA Methylation; DNA Mutational Analysis; DNA Primers; ErbB Receptors; Exons; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Protein Structure, Tertiary; Proto-Oncogene Proteins p21(ras); Quinazolines; Smoking; Tumor Suppressor Proteins | 2005 |
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; fas Receptor; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Quinazolines; RNA, Messenger; STAT1 Transcription Factor; Thiophenes; Tumor Suppressor Protein p53; Up-Regulation | 2005 |
Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2006 |
Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2005 |
Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gallbladder Neoplasms; Gefitinib; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors | 2006 |
Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Quinazolines | 2005 |
First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Sequence Deletion; Treatment Outcome | 2005 |
Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies | 2005 |
Acute myocardial infarction with lung cancer during treatment with gefitinib: the possibility of gefitinib-induced thrombosis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Myocardial Infarction; Quinazolines; Thrombosis | 2005 |
Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway.
Topics: Adenocarcinoma; Adult; Aged; Blotting, Western; Butadienes; Culture Media, Conditioned; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Matrix Metalloproteinase 7; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Invasiveness; Nitriles; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Tight Junctions; Tumor Cells, Cultured; Tyrphostins | 2005 |
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Ligands; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Neoplasms, Glandular and Epithelial; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured; Tyrosine | 2005 |
[A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Remission Induction; Retreatment; Tomography, X-Ray Computed | 2005 |
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Meningeal Neoplasms; Mutation; Quinazolines; Ribs; Treatment Failure | 2006 |
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
Topics: Adenocarcinoma; Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Paclitaxel; Prostatic Neoplasms; Quinazolines | 2006 |
Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies | 2006 |
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Incidence; Lung Neoplasms; Male; Molecular Biology; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Smoking | 2006 |
Tablet induced dysphagia in oesophageal cancer.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Aged, 80 and over; Deglutition Disorders; Delayed-Action Preparations; Esophageal Neoplasms; Esophagoscopy; Humans; Male; Quinazolines; Tablets | 2006 |
Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers; Biopsy; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mucin-1; Mucins; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Tomography, X-Ray Computed | 2006 |
High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Saudi Arabia; Tissue Array Analysis | 2006 |
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.
Topics: Adenocarcinoma; Biological Transport, Active; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Enzyme Inhibitors; Fibrosarcoma; Fluorouracil; HT29 Cells; Humans; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Thymidine; Thymidylate Synthase; Time Factors; Tritium | 2006 |
[Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease Susceptibility; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Proteins; Quinazolines; Staphylococcal Skin Infections; Superinfection | 2006 |
Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2006 |
EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Thiophenes | 2006 |
Urokinase plasminogen activator receptor (uPAR) expression is reduced by tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Cell Line, Tumor; Gene Expression; Genistein; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; RNA, Messenger; Tyrphostins | 2006 |
Gefitinib-sensitizing mutations in esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; DNA, Neoplasm; ErbB Receptors; Esophageal Diseases; Esophageal Neoplasms; Gefitinib; Humans; Mutation; Neoplasms, Squamous Cell; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2006 |
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Survival Rate; Tumor Cells, Cultured | 2006 |
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Structure, Tertiary; Quinazolines; Quinolines | 2006 |
Erlotinib induced skin rash spares skin in previous radiotherapy field.
Topics: Adenocarcinoma; Back; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Reoperation; Skin; Thoracic Wall | 2006 |
Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; Humans; Laminectomy; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Spinal Neoplasms | 2006 |
Synthesis and pharmacological study of novel pyrido-quinazolone analogues as anti-fungal, antibacterial, and anticancer agents.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Aspergillus; Cell Line, Tumor; Cell Proliferation; Humans; Klebsiella pneumoniae; Molecular Structure; Pseudomonas aeruginosa; Quinazolines; Staphylococcus aureus; Structure-Activity Relationship | 2006 |
Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Middle Aged; Quinazolines | 2006 |
Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biopsy; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Quinazolines; Recurrence | 2006 |
Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Korea; Lung Neoplasms; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate | 2006 |
K-ras mutations in lung cancer: the "mysterious mutation".
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA Primers; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2006 |
L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Genotype; Humans; Japan; Linear Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Statistics, Nonparametric; Survival Rate | 2006 |
Influence of whole-brain radiotherapy on remission of brain metastases.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Time Factors; Treatment Outcome | 2006 |
Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonoscopy; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Enterocolitis; Fatal Outcome; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2006 |
Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2006 |
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Characteristics; Smoking; Survival Analysis | 2006 |
Lymphangitis carcinomatosis as a potential predictor for a response to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Male; Quinazolines; Treatment Outcome | 2006 |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasms, Squamous Cell; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Smoking; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
A case of acute promyelocytic leukemia during gefitinib treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines; Remission Induction; Tretinoin | 2006 |
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.
Topics: Adenocarcinoma; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Isoleucine; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Serine; Valine | 2006 |
Molecular on/off switch.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Treatment Outcome | 2006 |
Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
Gefitinib is an additional prognostic factor in metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Drug Resistance; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2006 |
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2007 |
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Sensitivity and Specificity; Treatment Outcome | 2006 |
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Topics: Adenocarcinoma; Amino Acid Sequence; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; In Situ Hybridization; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Discriminant Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Reproducibility of Results; Tumor Cells, Cultured | 2006 |
[Meningeal carcinomatosis in patients with lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cerebrospinal Fluid; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Quality of Life; Quinazolines; Retrospective Studies; Survival Rate | 2006 |
[Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Young Adult | 2006 |
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Barrett Esophagus; Chromatography, High Pressure Liquid; Codon; ErbB Receptors; Esophageal Neoplasms; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Acute drug induced hepatitis due to erlotinib.
Topics: Adenocarcinoma; Aged; Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Quinazolines | 2006 |
Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transfection | 2007 |
Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Algorithms; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; ErbB Receptors; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2007 |
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; ErbB Receptors; Flow Cytometry; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred CBA; Neovascularization, Pathologic; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.
Topics: Adenocarcinoma; Animals; Biopsy, Fine-Needle; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Xenograft Model Antitumor Assays | 2007 |
[A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Radiosurgery; Remission Induction; Smoking | 2007 |
EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Tomography, X-Ray Computed | 2007 |
[A case of pulmonary hypertrophic osteoarthropathy associated with primary lung cancer in a young adult successfully treated with gefitinib].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Bone and Bones; Female; Gefitinib; Genes, erbB-1; Humans; Lung Diseases; Lung Neoplasms; Mutation; Osteoarthropathy, Secondary Hypertrophic; Quinazolines; Radionuclide Imaging; Tomography, X-Ray Computed | 2007 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Microsatellite Instability; Middle Aged; Quinazolines; Survival Rate | 2007 |
An unusual terminal hair growth on the nose tip associated with gefitinib therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Nose; Quinazolines | 2007 |
Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway.
Topics: Adenocarcinoma; Cell Adhesion; Cell Hypoxia; Cell Line, Tumor; Cell Movement; ErbB Receptors; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Quinazolines; Signal Transduction; Tyrphostins | 2007 |
The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Care; Quinazolines; Treatment Failure | 2008 |
[Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessment of the EGF-receptor mutation status].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sequence Deletion | 2007 |
Erlotinib-associated acute pneumonitis: report of two cases.
Topics: Acute Disease; Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Glucocorticoids; Humans; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Shock, Septic | 2007 |
[Differences in the therapeutic strategies for lung cancer between Europe/United States and Japan].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Europe; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tegafur; United States; Uracil | 2007 |
Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Rectal Neoplasms; Rosacea | 2007 |
The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Quinazolines | 2007 |
Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenomatosis, Pulmonary; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Quinazolines; Retrospective Studies | 2007 |
Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Masoprocol; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3 | 2007 |
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography | 2007 |
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; G(M3) Ganglioside; Gefitinib; Humans; Immunoblotting; Immunoprecipitation; Lung Neoplasms; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Sialyltransferases; Tumor Cells, Cultured | 2007 |
[EGFR gene mutation status among lung cancer patients in China].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Frequency; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Sex Factors; Smoking; Treatment Outcome | 2007 |
[EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Prognosis; Quinazolines; Sequence Deletion | 2007 |
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Humans; Leg; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Topics: Adenocarcinoma; Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Differentiation; Cell Line, Tumor; Culture Media, Serum-Free; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phosphorylation; Purines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays | 2007 |
Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Topics: Adenocarcinoma; Back; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Eruptions; Epidermal Growth Factor; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Skin | 2007 |
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Apoptosis; bcl-Associated Death Protein; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Mice; Mutation; Quinazolines; Sensitivity and Specificity | 2007 |
[An octogenarian case of postoperative recurrent lung cancer responding to treatments with radiation plus gefitinib].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines | 2007 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2007 |
Response of intracranial metastases to erlotinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2007 |
Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; RNA, Small Interfering; Transfection | 2007 |
[A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Survivors | 2007 |
[Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines; Tumor Burden | 2007 |
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Time Factors | 2008 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromosomes, Human, Pair 7; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines | 2007 |
[A case of lung cancer with alkaline phosphatase flare phenomenon during gefitinib therapy].
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
Predictors of survival in patients with bone metastasis of lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Time Factors; Treatment Outcome | 2008 |
Case report: dramatic recovery of lung adenocarcinoma-associated dermatomyositis with targeted lung cancer therapy alone.
Topics: Adenocarcinoma; Antineoplastic Agents; Dermatomyositis; Female; Gefitinib; Glucocorticoids; Humans; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Quinazolines; Treatment Outcome | 2008 |
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Treatment Outcome | 2008 |
Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Polymerase Chain Reaction; Quinazolines | 2008 |
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Sex Factors; Smoking; Treatment Outcome | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Leucovorin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Philadelphia Chromosome; Quinazolines; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thiophenes | 2008 |
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Topics: Adenocarcinoma; Aged; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Tomography Scanners, X-Ray Computed; Treatment Failure | 2008 |
Peritoneal carcinomatosis in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Retrospective Studies; Taiwan | 2008 |
[A case of lung adenocarcinoma effectively treated with sivelestat and corcicosteroid for drug-induced lung disease due to gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Gefitinib; Glycine; Humans; Lung Diseases; Lung Neoplasms; Male; Prednisolone; Quinazolines; Serine Proteinase Inhibitors; Sulfonamides | 2008 |
A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents.
Topics: Actins; Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Lobular; Cell Culture Techniques; Cell Line, Tumor; Coculture Techniques; Dose-Response Relationship, Drug; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Male; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Models, Biological; Muscle, Smooth; Quinazolines; Stromal Cells | 2008 |
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Meningitis; Middle Aged; Mutation; Quinazolines; Radiotherapy | 2008 |
Gefitinib-associated Propionibacterium acnes pleural empyema.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Empyema, Pleural; Female; Gefitinib; Gram-Positive Bacterial Infections; Humans; Lung Neoplasms; Middle Aged; Pleurodesis; Propionibacterium acnes; Quinazolines | 2008 |
[Acneiforme rash in woman with pulmonary adenocarcinoma].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo.
Topics: Adenocarcinoma; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2009 |
Iv administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Infusions, Parenteral; Leukemia, Erythroblastic, Acute; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines | 1983 |
Effects of 5,8-dideazaisopteroylglutamate and its possible tri-gamma-glutamyl metabolite (5,8-dideazaisoPteGlu3) on colon adenocarcinoma, and the folate dependent enzymes thymidylate synthase and dihydrofolate reductase.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; DNA Replication; Drug Resistance; Female; Humans; Kinetics; Leukemia; Methotrexate; Methyltransferases; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Peptide Synthases; Quinazolines; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 1983 |
Improved synthesis and antitumor evaluation of 5,8-dideazaisofolic acid and closely related analogues.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Chemical Phenomena; Chemistry; Folic Acid Antagonists; Gastrointestinal Neoplasms; Humans; Methotrexate; Quinazolines; Stereoisomerism; Structure-Activity Relationship | 1984 |
Biochemical and antitumor effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Colonic Neoplasms; Female; Folic Acid Antagonists; Humans; Leukemia L1210; Methotrexate; Methyltransferases; Mice; Mice, Inbred C57BL; Quinazolines; Thymidylate Synthase | 1983 |
New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Fatal Outcome; Fluorouracil; Folic Acid; Folic Acid Antagonists; Gastrointestinal Neoplasms; Gene Expression Regulation, Enzymologic; Humans; Interferon-alpha; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; RNA, Messenger; RNA, Neoplasm; Thymidylate Synthase | 1995 |
Benzo[f]quinazoline inhibitors of thymidylate synthase: methyleneamino-linked aroylglutamate derivatives.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Glutamates; Humans; Indoles; Isoindoles; Quinazolines; Structure-Activity Relationship; Thymidylate Synthase; Tumor Cells, Cultured | 1994 |
Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones.
Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; Escherichia coli; Humans; Quinazolines; Structure-Activity Relationship; Thymidylate Synthase; Tumor Cells, Cultured | 1993 |
Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Binding Sites; Cell Line; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Escherichia coli; Folic Acid Antagonists; Humans; Leukemia; Leukemia L1210; Mice; Models, Molecular; Molecular Conformation; Molecular Structure; Protein Conformation; Quinazolines; Structure-Activity Relationship; Thymidylate Synthase; Tumor Cells, Cultured | 1996 |
DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Cycle; Cell Division; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; DNA Replication; DNA, Neoplasm; G1 Phase; G2 Phase; Humans; Neoplasm Proteins; Quinazolines; S Phase; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).
Topics: Adenocarcinoma; Benzylidene Compounds; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Membrane; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; G(M3) Ganglioside; Humans; Lung Neoplasms; Nitriles; Phosphorylation; Protein Tyrosine Phosphatases; Quinazolines; Radioligand Assay; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 1997 |
p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex).
Topics: Adenocarcinoma; Carrier Proteins; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA-Binding Proteins; DNA, Neoplasm; E2F Transcription Factors; E2F1 Transcription Factor; Enzyme Inhibitors; Gene Expression; Humans; Ileal Neoplasms; Phosphorylation; Quinazolines; Retinoblastoma Protein; Retinoblastoma-Binding Protein 1; RNA, Messenger; Thiophenes; Thymidylate Synthase; Transcription Factor DP1; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |
Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Deoxyuracil Nucleotides; DNA-Directed DNA Polymerase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Kinetics; Pyrophosphatases; Quinazolines; Templates, Genetic; Thiophenes; Thymidylate Synthase; Thymine Nucleotides; Tumor Cells, Cultured | 1997 |
Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Nucleotides; Phosphoribosyl Pyrophosphate; Quinazolines; RNA, Neoplasm; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 1998 |
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electrocardiography; Female; Fluorouracil; Heart; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sigmoid Neoplasms; Thiophenes; Thymidylate Synthase | 1998 |
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Enzyme Inhibitors; ErbB Receptors; Female; Genes, erbB-2; Humans; Male; Phosphorylation; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Recombinant Proteins; Transfection; Uterine Cervical Neoplasms; Vulvar Neoplasms | 1997 |
Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
Topics: Adenocarcinoma; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Chromones; Epidermal Growth Factor; ErbB Receptors; Female; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 1999 |
A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
Topics: Adenocarcinoma; Animals; Autocrine Communication; Breast Neoplasms; Cell Line; Diffusion Chambers, Culture; Epidermal Growth Factor; ErbB Receptors; Estrenes; Female; Humans; Immunoblotting; Isoenzymes; Male; Mice; Neoplasm Invasiveness; Phosphodiesterase Inhibitors; Phospholipase C gamma; Phosphorylation; Prostatic Neoplasms; Pyrrolidinones; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Type C Phospholipases | 1999 |
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Geriatrics; Humans; Leucovorin; Male; Middle Aged; Palliative Care; Prospective Studies; Quality of Life; Quinazolines; Survival Analysis; Thiophenes | 1999 |
[Non-alcoholic steatohepatitis with cirrhosis after raltitrexed administration].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Disease Progression; Drug Monitoring; Fat Necrosis; Fatty Liver; Female; Humans; Liver Cirrhosis; Liver Function Tests; Middle Aged; Quinazolines; Rectal Neoplasms; Thiophenes; Thymidylate Synthase | 2001 |
Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxidoreductases; Quinazolines; Thiophenes | 2001 |
Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Colonic Neoplasms; Female; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Plant Extracts; Quinazolines; Tumor Cells, Cultured | 2001 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2001 |
Growth inhibition of prostate cancer xenografts by halofuginone.
Topics: Adenocarcinoma; Administration, Oral; Androgens; Animals; Antineoplastic Agents; Apoptosis; Collagen Type I; Disease Progression; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Phenotype; Piperidines; Prostatic Neoplasms; Quinazolines; Quinazolinones | 2002 |
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Apoptosis; Blotting, Northern; Blotting, Western; Cell Count; Cell Cycle; Cell Division; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Immunohistochemistry; Male; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Phosphorylation; Prostatic Neoplasms; Quinazolines; RNA, Messenger; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2002 |
Rapid development of resistance to antifolates in vitro: possible clinical implication.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Folic Acid Antagonists; Leukemia P388; Methotrexate; Mice; Quinazolines; Trimetrexate; Tumor Cells, Cultured | 1991 |
Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Survival; Colonic Neoplasms; Drug Synergism; Fluorouracil; Folic Acid; Interferon Type I; Leucovorin; Quinazolines; Recombinant Proteins; Thymidylate Synthase; Tumor Cells, Cultured | 1991 |
Uptake and metabolism of 5,8-dideazaisofolic acid in human colon carcinoma cells.
Topics: Adenocarcinoma; Biotransformation; Colonic Neoplasms; Folic Acid Antagonists; Humans; Methotrexate; Polyglutamic Acid; Quinazolines; Thymidylate Synthase; Tumor Cells, Cultured | 1988 |
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Units Assay; Drug Interactions; Drug Synergism; Floxuridine; Fluorouracil; Folic Acid Antagonists; Humans; Methotrexate; Quinazolines; Trimetrexate; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1989 |
Activity of batracylin (NSC-320846) against solid tumors of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Intraductal, Noninfiltrating; Cell Survival; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 1989 |
Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.
Topics: Adenocarcinoma; Animals; Cattle; Cell Adhesion; Colonic Neoplasms; Colony-Forming Units Assay; Culture Media; Dose-Response Relationship, Drug; Humans; Hypoxanthines; Leucovorin; Methotrexate; Neoplastic Stem Cells; Quinazolines; Thymidine; Trimetrexate | 1986 |
Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Chromatography, High Pressure Liquid; Deoxyuridine; Drug Evaluation; Female; Hematopoietic Stem Cells; Humans; Kinetics; Lung Neoplasms; Mathematics; Middle Aged; Quinazolines; Thrombocytopenia; Trimetrexate | 1987 |
Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells.
Topics: Adenocarcinoma; Colonic Neoplasms; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Leukemia; Methotrexate; Quinazolines; Trimetrexate; Tumor Cells, Cultured | 1987 |
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Cell Line; Colonic Neoplasms; Drug Resistance; Floxuridine; Humans; Hypoxanthine; Hypoxanthines; Methotrexate; Nucleosides; Quinazolines; Thymidine | 1985 |
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Folic Acid; Humans; Middle Aged; Quinazolines; Rectal Neoplasms; Thymidylate Synthase | 1988 |
Preclinical antitumor activity of batracylin (NSC 320846).
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation, Preclinical; Injections, Intraperitoneal; Leukemia P388; Leukemia, Experimental; Mice; Mice, Inbred Strains; Quinazolines; Tumor Cells, Cultured | 1988 |
A new antitumour agent, batracylin, selected by a preclinical solid tumour model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Screening Assays, Antitumor; Leukemia L1210; Leukemia P388; Melanoma, Experimental; Mice; Quinazolines | 1988 |
Synthesis of 5-chloro-5,8-dideaza analogues of folic acid and aminopterin targeted for colon adenocarcinoma.
Topics: Adenocarcinoma; Aminopterin; Cell Line; Chemical Phenomena; Chemistry; Colonic Neoplasms; Humans; Quinazolines; Structure-Activity Relationship | 1987 |